Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549​
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a)
of the Securities Exchange Act of 1934
Filed by the Registrant ☒
Filed by a Party other than the Registrant ☐
Check the appropriate box:
☒
Preliminary Proxy Statement
​
☐
Confidential, for Use of the SEC Only (as permitted by Rule 14a-6(e)(2))
​
☐
Definitive Proxy Statement
​
☐
Definitive Additional Materials
​
☐
Soliciting Material Pursuant to 14a-12
​
GRIDAI TECHNOLOGIES CORP.
​
(Name of Registrant as Specified in Its Charter)​
   
​
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)​
Payment of Filing Fee (Check all boxes that apply):
☒
No fee required.
​
☐
Fee paid previously with preliminary materials
​
☐
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.
​

Table of Contents
PRELIMINARY PROXY MATERIALS — SUBJECT TO COMPLETION,
DATED NOVEMBER 16, 2026
[MISSING IMAGE: lg_gridai-4clr.jpg]
GridAI Technologies Corp.
433 Plaza Real, Suite 275 Boca
Raton, Florida 33432
Dear Fellow Stockholder,   [*], 2026
On behalf of the Board of Directors and management of GridAI Technologies Corp. (“we”, “us”, “our”, “GridAI” or the “Company”), a Delaware corporation, you are invited to attend our 2026 Annual Meeting of Stockholders including any adjournment or postponement thereof (the “Annual Meeting”) to be held on December [   ], 2026 at [       ] [A./P.M.] Eastern Time. This year’s Annual Meeting will be a completely “virtual meeting” of stockholders. You will be able to attend the Annual Meeting, vote and submit your questions during the Annual Meeting by visiting www.virtualshareholdermeeting.com/GRDX2026. You will need the 16-digit control number on your proxy card to participate in the Annual Meeting. Online check-in will begin at [      ] [A./P.M.] (Eastern), on December [   ], 2026. Once admitted, you may participate in the Annual Meeting and vote during the Annual Meeting by following the instructions that will be available on the Annual Meeting website.
Details of the business to be conducted at the Annual Meeting are described in this proxy statement. We have also enclosed a copy of our Annual Report on Form 10-K for the year ended December 31, 2025 (filed with the Securities and Exchange Commission on May 1, 2026) (the “Annual Report”) with this proxy statement. We encourage you to read our Annual Report, which includes our audited financial statements and provides information about our business and services.
Your vote is important. Regardless of whether you plan to attend the Annual Meeting via the live webcast on the Internet, please read the accompanying proxy statement and then submit your proxy to vote by Internet, telephone or mail as promptly as possible. Returning your proxy will help us assure that a quorum will be present at the Annual Meeting and avoid the additional expense of duplicate proxy solicitations. Any stockholder attending the Annual Meeting may vote via this live webcast, even if he or she has previously voted. Please refer to your proxy card for voting instructions. Submitting your proxy promptly may save us additional expense in soliciting proxies and will ensure that your shares are represented at the Annual Meeting.
If you have questions about the Annual Meeting, you may contact the Company’s Investor Relations Department at Jason Assad (IR@gridaipower.com) or by calling (678) 570-6791.
Our Board of Directors has approved the proposals set forth in the proxy statement and recommends that you vote in favor of each such proposal.
Sincerely,
/s/ Jason D. Sawyer
​
Jason D. Sawyer
Chief Executive Officer and Director
​ ​
IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS
FOR THE ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD ON [      ], 2026
​ ​
​ ​
The proxy statement and the Annual Report are available at
https://www.proxyvote.com.
​ ​
​ ​
You may also obtain these materials at www.proxyvote.com and the U.S. Securities and Exchange
Commission website at www.sec.gov.
​ ​

Table of Contents
 
NOTICE OF THE GRIDAI TECHNOLOGIES CORP.
ANNUAL MEETING OF STOCKHOLDERS
​
Date and Time
​ ​ December [   ], 2026 at [      ] [A./ P.M.], Eastern Time. ​
​
Place
​ ​ The 2026 Annual Meeting will be held solely by remote communication, in a virtual meeting format. You will be able to attend and participate in the Annual Meeting online, vote your shares electronically and submit your questions during the meeting by visiting www.virtualshareholdermeeting.com/GRDX2026, at the meeting date and time described in the accompanying proxy statement. You will not be able to attend the 2026 Annual Meeting in person. You will need the 16-digit control number on your proxy card to participate in the Annual Meeting. Beneficial owners of shares held in street name will need to follow the instructions provided by the broker, bank or other nominee that holds their shares. Online check-in will begin at [      ]. (Eastern), on [      ], 2026. Once admitted, you may participate in the meeting and vote during the Annual Meeting by following the instructions that will be available on the meeting website. ​
​
Items of Business
​ ​
1.
Election of four director nominees named in this proxy statement, each for a term of one year expiring at our 2027 annual meeting of stockholders or until their respective successors are duly elected and qualified (the “Director Election Proposal”);
​
2.
Adoption and approval of an amendment to our Amended and Restated Certificate of Incorporation, as amended (the “Charter”), to effect a reverse stock split of our issued and outstanding shares of Common Stock, at a specific ratio, ranging from 1:2 to 1:20, at any time prior to the one-year anniversary date of the Annual Meeting, with the exact ratio to be determined by the Board without further approval or authorization of our stockholders (the “Reverse Split Proposal”);
​
3.
To approve an amendment to the Company’s 2020 Omnibus Equity Incentive Plan (the “Plan”) to: (i) increase the number of shares of Common Stock authorized for issuance under the Plan from 3,801,549 to 10,000,000, including an increase in the number of shares available for grants of incentive stock options (“ISOs”) from 357 to 10,000,000; and (ii) increase the maximum number of shares that may be granted to any non-employee director in a calendar year from 250,000 to 6,500,000 (the “Equity Plan Amendment Proposal”).
​
4.
To approve the issuance of up to 1,520,000 shares of Common Stock upon the exercise of warrants issued or issuable pursuant to that certain Securities Purchase Agreement dated October 17, 2025, as amended to date, by and among the Company and the investors party thereto, as required by and in accordance with Nasdaq Listing Rule 5635(d) (the “Nasdaq Proposal”);
​
5.
Approval, on an advisory basis, of the executive compensation of the Company’s named executive officers as described in this proxy statement (the “Say on Pay Proposal”);
​
6.
Ratification of Macias Gini & O’Connell LLP, as our independent registered public accounting firm for the fiscal year ending December 31, 2026 (the “Auditor Ratification Proposal”); and
​
7.
Approval of the adjournment of the annual meeting to the extent there are insufficient proxies at the annual meeting to approve any one or more of the foregoing proposals (the “Adjournment Proposal”).
​
​
 

Table of Contents
 
​
Adjournments and Postponements
​ ​ Any action on the items of business described above may be considered at the 2026 Annual Meeting at the time and on the date specified above or at any time and date to which the Annual Meeting may be properly adjourned or postponed. ​
​
Record Date
​ ​ October 20, 2026 (the “Record Date”). Only stockholders of record holding shares of our Common Stock, par value $0.0001 per share (the “Common Stock”) as of the close of business on the Record Date are entitled to notice of and to vote at the Annual Meeting. ​
​
Meeting Admission
​ ​ You are invited to attend the Annual Meeting if you are a stockholder of record or a beneficial owner of shares of our Common Stock as of the Record Date. ​
​ Availability of Proxy Materials ​ ​ Copies of the proxy statement and our Annual Report on Form 10-K for the year ended December 31, 2025 are available at https://gridaipower.com. also obtain these materials at www.proxyvote.com and the U.S. Securities and Exchange Commission (“SEC”) website at www.sec.gov. ​
​ Voting ​ ​ If your shares are held in the name of a bank, broker or other fiduciary, please follow the instructions on the proxy card. Whether or not you expect to attend the Annual Meeting, we urge you to submit your proxy to vote your shares as promptly as possible by following the instructions on your proxy card so that your shares may be represented and voted at the Annual Meeting. Your vote is very important. ​
The Proposals are described in the accompanying proxy statement, which we encourage you to read in its entirety before voting. Only holders of record of Common Stock at the close of business on October 20, 2026 are entitled to notice of the Annual Meeting and to vote and have their votes counted at the Annual Meeting and any adjournments or postponements of the Annual Meeting. A complete list of GridAI stockholders of record entitled to vote at the Annual Meeting will be available for at least ten days before the Annual Meeting at the principal executive offices of GridAI for inspection by stockholders during ordinary business hours for any purpose germane to the Annual Meeting.
The GridAI Board unanimously recommends that GridAI stockholders vote “FOR” each of the foregoing proposals.
The existence of any financial and personal interests of one or more of GridAI’s directors may be argued to result in a conflict of interest on the part of such director(s) between what he, she or they may believe is in the best interests of GridAI and its stockholders and what he, she or they may believe is best for himself, herself or themselves in determining to recommend that stockholders vote for the proposals. See the section entitled “Interests of Directors and Executive Officers in the Proposals” in the accompanying proxy statement for a further discussion of this issue.
Assuming a quorum is present at the Annual Meeting, the Director Election Proposal requires the affirmative vote of a plurality of the votes cast by stockholders present or represented by proxy and entitled to vote on the matter at the Annual Meeting, and each other proposal requires the affirmative vote of a majority of the votes cast by stockholders present or represented by proxy and entitled to vote on the matter at the Annual Meeting. Please vote by proxy over the internet or telephone using the instructions included with the accompanying proxy card, or promptly complete your proxy card and return it in the enclosed postage-paid envelope, in order to authorize the individuals named on your proxy card to vote your shares of GridAI Common Stock at the Annual Meeting. If you hold your shares through a broker, bank or other nominee in “street name” ​(instead of as a registered holder) please follow the instructions on the voting instruction form provided by your bank, broker or nominee to vote your shares. The list of GridAI stockholders entitled to vote at the Annual Meeting will be available at GridAI’s headquarters during regular business hours for examination by any GridAI stockholder for any purpose germane to the Annual Meeting for a period of at least ten days prior to the Annual Meeting.
 

Table of Contents
 
PLEASE VOTE AS PROMPTLY AS POSSIBLE, WHETHER OR NOT YOU PLAN TO ATTEND THE ANNUAL MEETING. IF YOU LATER DESIRE TO REVOKE OR CHANGE YOUR PROXY FOR ANY REASON, YOU MAY DO SO IN THE MANNER DESCRIBED IN THE ACCOMPANYING PROXY STATEMENT. FOR FURTHER INFORMATION CONCERNING THE PROPOSALS BEING VOTED ON, USE OF THE PROXY AND OTHER RELATED MATTERS, YOU ARE URGED TO READ THE ACCOMPANYING PROXY STATEMENT.
BY ORDER OF THE BOARD OF DIRECTORS,
​ Boca Raton, Florida
[      ], 2026
​ ​
/s/ Jason D. Sawyer
​
Jason D. Sawyer
Chief Executive Officer and Director
​
IF YOU RETURN YOUR PROXY CARD WITHOUT AN INDICATION OF HOW YOU WISH TO VOTE, YOUR SHARES WILL BE VOTED IN FAVOR OF EACH OF THE PROPOSALS.
This proxy statement is dated [      ], 2026 and is first being mailed to the stockholders of GridAI on or about [      ], 2026.
 

Table of Contents​
 
TABLE OF CONTENTS
​ ​ ​
Page
​
​ ​ ​ ​ 1 ​ ​
​ ​ ​ ​ 9 ​ ​
​ ​ ​ ​ 15 ​ ​
​ ​ ​ ​ 33 ​ ​
​ ​ ​ ​ 34 ​ ​
​ ​ ​ ​ 42 ​ ​
​ ​ ​ ​ 49 ​ ​
​ ​ ​ ​ 51 ​ ​
​ ​ ​ ​ 52 ​ ​
​ ​ ​ ​ 55 ​ ​
​ ​ ​ ​ 56 ​ ​
​ ​ ​ ​ 56 ​ ​
​ ​ ​ ​ 57 ​ ​
​ ​ ​ ​ 57 ​ ​
​ ​ ​ ​ 57 ​ ​
​ ​ ​ ​ A-1 ​ ​
​ ​ ​ ​ B-1 ​ ​
 
i

Table of Contents​
 
FREQUENTLY ASKED QUESTIONS
The following questions and answers briefly address some questions that you, as a GridAI stockholder, may have regarding the matters being considered at the Annual Meeting. You are urged to carefully read this proxy statement and the other documents referred to in this proxy statement in their entirety because this section may not provide all the information that is important to you regarding these matters.
Why am I receiving this proxy statement?
We are sending these proxy materials to you by mail in connection with the solicitation of proxies by our Board of Directors (the “Board” or the “GridAI Board”) for use at the 2026 Annual Meeting, and any continuations, postponements or adjournments thereof. The proxy materials include our Notice of 2026 Annual Meeting of Stockholders of GridAI, this proxy statement, the proxy card, and our Annual Report on Form 10-K for the year ended December 31, 2025 (the “Annual Report”). The proxy materials include detailed information about the matters that will be discussed and voted on at the Annual Meeting and furnish you with the information you need in order to vote, whether or not you participate in the Annual Meeting.
What is being voted on?
You are being asked to vote on seven proposals:
1.
Election of four director nominees named in this proxy statement, each for a term of one year expiring at our 2027 annual meeting of stockholders or until their respective successors are duly elected and qualified (the “Director Election Proposal”);
​
2.
Adoption and approval of an amendment to our Amended and Restated Certificate of Incorporation, as amended (the “Charter”), to effect a reverse stock split of our issued and outstanding shares of Common Stock, at a specific ratio, ranging from 1:2 to 1:20, at any time prior to the one-year anniversary date of the Annual Meeting, with the exact ratio to be determined by the Board without further approval or authorization of our stockholders (the “Reverse Split Proposal”);
​
3.
To approve an amendment to the Company’s 2020 Omnibus Equity Incentive Plan (the “Plan”) to: (i) increase the number of shares of Common Stock authorized for issuance under the Plan from 3,801,549 to 10,000,000, including an increase in the number of shares available for grants of incentive stock options (“ISOs”) from 357 to 10,000,000; and (ii) increase the maximum number of shares that may be granted to any non-employee director in a calendar year from 250,000 to 6,500,000 (the “Equity Plan Amendment Proposal”).
​
4.
To approve the issuance of up to 1,520,000 shares of Common Stock upon the exercise of warrants issued or issuable pursuant to that certain Securities Purchase Agreement dated October 17, 2025, as amended to date, by and among the Company and the investors party thereto, as required by and in accordance with Nasdaq Listing Rule 5635(d) (the “Nasdaq Proposal”);
​
5.
Approval, on an advisory basis, of the executive compensation of the Company’s named executive officers as described in this proxy statement (the “Say on Pay Proposal”);
​
6.
Ratification of Macias Gini & O’Connell LLP, as our independent registered public accounting firm for the fiscal year ending December 31, 2026 (the “Auditor Ratification Proposal”); and
​
7.
Approval of the adjournment of the annual meeting to the extent there are insufficient proxies at the annual meeting to approve any one or more of the foregoing proposals (the “Adjournment Proposal”).
​
When is this proxy statement and the accompanying materials scheduled to be sent to stockholders?
On or about [      ], 2026, we will begin mailing our proxy materials, including the Notice of the Annual Meeting, this proxy statement, and the accompanying proxy card or, for shares held in street name (i.e., shares held for your account by a broker or other nominee), a voting instruction form.
 
1

Table of Contents
 
Can I access these proxy materials on the Internet?
Yes. This Proxy Statement and the Annual Report are available free of charge at https://gridaipower.com. You may also obtain these materials at www.proxyvote.com and the SEC website at www.sec.gov.
When and where will the Annual Meeting take place?
The Annual Meeting will be held on December [  ], 2026 at [      ] [A./P.M.] Eastern Time. The Annual Meeting will be held solely by remote communication, in a virtual meeting format. Registered stockholders will be able to participate in the Annual Meeting online by visiting www.virtualshareholdermeeting.com/GRDX2026, where you will be able to vote electronically and submit questions. You will not be able to attend the Annual Meeting in person. You will need the 16-digit control number on your proxy card to participate in the Annual Meeting.
How can I participate and ask questions at the Annual Meeting?
In order to submit a question at the Annual Meeting, you will need your 16-digit control number that is printed on your proxy card. You may log in 15 minutes before the start of the Annual Meeting and submit questions online. If you would like to submit a question during the Annual Meeting, once you have logged into the webcast, simply click on the “Q&A” icon on the screen, type in your question, then click “Send” to submit. You can submit a question up until the time we indicate that the question-and-answer session is concluded.
What if I have technical or other “IT” problems logging into or participating in the Annual Meeting webcast?
The virtual meeting platform is fully supported across browsers (MS Edge, Firefox, Chrome and Safari) and devices (desktops, laptops, tablets and cell phones) running the most up-to-date version of applicable software and plugins. Note: Internet Explorer is not a supported browser. Participants should ensure that they have a strong WiFi connection. Stockholders are encouraged to log into the webcast at least 15 minutes prior to the start of the meeting to test their Internet connectivity. If you experience technical difficulties during the check-in process, call one of the appropriate numbers noted at the top of the login page.
What documentation must I provide to vote online at the Annual Meeting?
If you are a stockholder of record and provide your 16-digit control number when you access the meeting, you may vote all shares registered in your name during the Annual Meeting webcast. If you are not a stockholder of record as to any of your shares (i.e., instead of being registered in your name, all or a portion of your shares are registered in “street name” and held by your broker, bank or other institution for your benefit), you must follow the instructions provided by the broker, bank or other nominee that holds your shares.
When is the record date for the Annual Meeting?
The record date for determination of stockholders entitled to vote at the Annual Meeting is the close of business on October 20, 2026, which we refer to as the “record date.”
Who is entitled to vote at the Annual Meeting?
All holders of record of shares of GridAI Common Stock who held shares at the close of business on October 20, 2026, the record date, are entitled to receive notice of, and to vote at, the Annual Meeting. Attendance at the Annual Meeting is not required to vote. See below and the section titled “The Annual Meeting — Methods of Voting” for instructions on how to vote without attending the Annual Meeting.
Does my vote matter?
Yes, your vote is very important, regardless of the number of shares that you own.
How does the GridAI Board recommend that I vote at the Annual Meeting?
The GridAI Board unanimously recommends that GridAI stockholders vote “FOR” each of the proposals.
 
2

Table of Contents
 
Why should I vote for the Reverse Split Proposal?
Our Board has determined that it is advisable and in the best interests of the Company and its stockholders, for us to amend our Charter to authorize our Board to effect a reverse stock split (the “Charter Amendment”) of our issued and outstanding shares of Common Stock at a specific ratio, ranging from 1:2 to 1:20 (the “Approved Split Ratios”), to be determined by the Board (the “Reverse Split”). A vote for this Reverse Split Proposal will constitute approval of the Reverse Split that, once authorized by the Board and effected by filing the Charter Amendment with the Secretary of State of the State of Delaware, will combine between 2 and 20 shares of our Common Stock into one share of our Common Stock. If implemented, the Reverse Split will have the effect of decreasing the number of shares of our Common Stock issued and outstanding.
Accordingly, stockholders are asked to adopt and approve the Charter Amendment set forth in Annex A to effect the Reverse Split as set forth in the Charter Amendment, subject to the Board’s determination, in its sole discretion, whether or not to implement the Reverse Split, as well as the specific ratio within the range of the Approved Split Ratios, and provided that the Reverse Split must be effected on or prior to the one-year anniversary date of the Annual Meeting. The text of Annex A remains subject to modification to include such changes as may be required by the Secretary of State of the State of Delaware and as our Board deems necessary or advisable to implement the Reverse Split.
If adopted and approved by the holders of our outstanding voting securities, the Reverse Split would be applied at an Approved Split Ratio approved by the Board prior to the one-year anniversary date of the Annual Meeting. The Board reserves the right to elect to abandon the Reverse Split if it determines, in its sole discretion, that the Reverse Split is no longer in the best interests of the Company and its stockholders.
Why should I vote for the Equity Plan Amendment Proposal?
The general purpose of our 2020 Omnibus Equity Incentive Plan (the “Plan”), is to benefit our Company and its stockholders by assisting the Company and its subsidiaries to attract, retain and provide incentives to key management employees, officers, directors, and consultants of the Company and its affiliates, and to align the interests of such service providers with those of the Company’s stockholders.
Our Board believes that the granting of stock options, restricted stock awards, restricted stock units, stock appreciation rights and similar kinds of cash-based and equity-based compensation promotes continuity of management and provides a critical incentive to align the interests of those who are primarily responsible for shaping and carrying out our long range plans and securing our growth and financial success with the interests of our stockholders.
If the Company’s stockholders do not approve the increase in the number of shares available for issuance under the Plan, the Company will continue to operate the Plan under its current provisions, but will be limited in its ability to make future grants and incentives under the Plan to individuals we believe are, and in the future, will be critical to the Company’s success.
Why should I vote for the Nasdaq Proposal?
The Company is seeking stockholder approval of the issuance of shares of Common Stock upon exercise of the warrants issued or issuable pursuant to the Securities Purchase Agreement dated October 17, 2025, as amended, in order to comply with the applicable rules of The Nasdaq Stock Market LLC. Nasdaq Listing Rule 5635(d) requires stockholder approval prior to the issuance of securities in connection with a transaction, other than a public offering, involving the sale, issuance, or potential issuance by the Company of Common Stock (or securities convertible into or exercisable for Common Stock) equal to 20% or more of the Common Stock or 20% or more of the voting power outstanding before the issuance, at a price that is less than the lower of (i) the closing price immediately preceding the signing of the binding agreement or (ii) the average closing price of the Common Stock for the five trading days immediately preceding the signing of the binding agreement. The Company is asking stockholders to approve the issuance because in the absence of stockholder approval, such issuances could result in the issuance violating Nasdaq Listing Rule 5635(d).
 
3

Table of Contents
 
Why should I vote for the Say on Pay Proposal?
The Board believes that the Company’s compensation policies and practices are effective in achieving our goals of motivating and retaining executives by (i) rewarding excellence in leadership and sustained financial performance, and (ii) aligning our executives’ interests with those of our stockholders to create long-term value.
Why should I vote for the Auditor Ratification Proposal?
Macias Gini & O’Connell LLP (“MGO”) has served as the Company’s independent registered public accounting firm since August 27, 2024. Our Audit Committee and Board believe that stability and continuity in the Company’s auditor is important as we advance our business plan.
Why should I vote for the Adjournment Proposal?
If the Adjournment Proposal is not approved, the GridAI Board may not be able to adjourn the Annual Meeting to another time and place if necessary or appropriate to permit the solicitation of additional proxies if there are insufficient votes at the time of the Annual Meeting to approve the Director Election Proposal, the Reverse Split Proposal, the Equity Plan Amendment Proposal, the Nasdaq Proposal, the Say on Pay Proposal, or the Auditor Ratification Proposal.
What is a proxy?
A proxy is a stockholder’s legal designation of another person to vote shares owned by such stockholder on their behalf. If you are a stockholder of record, you can vote by proxy over the internet, by mail or by telephone, by following the instructions provided in this proxy statement. If you hold shares beneficially through a broker, bank or other nominee in “street name,” you should follow the voting instructions provided by your broker, bank or other nominee.
How many votes do I have at the Annual Meeting?
Each GridAI stockholder is entitled to one vote on each proposal for each share of Common Stock held of record at the close of business on the record date. At the close of business on the record date, there were 8,540,172shares of Common Stock outstanding.
What constitutes a quorum for the Annual Meeting?
A quorum is the minimum number of shares required to be represented, either through virtual attendance or through representation by proxy, to hold a valid meeting.
In order for any business to be conducted at the Annual Meeting, both (i) the holders of one-third of the voting power of the shares of the capital stock of the Company issued and outstanding and entitled to vote at the Annual Meeting, and (ii) the holders of at least one-third of the shares of Common Stock issued and outstanding and entitled to vote at the Annual Meeting must be represented at the Annual Meeting, either in person, by means of remote communication in a manner, if any, authorized by the Board in its sole discretion, or represented by proxy. If a quorum is not present at the scheduled time of the Annual Meeting, the Board, the chairman of the meeting or, if directed to be voted on by the chairman of the meeting, the stockholders present or represented at the Annual Meeting and entitled to vote thereon, although less than a quorum, may adjourn the Annual Meeting until a quorum is present. The date, time and place and the means of remote communication, if any, of the adjourned Annual Meeting will be announced at the time the adjournment is taken, and no other notice will be given unless the adjournment is for more than 30 days, in which case a notice of the adjourned meeting will be given to each stockholder of record entitled to vote at the Annual Meeting. An adjournment will have no effect on the business that may be conducted at the Annual Meeting.
Since the Reverse Split Proposal and the Auditor Ratification Proposal are considered a routine matters, shares held in “street name” through a broker, bank or other nominee will be counted as present for the purpose of determining the existence of a quorum if such broker, bank or other nominee does not have instructions to vote on such proposals.
 
4

Table of Contents
 
How can I vote my shares at the Annual Meeting?
Shares held directly in your name as a GridAI stockholder of record may be voted at the Annual Meeting. If you are not a stockholder of record as to any of your shares (i.e., instead of being registered in your name, all or a portion of your shares are registered in “street name” and held by your broker, bank or other institution for your benefit), you must follow the instructions provided by the broker, bank or other nominee that holds your shares.
You may attend the Annual Meeting via the Internet www.virtualshareholdermeeting.com/GRDX2026 and vote during the meeting. Have the information that is printed in the box marked by the arrow on your proxy card available and follow the instructions.
Even if you plan to attend the Annual Meeting, GridAI recommends that you vote by proxy in advance as described below so that your vote will be counted if you later decide not to or become unable to attend the Annual Meeting.
For additional information on attending the Annual Meeting, see the section titled “The Annual Meeting.”
How can I vote my shares without attending the Annual Meeting?
Whether you hold your shares directly as a stockholder of record of GridAI or beneficially in “street name,” you may direct your vote by proxy without attending the Annual Meeting.
If you are a stockholder of record, you can vote by proxy:
•
by the Internet (www.proxyvote.com) — 24 hours a day, seven days a week, until 11:59 P.M. Eastern Time on the day before the Annual Meeting (have your proxy card in hand when you visit the website and follow the instructions to obtain your records and to create an electronic voting instruction form);
​
•
by telephone (1-800-690-6903) — use any touch-tone telephone to transmit your voting instructions in accordance with the instructions on your proxy card, until 11:59 P.M. Eastern Time on the day before the Annual Meeting (have your proxy card in hand when you call and follow the instructions); or
​
•
by mail — mark, sign and date your proxy card and return it in the postage-paid envelope we have provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717.
​
If you hold shares beneficially in “street name,” you should follow the voting instructions provided by your bank, broker, or other nominee.
If you vote by proxy, the individuals named on the proxy card, or your “proxies,” will vote in the manner you indicate. If you submit a proxy but do not indicate any voting instructions, your votes will be voted in accordance with the Board’s recommendations. Voting by proxy will not affect your right to participate in the 2026 Annual Meeting.
For additional information on voting procedures, see the section titled “The Annual Meeting.”
What stockholder vote is required for the approval of each proposal at the Annual Meeting?
The Reverse Split Proposal, the Equity Plan Amendment Proposal, the Nasdaq Proposal, the Say on Pay Proposal, the Auditor Ratification Proposal and the Adjournment Proposal require the affirmative vote of the majority of the votes cast by stockholders present or represented by proxy and entitled to vote on the matter at the Annual Meeting.
The Director Election Proposal requires the affirmative vote of a plurality of votes cast by stockholders present or represented by proxy and entitled to vote on the matter at the Annual Meeting.
 
5

Table of Contents
 
What is a “broker non-vote?”
Under the rules of the New York Stock Exchange (“NYSE”) that govern voting by brokers that are NYSE members, which apply regardless of the exchange on which our Common Stock is listed, banks, brokers and other nominees may use their discretion to vote “uninstructed” shares (i.e., shares of record held by banks, brokers or other nominees, but with respect to which the beneficial owner of such shares has not provided instructions on how to vote on a particular proposal) with respect to matters that are considered to be “routine,” but not with respect to “non-routine” matters. The Reverse Split Proposal and the Auditor Ratification Proposal are expected to be considered “routine” matters. However, the routine or non-routine classification is determined by the NYSE, not by the Company, and beneficial owners are encouraged to provide voting instructions in all events to ensure that their shares are voted in accordance with their wishes. If either proposal is determined by the NYSE to be non-routine, brokers will not be permitted to vote uninstructed shares on that proposal, and any resulting broker non-votes will have no effect on the outcome because they will not be counted as votes cast.
A “broker non-vote” occurs on a proposal when (i) a broker, bank or other nominee has discretionary authority to vote on one or more proposals to be voted on at a meeting of stockholders, but is not permitted to vote on other proposals without instructions from the beneficial owner of the shares, and (ii) the beneficial owner fails to provide the broker, bank or other nominee with such instructions. Brokers generally have discretionary authority to vote on the routine Reverse Split Proposal and Auditor Ratification Proposal, so no broker non-votes are expected on those proposals; broker non-votes may occur on the non-routine proposals.
What will happen if I fail to vote or abstain from voting on each proposal at the Annual Meeting?
An abstention represents a stockholder’s affirmative choice to decline to vote on a proposal. If a stockholder indicates on its proxy card that it wishes to abstain from voting its shares, or if a broker, bank or other nominee holding its customers’ shares of record causes abstentions to be recorded for shares, these shares will be considered present and entitled to vote at the annual meeting. Under Delaware law and our Amended and Restated Bylaws (our “Bylaws”), abstentions, if any, with respect to the Director Election Proposal, the Reverse Split Proposal, the Equity Plan Amendment Proposal, the Nasdaq Proposal, the Say on Pay Proposal, the Auditor Ratification Proposal, and the Adjournment Proposal are not counted as votes cast on the matter and therefore will not affect the outcome of such proposal. Abstentions will be counted for purposes of determining the presence or absence of a quorum at the Annual Meeting.
What is the difference between holding shares as a stockholder of record and as a beneficial owner of shares held in “street name”?
If your shares of Common Stock are registered directly in your name with the transfer agent of GridAI, you are considered the stockholder of record with respect to those shares. As the stockholder of record, you have the right to vote directly at the Annual Meeting. You may also grant a proxy directly to GridAI, or to a third party to vote your shares at the Annual Meeting.
If your shares of Common Stock are held by brokerage firm, bank, dealer or other similar organization, trustee, or nominee, you are considered the beneficial owner of shares held in “street name.” Your brokerage firm, bank, dealer or other similar organization, trustee, or nominee will send you, as the beneficial owner, a package describing the procedures for voting your shares. You should follow the instructions provided by your brokerage firm, bank, dealer or other similar organization, trustee, or nominee to vote your shares.
If my shares of Common Stock are held in “street name” by my brokerage firm, bank, dealer or other similar organization, trustee, or nominee, will my brokerage firm, bank, dealer or other similar organization, trustee, or nominee automatically vote those shares for me?
Not on all proposals. Your bank, broker or other nominee may vote your shares on the Reverse Split Proposal and the Auditor Ratification Proposal, which are considered routine matters, but will only be permitted to vote your shares on the other proposals if you provide voting instructions. You should follow the procedures provided by your bank, broker or other nominee regarding the voting of your shares. Banks, brokers and other nominees who hold shares of Common Stock in “street name” for their customers have
 
6

Table of Contents
 
authority to vote on “routine” proposals when they have not received instructions from beneficial owners. However, banks, brokers and other nominees are prohibited from exercising their voting discretion with respect to non-routine matters, which include all proposals other than the Reverse Split Proposal and the Auditor Ratification Proposal. As a result, absent specific instructions from the beneficial owner of such shares, banks, brokers and other nominees are not empowered to vote such shares on such proposals.
What should I do if I receive more than one set of voting materials for the Annual Meeting?
If you hold shares of Common Stock in “street name” and also directly in your name as a stockholder of record or otherwise, or if you hold shares of Common Stock in more than one brokerage account, you may receive more than one set of voting materials relating to the Annual Meeting.
Record Holders.   For shares held directly, please vote by proxy over the internet or by telephone, using the instructions included with the accompanying proxy card, or promptly complete your proxy card and return it in the enclosed postage-paid envelope, in order to ensure that all of your shares of Common Stock are voted.
Shares Held in “Street Name.”   For shares held in “street name” through a bank, broker or other nominee, you should follow the procedures provided by bank, broker or other nominee to submit a proxy or vote your shares.
If a stockholder gives a proxy, how are the shares of Common Stock voted?
Regardless of the method you choose to vote, the individuals named on the enclosed proxy card will vote your shares of Common Stock in the way that you indicate. For the Director Election Proposal, you may vote “FOR” all or any of the director nominees or “WITHHOLD” authority to vote for all or any of the director nominees. For each item before the Annual Meeting, you may specify whether your shares of Common Stock should be voted “FOR” or “AGAINST,” or “ABSTAIN” from voting.
For more information regarding how your shares will be voted if you properly sign, date and return a proxy card, but do not indicate how your Common Stock should be voted, see below “— How will my shares be voted if I return a blank proxy?”
How will my shares be voted if I return a blank proxy?
If you sign, date and return your proxy and do not indicate how you want your shares of Common Stock to be voted, then your shares of Common Stock will be voted in accordance with the recommendation of the GridAI Board, “FOR” each of the proposals.
Can I change my vote after I have submitted my proxy?
Any GridAI stockholder giving a proxy has the right to revoke the proxy and change their vote before the proxy is voted at the Annual Meeting by doing any of the following:
•
subsequently submitting a new proxy for the Annual Meeting that is received by the deadline specified on the accompanying proxy card;
​
•
giving written notice of your revocation to GridAI’s Chief Financial Officer; or
​
•
attending and voting at the Annual Meeting. Note that a proxy will not be revoked if you attend, but do not vote at, the Annual Meeting.
​
Execution or revocation of a proxy will not in any way affect your right to attend and vote at the Annual Meeting. See the section titled “The Annual Meeting — Revocability of Proxies.”
If I hold my shares in “street name,” can I change my voting instructions after I have submitted voting instructions to my bank, broker or other nominee?
If your shares are held in the name of a bank, broker or other nominee and you previously provided voting instructions to your bank, broker or other nominee, you should follow the instructions provided by your bank, broker or other nominee to revoke or change your voting instructions.
 
7

Table of Contents
 
Where can I find the voting results of the Annual Meeting?
The preliminary voting results for the Annual Meeting are expected to be announced at the Annual Meeting. GridAI will file the final voting results with the SEC on a Current Report on Form 8-K within four business days after the Annual Meeting.
If the final voting results have not yet been certified, GridAI will file the preliminary results and then amend the Form 8-K within four business days after certification of the final voting results.
Do GridAI stockholders have dissenters’ or appraisal rights?
The stockholders of GridAI are not entitled to appraisal rights in connection with the proposals at the Annual Meeting under Delaware law.
What happens if I sell my shares of Common Stock after the record date but before the Annual Meeting?
The record date is earlier than the date of the Annual Meeting. If you sell or otherwise transfer your shares of Common Stock after the record date but before the Annual Meeting, you will, unless special arrangements are made, retain your right to vote at the Annual Meeting.
Who will solicit and pay the cost of soliciting proxies?
GridAI may reimburse banks, brokers and other custodians, nominees and fiduciaries or their respective agents for their expenses in forwarding proxy materials to beneficial owners of Common Stock. GridAI directors, officers and employees also may solicit proxies by telephone, by electronic means or in person. They will not be paid any additional amounts for soliciting proxies.
What should I do now?
You should read this proxy statement carefully and in its entirety, including the annexes. Then, you may vote by proxy over the internet or by telephone, using the instructions included with the accompanying proxy card, or promptly complete your proxy card and return it in the enclosed postage-paid envelope, so that your shares will be voted in accordance with your instructions.
Whom do I call if I have questions about the Annual Meeting?
If you have questions about the Annual Meeting, or desire additional copies of this proxy statement or additional proxies, you may contact GridAI’s Investor Relations Department at Jason Assad (IR@gridaipower.com) or by calling (678) 570-6791.
 
8

Table of Contents​
 
THE ANNUAL MEETING
This proxy statement is being provided to GridAI stockholders in connection with the solicitation of proxies by the GridAI Board for use at the Annual Meeting and at any adjournments or postponements thereof. GridAI stockholders are encouraged to read this entire document carefully.
Date, Time and Place of the Annual Meeting
The Annual Meeting is scheduled to be held on December [  ], 2026, beginning at [       A./P.M.] Eastern Time.
The Annual Meeting will be held solely by remote communication, in a virtual meeting format. You will be able to attend and participate in the Annual Meeting online, vote your shares electronically and submit your questions during the meeting by visiting www.virtualshareholdermeeting.com/GRDX2026 at the meeting date and time described in the accompanying proxy statement. You will not be able to attend the 2026 Annual Meeting in person. You will need the 16-digit control number on your proxy card to participate in the Annual Meeting.
Voting
The specific proposals to be considered and acted upon at our Annual Meeting are each described in this proxy statement. Only stockholders holding shares of Common Stock as of the close of business on the Record Date are entitled to notice of and to vote at the Annual Meeting. As of the Record Date, there were8,540,172 shares of Common Stock issued and outstanding. Holders of record of shares of Common Stock have the right to vote on all matters brought before the Annual Meeting. Each holder of record of our Common Stock is entitled to one vote per share of Common Stock on each matter to be acted upon at the Annual Meeting.
Matters to be Considered at the Annual Meeting
Proposal No.
​ ​
Required Vote for Approval
​
1.
​ ​ Election of Directors (the “Director Election Proposal”). The four director nominees who receive the highest number of affirmative votes cast by shares of our Common Stock present or represented by proxy and entitled to vote at the Annual Meeting will be elected. ​
2. ​ ​ Adoption and approval of an amendment to our Amended and Restated Certificate of Incorporation, as amended (the “Charter”), to effect a reverse stock split of our issued and outstanding shares of Common Stock, at a specific ratio, ranging from 1:2 to 1:20, at any time prior to the one-year anniversary date of the Annual Meeting, with the exact ratio to be determined by the Board without further approval or authorization of our stockholders (the “Reverse Split Proposal”). This proposal requires the affirmative (“FOR”) vote of a majority of votes cast by shares of our Common Stock present or represented by proxy and entitled to vote at the Annual Meeting. Shares that are not represented at the Annual Meeting, abstentions and broker non-votes, if any, with respect to this proposal are not counted as votes cast and will not affect the outcome of the voting on this proposal. ​
3. ​ ​ To approve an amendment to the Company’s 2020 Omnibus Equity Incentive Plan (the “Plan”) to: (i) increase the number of shares of Common Stock authorized for issuance under the Plan from 3,801,549 to 10,000,000, including an increase in the number of shares available for grants of incentive stock options (“ISOs”) from 357 to 10,000,000; and (ii) increase the maximum number of shares that may be granted to any non-employee director in a calendar year from 250,000 to 6,500,000 (the “Equity Plan Amendment Proposal”). This proposal requires the affirmative (“FOR”) vote of a majority of votes cast by shares of our Common Stock present or represented by proxy and entitled to vote at the Annual Meeting. Shares that are not represented at the Annual Meeting, abstentions and broker non-votes, if any, with respect to this proposal are not counted as votes cast and will not affect the outcome of such proposal. ​
 
9

Table of Contents
 
Proposal No.
​ ​
Required Vote for Approval
​
4. ​ ​ To approve the issuance of up to 1,520,000 shares of Common Stock upon the exercise of warrants issued or issuable pursuant to that certain Securities Purchase Agreement dated October 17, 2025, as amended to date, by and among the Company and the investors party thereto, as required by and in accordance with Nasdaq Listing Rule 5635(d) (the “Nasdaq Proposal”). This proposal requires the affirmative (“FOR”) vote of a majority of votes cast by shares of our Common Stock present or represented by proxy and entitled to vote at the Annual Meeting. Shares that are not represented at the Annual Meeting, abstentions and broker non-votes, if any, with respect to this proposal are not counted as votes cast and will not affect the outcome of the voting on this proposal. ​
5.
​ ​ Approval, on an advisory basis, of the executive compensation of the Company’s named executive officers as described in this proxy statement (the “Say on Pay Proposal”). This proposal requires the affirmative (“FOR”) vote of a majority of votes cast by shares of our Common Stock present or represented by proxy and entitled to vote at the Annual Meeting. Shares that are not represented at the Annual Meeting, abstentions and broker non-votes, if any, with respect to this proposal are not counted as votes cast and will not affect the outcome of the voting on this proposal. ​
6.
​ ​ Ratification of Macias Gini & O’Connell LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026 (the “Auditor Ratification Proposal”). To approve the ratification of Macias Gini & O’Connell LLP as our independent registered public accounting firm for the current fiscal year. This proposal requires the affirmative (“FOR”) vote of a majority of votes cast by shares of our Common Stock present or represented by proxy and entitled to vote at the Annual Meeting. Shares that are not represented at the Annual Meeting and abstentions, if any, with respect to this proposal are not counted as votes cast and will not affect the outcome of the voting on this proposal. ​
7.
​ ​ Approval of the Adjournment of the Annual Meeting to the Extent There Are Insufficient Proxies at the Annual Meeting to Approve Any One or More of the Foregoing Proposals. To approve the adjournment of the Annual Meeting in the event that the number of shares of Common Stock present or represented by proxy at the Annual Meeting and voting “FOR” the adoption of any one or more of the foregoing proposals are insufficient to approve any proposal. This proposal requires the affirmative (“FOR”) vote of a majority of votes cast by shares of our Common Stock present or represented by proxy and entitled to vote at the Annual Meeting. Shares that are not represented at the Annual Meeting, abstentions and broker non-votes, if any, with respect to this proposal are not counted as votes cast and will not affect the outcome of the voting on this proposal. ​
Recommendation of the GridAI Board
After careful consideration, the GridAI Board unanimously recommends that GridAI’s stockholders vote “FOR” each of the proposals.
Quorum; Abstentions and Broker Non-Votes
A quorum of GridAI stockholders is necessary to conduct business at the Annual Meeting. In order for any business to be conducted at the Annual Meeting, both (i) the holders of one-third of the voting power of the shares of the capital stock of the Company issued and outstanding and entitled to vote at the Annual Meeting, and (ii) the holders of at least one-third of the shares of Common Stock issued and outstanding and entitled to vote at the Annual Meeting must be represented at the Annual Meeting, either in person, by means of remote communication in a manner, if any, authorized by the Board in its sole discretion, or represented by proxy. Shares of Common Stock present at the Annual Meeting or represented by proxy and entitled to vote, including shares for which a GridAI stockholder directs an “abstention” from voting, will be counted for purposes of determining a quorum. Since the Reverse Split Proposal and the Auditor Ratification Proposal are considered routine matters, shares held in “street name” through a broker, bank or other nominee will be counted as present for the purpose of determining the existence of a quorum if such broker, bank or other nominee does not have instructions to vote on such proposals.
 
10

Table of Contents
 
If a quorum is not present, the Annual Meeting will be adjourned or postponed until the holders of the number of shares of Common Stock required to constitute a quorum attend.
Under Nasdaq rules, banks, brokers or other nominees who hold shares in “street name” on behalf of the beneficial owner of such shares have the authority to vote such shares in their discretion on certain “routine” proposals when they have not received voting instructions from the beneficial owners. However, banks, brokers or other nominees are not allowed under Nasdaq rules to exercise their voting discretion with respect to matters that are “non-routine.” This can result in a “broker non-vote,” which occurs on a proposal when (i) a bank, broker or other nominee has discretionary authority to vote on one or more “routine” proposals to be voted on at a meeting of stockholders, but is not permitted to vote on other “non-routine” proposals without instructions from the beneficial owner of the shares, and (ii) the beneficial owner fails to provide the bank, broker or other nominee with voting instructions on a “non-routine” matter.
The Reverse Split Proposal and the Auditor Ratification Proposal are considered “routine” matters, and banks, brokers or other nominees may have discretionary authority to vote on those proposals without instructions from beneficial owners. Accordingly, no broker non-votes are expected on those Proposals. The other proposals are considered “non-routine” matters, and banks, brokers or other nominees will not have discretionary authority to vote on those matters before the Annual Meeting unless they have received voting instructions from the beneficial owners. Broker non-votes may therefore occur with respect to the non-routine proposals. If you hold your shares of Common Stock in “street name,” your shares will not be voted on a non-routine matter unless you affirmatively instruct your bank, broker or other nominee how to vote your shares in accordance with the voting instructions provided by your bank, broker or other nominee. It is therefore critical that you cast your vote by instructing your bank, broker or other nominee on how to vote.
Vote of GridAI Directors and Executive Officers
As of the Record Date, GridAI directors and executive officers and their affiliates beneficially owned and were entitled to vote in the aggregate 975,000 shares of Common Stock, which represented approximately 11.4% of the Common Stock issued and outstanding on the record date. GridAI currently expects that all GridAI directors and executive officers will vote their shares “FOR” each of the proposals. See the section titled “Interests of Directors and Executive Officers in the Proposals” in this proxy statement.
Methods of Voting
Stockholders of Record
If you are a GridAI stockholder of record, you may vote at the Annual Meeting by proxy over the internet or telephone or by mail, or by attending and voting at the Annual Meeting, as described below.
•
Via the Internet (www.proxyvote.com): Use the Internet to transmit your voting instructions. Vote by 11:59 P.M. Eastern Time on December [  ], 2026. Have your proxy card in hand when you access the web site and follow the instructions to obtain your records and to create an electronic voting instruction form.
​
•
By Telephone (1-800-690-6903): Use any touch-tone telephone to transmit your voting instructions. Vote by 11:59 P.M. Eastern Time on December [  ], 2026. Have your proxy card in hand when you call and then follow the instructions.
​
•
By Mail:   Mark, sign and date your proxy card and return it in the postage-paid envelope we have provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717.
​
•
During the Annual Meeting (www.virtualshareholdermeeting.com/GRDX2026): You may attend the Annual Meeting via the Internet and vote during the meeting. Have the information that is printed in the box marked by the arrow on your proxy card available and follow the instructions.
​
Unless revoked, all duly executed proxies representing shares of Common Stock entitled to vote at the Annual Meeting will be voted at the Annual Meeting and, where a choice has been specified on the proxy
 
11

Table of Contents
 
card, will be voted in accordance with such specification. If you submit an executed proxy without providing instructions for any proposal, your shares will be voted “FOR” each of the proposals.
Beneficial (Street Name) Stockholders
If you hold your shares of Common Stock through a bank, broker or other nominee in “street name” instead of as a registered holder, you must follow the voting instructions provided by your bank, broker or other nominee in order to vote your shares. Your voting instructions must be received by your bank, broker or other nominee prior to the deadline set forth in the information from your bank, broker or other nominee on how to submit voting instructions. If you do not provide voting instructions to your bank, broker or other nominee for a proposal, your shares of Common Stock will not be voted on any proposals other than the Reverse Split Proposal and the Auditor Ratification Proposal because your bank, broker or other nominee does not have discretionary authority to vote on such proposals. See the section titled “The Annual Meeting —  Quorum; Abstentions and Broker Non-Votes.”
Attending the Annual Meeting
If you wish to attend the Annual Meeting, you must (i) be a GridAI stockholder of record at the close of business on October 20, 2026, the record date, (ii) hold your shares of Common Stock beneficially in the name of a broker, bank or other nominee as of the record date or (iii) hold a valid proxy for the Annual Meeting.
If you plan to attend and vote at the Annual Meeting, GridAI still encourages you to vote in advance by the internet, telephone or mail so that your vote will be counted even if you later decide not to attend the Annual Meeting. Voting your proxy by the internet, telephone or mail will not limit your right to attend and vote at the Annual Meeting if you later decide to do so.
Revocability of Proxies
Any GridAI stockholder giving a proxy has the right to revoke it at any time before the proxy is voted at the Annual Meeting. If you are a GridAI stockholder of record, you may revoke your proxy by any one of the following actions:
•
by sending a signed written notice of revocation to GridAI’s Chief Financial Officer, provided such notice is received no later than the close of business on the day before the Annual Meeting;
​
•
by voting again over the internet or telephone as instructed on your proxy card before the closing of the voting facilities at 11:59 P.M., Eastern Time, on the day before the Annual Meeting;
​
•
by submitting a properly signed and dated proxy card with a later date that is received by GridAI’s Chief Financial Officer no later than the close of business the day before the Annual Meeting; or
​
•
by attending the Annual Meeting and requesting that your proxy be revoked, as described above.
​
Only your last submitted proxy will be considered.
Execution or revocation of a proxy will not in any way affect a GridAI stockholder’s right to attend and vote at the Annual Meeting.
Written notices of revocation and other communications relating to the revocation of proxies should be addressed to:
GridAI Technologies Corp.
Attention: Chief Financial Officer
433 Plaza Real, Suite 275,
Boca Raton, Florida 33432
If your shares of Common Stock are held in “street name” and you previously provided voting instructions to your broker, bank or other nominee, you should follow the instructions provided by your broker, bank or other nominee to revoke or change your voting instructions. You may also change your vote
 
12

Table of Contents
 
by obtaining your specific control number and instructions from your bank, broker or other nominee and voting your shares at the Annual Meeting.
Proxy Solicitation Costs
GridAI is soliciting proxies on behalf of the GridAI Board. GridAI will bear the entire cost of soliciting proxies from GridAI stockholders. Proxies may be solicited on behalf of GridAI or by GridAI directors, officers and other employees in person or by mail, telephone, facsimile, messenger, the internet or other means of communication, including electronic communication. GridAI directors, officers and employees will not be paid any additional amounts for their services or solicitation in this regard.
GridAI will request that banks, brokers and other nominee record holders send proxies and proxy material to the beneficial owners of GridAI Common Stock and secure their voting instructions, if necessary. GridAI may be required to reimburse those banks, brokers and other nominees on request for their reasonable expenses in taking those actions.
Householding
SEC rules permit companies and intermediaries such as brokers to satisfy delivery requirements for proxy statements with respect to two or more stockholders sharing the same address by delivering a single proxy statement addressed to those stockholders. This process, which is commonly referred to as “householding,” provides cost savings for companies. GridAI has previously adopted householding for GridAI stockholders of record. As a result, GridAI stockholders with the same address and last name may receive only one copy of this proxy statement. Registered GridAI stockholders (those who hold shares of Common Stock directly in their name with GridAI’s transfer agent) may opt out of householding and receive a separate proxy statement or other proxy materials by sending a written request to GridAI at the address below.
Some brokers household proxy materials, delivering a single proxy statement to multiple GridAI stockholders sharing an address unless contrary instructions have been received from the affected stockholders. Once you have received notice from your broker that they will be householding materials to your address, householding will continue until you are notified otherwise or until you revoke your consent. If, at any time, you no longer wish to participate in householding and would prefer to receive a separate proxy statement, or if you are receiving multiple copies of these documents and you wish to request that future deliveries be limited to a single copy, please notify your broker.
GridAI will promptly deliver a copy of this proxy statement to any GridAI stockholder who only received one copy of these materials due to householding upon request in writing to: GridAI Technologies Corp., Attention: Chief Financial Officer at 433 Plaza Real, Suite 275, Boca Raton, Florida 33432 or by calling (416) 312-0442.
Adjournments
If a quorum is present at the Annual Meeting but there are insufficient votes at the time of the Annual Meeting to approve the Director Election Proposal, the Reverse Split Proposal, the Equity Plan Amendment Proposal, the Nasdaq Proposal, the Say on Pay Proposal or the Auditor Ratification Proposal, then GridAI stockholders may be asked to vote on the Adjournment Proposal. If a quorum is not present, the presiding officer may adjourn the Annual Meeting, from time to time, without notice other than announcement at the meeting of the hour, date and place, if any, to which the meeting is adjourned, and the means of remote communications, if any, by which GridAI stockholders and proxyholders may be deemed to be present in person and vote at such adjourned meeting. The presiding officer may also adjourn the meeting to another hour, date or place, even if a quorum is present.
At any subsequent reconvening of the Annual Meeting at which a quorum is present, any business may be transacted that might have been transacted at the original meeting, and all proxies will be voted in the same manner as they would have been voted at the original convening of the Annual Meeting, except for any proxies that have been effectively revoked or withdrawn prior to the time the proxy is voted at the reconvened meeting.
 
13

Table of Contents
 
No Appraisal Rights
Our stockholders have no dissenter’s or appraisal rights in connection with any of the proposals described herein.
Assistance
If you need assistance voting or completing your proxy card, or if you have questions regarding the Annual Meeting, please contact, GridAI’s Investor Relations Department at Jason Assad (IR@gridaipower.com) or by calling(678) 570-6791.
GRIDAI STOCKHOLDERS SHOULD CAREFULLY READ THIS PROXY STATEMENT IN ITS ENTIRETY FOR MORE DETAILED INFORMATION CONCERNING THE PROPOSALS.
 
14

Table of Contents​
 
PROPOSAL NO. 1: ELECTION OF DIRECTORS
General
Our Bylaws provide that the Board shall consist of one or more members, and that any newly created directorship that results from an increase in the number of directors or any vacancy on the Board will be filled solely by the affirmative vote of a majority of the directors then in office; provided that a vacancy created by the removal of a director by the stockholders may be filled by the stockholders. A director elected by the Board in the case of a newly created directorship will hold office for his or her full term until his or her successor is elected and qualified. A director elected by the Board in the case of a vacancy will hold office for the remaining term of his or her predecessor until his or her successor is elected and qualified.
Our Board currently consists of Manpreet Uppal resigned from the Board, and from each committee of the Board on which he served, effective October 19, 2026. Mr. Uppal’s resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Each of the director nominees identified below has confirmed that he is able and willing to serve as a director if elected. If any of the director nominees becomes unable or unwilling to serve, your proxy will be voted for the election of a substitute director nominee recommended by the current Board.
Upon recommendation of the independent directors, the Board has nominated Edward J. Borkowski, Jason D. Sawyer, Jack Syage and Geordan G. Pursglove, for election at the Annual Meeting, each to serve for a one-year term until the conclusion of the 2027 annual meeting of stockholders or until their successor is duly elected and qualified.
Please see “Information About Our Director Nominees” below for more information, including the background and business experience of each director nominee taken into consideration by the independent directors.
Required Vote and Recommendation
The election of directors requires the affirmative (“FOR”) vote of a plurality of votes cast by shares of our Common Stock present or represented by proxy and entitled to vote at the Annual Meeting. The four director nominees receiving the highest number of affirmative votes cast will be elected. Unless otherwise instructed on the proxy or unless authority to vote is withheld, shares represented by executed proxies will be voted “FOR” the election of each of the below director nominees. Any abstentions or broker non-votes are not counted as votes cast and will not affect the outcome of this proposal, although they will be counted for purposes of determining whether there is a quorum present.
OUR BOARD RECOMMENDS A VOTE “FOR” THE ELECTION OF
MESSRS. BORKOWSKI, SAWYER, PURSGLOVE AND DR. SYAGE
UNDER PROPOSAL ONE.
 
15

Table of Contents
 
INFORMATION ABOUT OUR DIRECTOR NOMINEES
The following section sets forth certain information regarding the nominees for election as directors. There are no family relationships among any of our directors and executive officers.
Director, Title
​ ​
Age
​
Edward J. Borkowski – Chairman
​ ​ ​ ​ 66 ​ ​
Jason D. Sawyer
​ ​ ​ ​ 54 ​ ​
Jack Syage, Ph.D
​ ​ ​ ​ 71 ​ ​
Geordan G. Pursglove
​ ​ ​ ​ 37 ​ ​
Jason D. Sawyer was appointed as a member of the Board of Directors in August 2025 and as our Chief Executive Officer in September 2025, initially as Interim Chief Executive Officer, and formally appointed Chief Executive Officer effective December 19, 2025. In his role as Chief Executive Officer, Mr. Sawyer is responsible for managing the Company’s day-to-day operations and implementing its strategic plan. Mr. Sawyer provides his services through Access Alternative Group S.A., a Bahamian venture investment and advisory firm, of which he has served as General Manager since 2004. He currently serves on the boards of NOMAD Power Solutions, Inc. (Nasdaq: NMAD), where he is a member of the Audit Committee, Greenland Mines Ltd. (Nasdaq: GRML), Perpetuals.com Ltd. (Nasdaq: PDC), where he acts as its Statutory Auditor, and The FUTR Corp. (TSX-V: FTRC). Over his more than 30-year career in alternative investments, Mr. Sawyer has advised on and deployed significant principal venture capital across software, fintech, blockchain, biotechnology, clean energy, power and BESS, natural resources, and consumer products.
Mr. Sawyer is well-qualified to serve on the Board due to his substantial experience in mergers and acquisitions, private and public investment, and in offerings of debt and equity securities.
Edward J. Borkowski joined the Board in May 2015 and served as Chairman until February 2021, when he stepped down as Chairman and became Lead Independent Director. He served in that capacity until October 2025, when he was elected Chairman. Mr. Borkowski is an accomplished executive and public company director with extensive experience in corporate finance, capital markets, strategic transactions, operational leadership, and corporate governance. His career includes senior leadership roles at global pharmaceutical and medical technology companies, as well as businesses undergoing significant growth, transformation, and restructuring. Mr. Borkowski served as Executive Vice President of TherapeuticsMD from January 2020 to October 2022. Previously, he held executive leadership positions at MiMedx Group and Concordia International; served as Chief Financial Officer and Executive Vice President of Mylan; and served as Chief Financial Officer of Aceto Corporation, Amerigen Pharmaceuticals, ConvaTec, and CareFusion. At CareFusion, he helped lead the company’s separation from Cardinal Health and establishment as an independent public company. He also served on the board of Co-Diagnostics and held senior financial positions at Pharmacia and American Home Products, later known as Wyeth. He began his career at Arthur Andersen. Mr. Borkowski earned an MBA in accounting from Rutgers University and an undergraduate degree in economics and political science from Allegheny College, where he serves as a Trustee and member of the Executive Committee.
The Board believes Mr. Borkowski’s executive leadership, financial expertise, and public company board experience qualify him to serve as a director. His experience in capital raising, complex transactions, business transformation, and financial oversight provides valuable perspective as GridAI executes its strategy and pursues growth opportunities.
Jack Syage, Ph.D. was appointed to the Board in March 2024 and serves as a member of the Audit and Compensation Committees. In this role, Dr. Syage provides oversight of the Company’s scientific strategy and audit and governance functions. Dr. Syage served as the Chief Executive Officer of ImmunogenX from July 2013 until the closing of the merger with the Company and as a member of the board of directors of ImmunogenX from January 2021 until the closing of the merger with the Company. Dr. Syage has over 30 years of experience in creating and leading the development of innovative technologies in the analytical instrumentation field. He is regarded as a leading expert in mass spectrometry and trace chemical detection. Dr. Syage served as Chief Executive Officer and co-founder of ImmunogenX, a global leader in the
 
16

Table of Contents
 
development of treatments for celiac disease, which developed latiglutenase with the Company. Previously he founded Syagen Technology, Inc. and led its growth culminating in its successful acquisition by French multinational Safran S.A. in 2011. Dr. Syage currently serves on the boards of directors of Advanced Telesensors, Analytical Detection, and Appellation Ventures. He has published over 140 papers, delivered about 100 invited talks, has over 30 U.S. patents issued or pending. His honorary positions include Fellow of the American Physical Society, Visiting Professor at UC Irvine, Visiting Professor at the Université de Paris-Sud, and Editorial Board member of the Journal of Physical Chemistry. He received BA and PhD degrees from Hamilton College and Brown University, respectively, and completed a postdoctoral fellowship at Caltech under Nobel Laureate Ahmed Zewail.
Dr. Syage is well qualified to serve on the Board due to his over 30 years of executive leadership as a founder and CEO, his extensive governance experience across public and private boards, and his experience with M&A transactions and commercializing scientific technologies.
Geordan G. Pursglove was appointed to the Board in August 2025 and serves as a member of the Audit Committee and Compensation Committee. In this role, Mr. Pursglove provides oversight of the Company’s strategic direction and corporate governance. From June 16, 2025 until November 9, 2026, Mr. Pursglove served as Chief Executive Officer and Chairman of NOMAD Power Solutions, Inc. (Nasdaq: NMAD), formerly Lixte Biotechnology Holdings, Inc. On November 9, 2026, NOMAD announced that he had stepped down from those roles and would remain as a consultant to support the transition. From January 30, 2026 to present, he has served as Chief Executive Officer and Chairman of Powell Max Limited (Nasdaq: PMAX). From April 23, 2015 to present, he has served as Managing Director of The 2GP Group LLC, an investment and advisory firm. Previously, Mr. Pursglove played a pivotal role at SemiCab Holdings, the primary subsidiary of Algorhythm Holdings, Inc. (Nasdaq: RIME), where he helped drive its strategic merger and led capital-raising efforts. He brings extensive expertise in capital markets, mergers and acquisitions, corporate governance, and scaling public companies. Mr. Pursglove has a proven track record of creating long-term value at the intersection of innovation, finance, and execution.
Mr. Pursglove is well qualified to serve on the board due to his specialization in capital allocation and corporate finance.
Involvement in Certain Legal Proceedings
None
Non-Executive Director Compensation
Effective October 1, 2022, following an independent review of external benchmarks, our Board adopted an updated Non-Executive Director Compensation Policy under which each of our non-executive directors is entitled to receive the following cash compensation for their service on the Board (paid quarterly): (i) an annual retainer of $60,000, (ii) the lead independent director an annual retainer of $20,000, (iii) the chair of the Audit Committee is entitled to receive an additional annual retainer in the amount of $15,000, (iv) each non-chairperson member of the Audit Committee is entitled to receive an additional annual retainer in the amount of $7,500, (v) the chair of the Compensation Committee is entitled to receive an additional annual retainer in the amount of $12,500, (vi) each non-chairperson member of the Compensation Committee is entitled to receive an additional annual retainer in the amount of $6,000, (vii) the chair of the Corporate Governance and Nominating Committee is entitled to receive an additional annual retainer in the amount of $10,000, and (viii) each non-chairperson member of the Corporate Governance and Nominating Committee is entitled to receive an additional annual retainer in the amount of $5,000. Additionally, under this policy, each of our non-executive directors is entitled to receive an annual grant, effective on the date of the Company’s annual meeting of stockholders, of restricted stock unit awards for their service on the Board equivalent to $75,000, which vests in equal quarterly installments.
Our Board will review the Non-Executive Director Compensation Policy on an annual basis prior to September 1 of each year.
On October 26, 2026, the Board approved the following equity awards to non-employee directors under the Plan, subject to share availability and applicable individual limits under the Plan: (i) to
 
17

Table of Contents
 
Mr. Borkowski, 100,000 fully vested restricted stock units and an immediately exercisable option to purchase 100,000 shares of Common Stock at an exercise price of $5.55 per share, equal to the Nasdaq closing price of our Common Stock on October 26, 2026; (ii) to Dr. Syage, 40,000 fully vested restricted stock units; and (iii) to Mr. Pursglove, 100,000 fully vested restricted stock units. These awards are subject to share availability under the Plan and the applicable award agreements. In addition, on October 26, 2026, the Company issued 17,079 shares of Common Stock to Mr. Borkowski in settlement of $94,790.77 of accrued and unpaid director fees. These 2026 awards are not reflected in the 2025 Director Compensation Table below and will be reported in next year’s proxy statement. Mr. Borkowski’s Form 4 filed October 28, 2026 reported the option as immediately exercisable and the 17,079-share settlement of accrued director fees.
The following table provides information regarding compensation paid to the directors for their services as directors for the year ended December 31, 2025. Information regarding compensation paid to Mr. Sawyer in his capacity as Chief Executive Officer is reflected in the Summary Compensation Table under “Executive Compensation.”
Non-Executive Directors
​ ​
Fees Earned or
Paid in Cash
(1)
​ ​
Stock
Award
(2)
​ ​
Option
Award
​ ​
All Other
Compensation
​ ​
Total
​
Edward J. Borkowski
​ ​ ​ $ 70,841 ​ ​ ​ ​ $ 93,200 ​ ​ ​ ​ $    — ​ ​ ​ ​ $    — ​ ​ ​ ​ $ 164,041 ​ ​
Manpreet Uppal(3)
​ ​ ​ $ 40,787 ​ ​ ​ ​ $ 93,200 ​ ​ ​ ​ $ — ​ ​ ​ ​ $ — ​ ​ ​ ​ $ 133,987 ​ ​
Geordan G. Pursglove
​ ​ ​ $ 18,125 ​ ​ ​ ​ $ 93,200 ​ ​ ​ ​ $ — ​ ​ ​ ​ $ — ​ ​ ​ ​ $ 111,325 ​ ​
Eric Corbett(3)
​ ​ ​ $ 33,915 ​ ​ ​ ​ $ — ​ ​ ​ ​ $ — ​ ​ ​ ​ $ — ​ ​ ​ ​ $ 33,915 ​ ​
Jason Sawyer
​ ​ ​ $ 12,500 ​ ​ ​ ​ $ — ​ ​ ​ ​ $ — ​ ​ ​ ​ $ — ​ ​ ​ ​ $ 12,500 ​ ​
Jack Syage
​ ​ ​ $ 26,518 ​ ​ ​ ​ $ 93,200 ​ ​ ​ ​ $ — ​ ​ ​ ​ $ — ​ ​ ​ ​ $ 119,718 ​ ​
​
(1)
Represents cash compensation earned for board service during the year ended December 31, 2025.
​
(2)
Represents the aggregate grant date fair value of restricted stock units granted to non-employee directors, determined in accordance with ASC Topic 718. Although the awards are dated January 1, 2026, they were approved in December 2025 and are considered granted as of December 31, 2025.
​
(3)
Manpreet Uppal served as a member of the Board of Directors from February 2025 until his resignation effective October 19, 2026.
​
(4)
Eric Corbett served as a member of the Board of Directors from February 2025 until his departure in September 2025.
​
 
18

Table of Contents
 
CORPORATE GOVERNANCE AND BOARD MATTERS
Director Independence
The Board has determined that all of its members, other than Mr. Sawyer, our Chief Executive Officer, are “independent” within the meaning of Nasdaq Listing Rule 5605(a)(2) under the rules of Nasdaq, and the SEC rules regarding independence. In making these determinations, the Board considered Dr. Syage’s prior service as Chief Executive Officer of ImmunogenX, and the transactions described under “Related Party Transactions,” including the Syage Note, the Rescission Agreement and the Settlement Agreement, and, with respect to Mr. Pursglove, that Ms. Skowron, our Interim Chief Financial Officer, serves as Fractional Chief Financial Officer of Powell Max Limited, of which Mr. Pursglove is Chief Executive Officer and Chairman, and that Mr. Sawyer serves on the board of NOMAD Power Solutions, Inc., where Mr. Pursglove served as Chief Executive Officer until November 9, 2026, and determined that such relationships do not interfere with the exercise of independent judgment in carrying out the responsibilities of a director.
Director Nomination Process
On November 13, 2025, the Board of Directors dissolved the Nominating and Corporate Governance Committee. Following the dissolution of that committee, the full Board assumed responsibility for identifying qualified individuals to become members of the Board, determining the composition of the Board, monitoring the effectiveness of the Board, and overseeing corporate governance matters.
In considering director candidates, the Board first considers those current members of the Board who are willing to continue in service. Current members of the Board with skills and experience relevant to our business and who are willing to continue their service as directors are considered for re-election, balancing the value of continuity of service by existing Board members with the benefit of obtaining new perspectives. Director nominees are selected, or recommended for the Board’s selection, by a majority of the Board’s independent directors in a vote in which only independent directors participate, as required by Nasdaq Listing Rule 5605(e).
Although we do not maintain a formal diversity policy, in considering the suitability of director nominees, the Board considers such factors as it deems appropriate to develop a Board and committees that are diverse in background and experience and comprised of qualified and experienced individuals. These factors may include sound judgment, knowledge, skill, diversity, integrity, business and financial experience, experience with public companies, corporate governance, capital markets, accounting and financial reporting, regulatory and legal compliance, strategic transactions, technology, operations, and the relevance of a candidate’s experience to the needs of the Company and the experience of other Board members. The Board also considers the benefit of continuity together with the periodic addition of new perspectives.
Nominations of persons for election to the Board may be made at an annual meeting of stockholders only (a) pursuant to the Company’s notice of meeting, (b) by or at the direction of the Board or any committee thereof, or (c) by any stockholder of the Company who was a stockholder of record of the Company at the time the notice is delivered by such stockholder to the Secretary of the Company, who is entitled to vote at the meeting upon such election of directors or upon such other business, as the case may be, and who complies with the notice procedures set forth in the Company’s bylaws.
For any nominations to be properly brought before an annual meeting by a stockholder, the stockholder must have given timely notice, which must be delivered to the Secretary of the Company at the Company’s principal executive offices not later than the close of business on the 90th day, nor earlier than the close of business on the 120th day, prior to the first anniversary of the preceding year’s annual meeting; provided, however, that in the event that the date of the annual meeting is more than 30 days before or more than 70 days after such anniversary date, notice by the stockholder must be so delivered not earlier than the close of business on the 120th day prior to such annual meeting and not later than the close of business on the later of the 90th day prior to such annual meeting or the 10th day following the day on which public announcement of the date of such meeting is first made by the Company. In no event shall the public announcement of an adjournment, postponement or recess of an annual meeting commence a new time period or extend any time period for the giving of a stockholder’s notice as described above. The number of nominees a stockholder may nominate for election at the annual meeting, or in the case of a stockholder giving notice on behalf of
 
19

Table of Contents
 
a beneficial owner, the number of nominees a stockholder may nominate for election at the annual meeting on behalf of such beneficial owner, shall not exceed the number of directors to be elected at such annual meeting.
To be in proper form, such stockholder’s notice shall set forth: (a) as to each person whom the stockholder proposes to nominate for election as a director, (i) the name, age, business and residence address, and principal occupation or employment of the nominee, (ii) all other information relating to such nominee that is required to be disclosed in solicitations of proxies for election of directors in an election contest, or is otherwise required, in each case pursuant to Section 14(a) of the Exchange Act and the rules and regulations promulgated thereunder, (iii) a reasonably detailed description of any compensatory, payment or other financial agreement, arrangement or understanding that such nominee has with any other person or entity other than the Company, including the amount of any payment or payments received or receivable thereunder, in each case in connection with candidacy or service as a director of the Company, (iv) such person’s written consent to being named in the Company’s proxy statement and associated proxy card as a nominee of the stockholder and to serving as a director if elected, and (v) all information with respect to such nominee that would be required to be set forth in a stockholder’s notice if such nominee were the stockholder giving notice hereunder, and (b) as to the stockholder giving the notice and the beneficial owner, if any, on whose behalf the nomination or proposal is made, (i) the name and address of such stockholder, as they appear on the Company’s books, and of such beneficial owner, (ii) the class or series and number of shares of capital stock of the Company which are, directly or indirectly, owned beneficially, within the meaning of Rule 13d-3 under the Exchange Act, or of record by such stockholder and such beneficial owner, (iii) a description of any agreement, arrangement or understanding with respect to the nomination between or among such stockholder and or such beneficial owner, any of their respective affiliates or associates, and any others acting in concert with any of the foregoing, including the nominee, (iv) a description of any agreement, arrangement or understanding, including any derivative or short positions, profit interests, options, warrants, convertible securities, stock appreciation or similar rights, hedging transactions, and borrowed or loaned shares, that has been entered into as of the date of the stockholder’s notice by, or on behalf of, such stockholder and such beneficial owner, whether or not such instrument or right shall be subject to settlement in underlying shares of capital stock of the Company, the effect or intent of which is to mitigate loss to, manage risk or benefit from share price changes for, or increase or decrease the voting power of, such stockholder or such beneficial owner with respect to securities of the Company, (v) a representation that the stockholder is a holder of record of stock of the Company entitled to vote at such meeting upon such business or nomination, as the case may be, and intends to appear in person or by proxy at the meeting to propose such business or nomination, (vi) a representation as to whether the stockholder or beneficial owner, if any, intends or is part of a group which intends to deliver a proxy statement and or form of proxy to holders of at least the percentage of the Company’s outstanding capital stock required to elect the nominee and or otherwise to solicit proxies or votes from stockholders in support of such nomination, and (vii) any other information relating to such stockholder and beneficial owner, if any, required to be disclosed in a proxy statement or other filings required to be made in connection with solicitations of proxies for the election of directors in an election contest pursuant to Section 14(a) of the Exchange Act and the rules and regulations promulgated thereunder. The Company may require any proposed nominee to furnish such other information as the Company may reasonably require to determine the eligibility of such proposed nominee to serve as a director of the Company. If requested by the Company, the information required on such nominee shall be supplemented by such stockholder and any such beneficial owner not later than 10 days after the record date for the meeting to disclose such information as of the record date. In addition, a stockholder seeking to nominate a director candidate shall promptly provide any other information reasonably requested by the Company.
Provided that stockholders provide the information required above for candidates recommended by stockholders, the Board will evaluate those candidates by following substantially the same process, and applying substantially the same criteria, as it uses for candidates identified by the Board or other persons.
Board Leadership Structure
Our Board does not have a policy requiring that the roles of Chairman of the Board and Chief Executive Officer be separated or combined, and the Board believes it should retain the flexibility to determine the leadership structure that best serves the Company and its stockholders based on the Company’s
 
20

Table of Contents
 
circumstances from time to time. Currently, the roles are held by separate individuals: Edward J. Borkowski, an independent director, serves as Chairman of the Board, and Jason D. Sawyer serves as our Chief Executive Officer and as a member of the Board.
As Chief Executive Officer, Mr. Sawyer is responsible for managing the Company’s day-to-day operations, implementing the strategic plan approved by the Board, and leading the management team, including in connection with the integration and development of our Grid AI Corp. business and our capital-raising activities. As Chairman, Mr. Borkowski presides over meetings of the Board and of stockholders, presides over regularly scheduled executive sessions of the independent directors, sets Board meeting agendas and schedules in consultation with the Chief Executive Officer, oversees the quality, quantity and timeliness of information provided to the Board, serves as the principal liaison between the independent directors and management, and is available, as appropriate, for consultation and direct communication with our stockholders.
The Board believes that separating these roles is appropriate for the Company at this time. The separation allows Mr. Sawyer to focus on executing our business strategy during a period of significant transition, including our acquisition of Grid AI Corp., and recent changes in our management and Board, while allowing an independent Chairman to lead the Board in its oversight of management, including oversight of the Company’s strategy, risk management, executive compensation and related party matters. The Board also believes the structure is enhanced by Mr. Borkowski’s extensive public company financial and governance experience. Because the Chairman is an independent director, the Board has not designated a separate lead independent director.
The Role of the Board in Risk Oversight
Our Board oversees a company-wide approach to risk management, determines our appropriate risk level in general, assesses the specific risks faced by us and reviews steps taken by management to manage those risks. Although our Board has ultimate oversight responsibility for the risk management process, specific areas of risk are overseen by designation of such duties and responsibilities to certain committees of the Board.
Specifically, the Board has designated certain fiduciary duties to its Compensation Committee, which is responsible for overseeing the management of risks relating to our executive compensation plans and arrangements, and the incentives created by the compensation awards it administers. The Board has also designated specific fiduciary duties to its Audit Committee, which is responsible for overseeing the management of enterprise risks and financial risks, as well as potential conflicts of interests. The Board is responsible for overseeing the management of risks associated with the independence of the Board.
Code of Business Conduct and Ethics
The Board adopted a code of ethics (the “Code”) that applies to our directors, officers and employees. A copy of this Code is available on our website at https://gridaipower.com We intend to disclose on our website any amendments to and waivers of the Code that apply to our principal executive officer, principal financial officer, principal accounting officer, controller, or persons performing similar functions.
Insider Trading Policy
Our board of directors has adopted a revised insider trading policy. The Company’s Revised Insider Trading Policy (“Insider Trading Policy”) governs the purchase, sale, hedges, shorts, or any other direct or indirect transactions in our securities by our employees, officers, directors, consultants, contractors and members of their immediate families and households (collectively, “Insiders”) and is reasonably designed to promote compliance with insider trading laws, rules, and regulations and any applicable Nasdaq listing standards.
Our Insider Trading Policy prohibits the Insiders from purchasing, selling or any other direct or indirect transaction in our securities while in possession of material nonpublic information and contains additional restrictions and guidelines in connection with Inside Information that Insiders might hold. In addition, our Insider Trading Policy sets forth restrictions for trading blackout periods applicable to certain
 
21

Table of Contents
 
covered persons. The Insider Trading Policy also states that all transactions by an Insider in the Company’s securities must be pre-cleared by the office of our Chief Financial Officer. The Insider Trading Policy also includes guidelines for Rule 10b5-1 trading plans in accordance with applicable SEC rules.
Employee, Officer and Director Hedging
Our Revised Insider Trading Policy expressly prohibits direct and indirect short selling of our securities by our employees, officers, directors, consultants, contractors and members of their immediate families and households (collectively, “Insiders”). Insiders are prohibited from hedging transactions if they have a trading plan in place under Rule 10b5-1. All transactions in our securities by Insiders must be pre-cleared by the Chief Financial Officer.
Stockholder Communications
If you wish to communicate with the Board, you may send your communication in writing to GridAI Technologies Corp., Attention: Chief Financial Officer at 433 Plaza Real, Suite 275, Boca Raton, Florida 33432.
You must include your name and address in the written communication and indicate whether you are a stockholder of the Company. The Chief Financial Officer will review any communication received from a stockholder, and all material and appropriate communications from stockholders will be forwarded to the appropriate director or directors or committee of the Board based on the subject matter.
Meetings of the Board
Each of our directors who served during the year ended December 31, 2025 attended at 100% of the aggregate of (i) the total number of meetings of the Board; and (ii) the total number of meetings held by all committees of the Board on which such director served as a member during such year. Although directors are not required to attend our annual meeting of stockholders, they are encouraged to attend and all directors attended the 2025 Annual Meeting held in June 2025.
The following table represents the composition of each committee of the Board as of the date of this proxy statement and meetings held as well as actions taken by unanimous written consent (“UWC”) in lieu of holding a meeting, during the fiscal year ended December 31, 2025:
​ ​ ​
Committees
​
Director
​ ​
Board
​ ​
Audit
​ ​
Compensation
​
Edward J. Borkowski
​ ​ ​ ​ C ​ ​ ​ ​ ​ CC ​ ​ ​ ​ ​ CC ​ ​
Jason D. Sawyer
​ ​ ​ ​ X ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Jack Syage, Ph.D
​ ​ ​ ​ X ​ ​ ​ ​ ​ X ​ ​ ​ ​ ​ X ​ ​
Geordan G. Pursglove
​ ​ ​ ​ X ​ ​ ​ ​ ​ X ​ ​ ​ ​ ​ ​ ​ ​
Meetings Held During 2025
​ ​ ​ ​ 9 ​ ​ ​ ​ ​ 4 ​ ​ ​ ​ ​ 1 ​ ​
Actions Taken by UWC During 2025
​ ​ ​ ​ 5 ​ ​ ​ ​ ​ 0 ​ ​ ​ ​ ​ 2 ​ ​
​
C — Chairman of the Board
CC — Committee Chairman
X — Member
Board Committees
The standing committees of the Board consist of the Audit Committee and Compensation Committee. Our Board has adopted written charters for each of these committees, copies of which are available on our website at https://gridaipower.com Our Board may establish other committees as it deems necessary or appropriate from time to time.
 
22

Table of Contents
 
Audit Committee
The duties and responsibilities of the Audit Committee include but are not limited to:
•
appointing, compensating, retaining, evaluating, terminating, and overseeing our independent registered public accounting firm;
​
•
discussing with our independent registered public accounting firm the independence of its members from its management;
​
•
reviewing with our independent registered public accounting firm the scope and results of their audit;
​
•
approving all audit and permissible non-audit services to be performed by our independent registered public accounting firm;
​
•
overseeing the financial reporting process and discussing with management and our independent registered public accounting firm the interim and annual financial statements that are filed with the SEC;
​
•
reviewing and monitoring our accounting principles, accounting policies, financial and accounting controls, and compliance with legal and regulatory requirements;
​
•
coordinating oversight of the Code and our disclosure controls and procedures on behalf of the Board;
​
•
establishing procedures for the confidential and/or anonymous submission of concerns regarding accounting, internal controls or auditing matters; and
​
•
reviewing and approving related-person transactions.
​
The rules of Nasdaq require our Audit Committee to consist of at least three directors, all of whom must be deemed to be independent directors under Nasdaq rules. The Audit Committee currently consists of Messrs. Borkowski and Pursglove and Dr. Syage. The Board has affirmatively determined that Messrs. Borkowski and Pursglove and Dr. Syage each meet the definition of “independent director” for purposes of serving on an Audit Committee under Nasdaq rules. Additionally, the Board has determined that Mr. Borkowski qualifies as an “audit committee financial expert,” as such term is defined in Item 407(d)(5) of Regulation S-K.
Compensation Committee
The duties and responsibilities of the Compensation Committee include but are not limited to:
•
reviewing key employee compensation goals, policies, plans and programs;
​
•
reviewing and approving the compensation of our directors and executive officers;
​
•
reviewing and approving employment agreements and other similar arrangements between us and our executive officers; and
​
•
appointing and overseeing any compensation consultants or advisors to the Company.
​
The rules of Nasdaq require our Compensation Committee to consist entirely of independent directors. The executive officers of the Company have no determinative authority over the amount or form of executive and director compensation, though they may make recommendations to the Compensation Committee for consideration.
The rules of Nasdaq require our Compensation Committee to consist entirely of independent directors. The Board has determined that Messrs. Borkowski, Pursglove and Dr. Syage are independent within the meaning of the Nasdaq listing standards applicable to compensation committee service.
Compensation Committee Interlocks and Insider Participation
During 2025, the members of the Compensation Committee were Mr. Borkowski, Mr. Uppal and Mr. Pursglove. None of these individuals is or has been an officer or employee of the Company. Mr. Sawyer,
 
23

Table of Contents
 
our Chief Executive Officer, served as a director of NOMAD Power Solutions, Inc., of which Mr. Pursglove, a member of our Compensation Committee, served as Chief Executive Officer and Chairman until November 9, 2026. The period of overlapping service was July 18, 2025 through November 9, 2026. Other than as described above, no executive officer of the Company served as a member of the board of directors or compensation committee of any entity that has one or more executive officers serving on our Board or Compensation Committee.
Corporate Governance and Nominating Committee
On November 13, 2025, the Board of Directors dissolved the Nominating and Corporate Governance Committee. Following the dissolution of that committee, the full Board assumed responsibility for identifying qualified individuals to become members of the Board, determining the composition of the Board, monitoring the effectiveness of the Board, and overseeing corporate governance matters.
EXECUTIVE COMPENSATION
The following table sets forth information regarding our current executive officers as appointed by the Board, each to serve in such position until their respective successors have been duly appointed and qualified or until their earlier death, resignation or removal from office.
Executive Officer
​ ​
Age
​ ​
Title
​
Jason D. Sawyer
​ ​ ​ ​ 54 ​ ​ ​ Chief Executive Officer ​
Anna Skowron
​ ​ ​ ​ 39 ​ ​ ​
Interim Chief Financial Officer
​
Our executive officers are appointed by and serve at the discretion of the Board, subject to the terms of any employment agreements they may have with us. The following is a brief description of the qualifications and business experience of each of our current executive officers.
Jason D. Sawyer.   Please see Mr. Sawyer’s biography under the “Directors” section of this proxy statement.
Anna Skowron was appointed to serve as our Interim Chief Financial Officer on March 7, 2025. In this role, she oversees the Company’s financial reporting, SEC compliance, internal controls, capital markets activities, and finance function. Her consulting arrangement with the Company was previously through Skowron Accounting Professional Corporation and subsequently transitioned to BPC Consulting Ltd. starting June 1, 2026. BPC Consulting Ltd. provides Chief Financial Officer and other consulting and accounting services to the Company. Ms. Skowron has served as the Director of BPC Consulting Ltd. since September 2025. From 2020 through June 2026, Ms. Skowron served as the Principal of Skowron Accounting Professional Corporation, where she provided chief financial officer, accounting, financial reporting, mergers and acquisitions advisory, and capital markets consulting services to public and private companies across a range of industries. During this period, she advised on financings and supported strategic transactions. Since February 9, 2026, Ms. Skowron has served as Fractional Chief Financial Officer of Powell Max Limited. In these roles, she has provided executive financial leadership and strategic oversight while being supported by her finance team, which assists in the execution of financial reporting, SEC compliance, corporate finance, and other finance functions under her direction and supervision. Ms. Skowron holds a Bachelor of Commerce with a Specialist in Accounting and Major in Economics degree from University of Toronto.
Summary Compensation
The table set forth below reflects certain information regarding the compensation paid or accrued during the years ended December 31, 2025 and 2024 to our Chief Executive Officer and our executive officers, other than our Chief Executive Officer, who were serving as an executive officer as of December 31, 2025, and whose annual compensation exceeded $100,000 during such year (collectively the “Named Executive Officers”).
 
24

Table of Contents
 
Named Executive Officers
​ ​
Year
​ ​
Salary
​ ​
Bonus
​ ​
Stock
Award
​ ​
All Other
Compensation
​ ​
Total
​
Jason Sawyer (CEO)
​ ​ ​ ​ 2025 ​ ​ ​ ​ $ ​ ​ ​ ​ $ — ​ ​ ​ ​ $ 93,200(1) ​ ​ ​ ​ $ 87,500(2) ​ ​ ​ ​ $ 180,700 ​ ​
Richard Paolone (Former CEO)(6)
​ ​ ​ ​ 2025 ​ ​ ​ ​ ​ 87,500 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 15,228(3) ​ ​ ​ ​ ​ 102,728 ​ ​
James Sapirstein (Former CEO)
​ ​ ​ ​ 2024 ​ ​ ​ ​ ​ 416,300 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 76,400(4) ​ ​ ​ ​ ​ 17,608(5) ​ ​ ​ ​ ​ 510,308 ​ ​
Anna Skowron
​ ​ ​ ​ 2025 ​ ​ ​ ​ ​ 103,387 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 151,450(1) ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 254,837 ​ ​
Sarah Romano (Former CFO)
​ ​ ​ ​ 2024 ​ ​ ​ ​ ​ 390,550 ​ ​ ​ ​ ​ 117,165(1) ​ ​ ​ ​ ​ 185,676(4) ​ ​ ​ ​ ​ 117,165 ​ ​ ​ ​ ​ 810,556 ​ ​
​
(1)
Represents the grant date fair value of restricted stock units issued during the year ended December 31, 2025, calculated in accordance with ASC Topic 718. The assumptions used in the calculation of these amounts are included in Note 11 of the consolidated financial statements contained in our Annual Report.
​
(2)
Jason Sawyer served as Chief Executive Officer pursuant to a consulting agreement and was not an employee of the Company during 2025. Accordingly, amounts paid to Mr. Sawyer, including consulting fees of $75,000 and director fees of $12,500, are reflected in “All Other Compensation.”
​
(3)
Represents director fees of $15,228 paid to Richard Paolone during the period he served as a member of the Board of Directors.
​
(4)
Represents the grant date fair value of restricted stock units issued during the year ended December 31, 2024. The assumptions used in the calculation of these amounts are included in Note 11 of the notes to the consolidated financial statements contained in our Annual Report.
​
(5)
Represents reimbursement of COBRA paid during the year ended December 31, 2024.
​
(6)
Mr. Paolone served as Interim Chief Executive Officer until his termination without cause effective September 3, 2025.
​
(7)
Mr. Sawyer was appointed Interim Chief Executive Officer effective September 4, 2025.
​
Employment Arrangements and Potential Payments upon Termination or Change of Control
Sawyer Consulting Agreement.   Effective as of September 4, 2025, we entered into a consulting agreement with Access Alternative Group S.A., a Bahamian corporation (the “Consultant”), in connection with Mr. Sawyer’s role as Interim Chief Executive Officer (the “Consulting Agreement”). Pursuant to the Consulting Agreement the company paid compensation of $12,500 per month. The Company was also obligated to defend and indemnify Mr. Sawyer in his capacity as Interim Chief Executive Officer to the fullest extent permitted under the Delaware General Corporation Law (“DGCL”) and also to maintain a policy for indemnifying its officers and directors, including Mr. Sawyer, for all actions permitted under the DGCL taken in good faith pursuit of their duties for the Company. On December 19, 2025, we entered into Amended and Restated Consulting Agreement (the “A&R Consulting Agreement”) with the Consultant in connection with the appointment of Mr. Sawyer as the Company’s Chief Executive Officer.
Pursuant to the A&R Consulting Agreement, the Consultant is entitled to (i) base compensation of $25,000 per month, retroactive to October 1, 2025, (ii) a quarterly fee of $20,000 per quarter for each quarter that the Company remains in compliance with Nasdaq rules and listing requirements with the first of such quarterly payments beginning on January 1, 2026 (if applicable), and (iii) a one-time payment of $150,000 and 400,000 shares issuable under the Company’s equity incentive plan, payable upon shareholder approval of the Company’s acquisition of Grid AI Corp. The A&R Consulting Agreement further provides for equity compensation in the form of restricted stock units covering 1,000,000 shares of the Company’s Common Stock, with 25% vesting at the end of each calendar quarter of 2026 upon successful execution of the Company’s quarterly objectives and tasks, and with immediate vesting upon the earlier of: (a) termination without Cause, (b) a Change in Control (as defined in the A&R Consulting Agreement), or (c) the time more than 50% of the Company’s Series H preferred stock has been converted into shares of Common Stock of the Company. As of September 30, 2026, 750,000 RSUs under this award had vested and 250,000 remained unvested. Separately, a Compensation Committee written consent dated December 20, 2025 approved an additional 40,000 RSUs for Mr. Sawyer, which vested immediately upon issuance.
 
25

Table of Contents
 
The A&R Consulting Agreement has an initial two-year term commencing on December 19, 2025, and is renewable on a yearly basis at the Company’s discretion. The Consultant may terminate the Consulting Agreement upon not less than 30 days’ prior notice, and the Company may terminate the Consulting Agreement upon 10 business days’ prior notice. If the A&R Consulting Agreement is terminated for any reason other than for “Cause” ​(as defined in the A&R Consulting Agreement) before the end of the initial two-year term (or any renewal term), the Consultant is entitled to pro-rated cash severance equal to the remaining base compensation and the quarterly fee related to compliance with the Nasdaq rules and listing requirements for the unexpired portion of such term. The A&R Consulting Agreement also provides that the Company will defend and indemnify Mr. Sawyer in his capacity as Chief Executive Officer to the fullest extent permitted under the DGCL and maintain directors’ and officers’ liability insurance, subject to the terms set forth in the Consulting Agreement.
Skowron Consulting Agreement.   We entered into a consulting agreement in connection with Ms. Skowron’s role as Interim Chief Financial Officer, pursuant to which the consultant initially received a fixed monthly fee of $8,333, effective as of March 7, 2025. The Company will also defend and indemnify Ms. Skowron in her capacity as Chief Financial Officer of the Company to the fullest extent permitted under the DGCL and shall also maintain a policy for indemnifying its officers and directors, including Ms. Skowron, for all actions permitted under the DGCL taken in good faith pursuit of their duties for the Company. Under Amendment No. 1, the monthly consulting retainer increased to $13,750. Under Amendment No. 2, the monthly consulting retainer increased to $20,625. Under Amendment No. 3, BPC Consulting Ltd. replaced Skowron Accounting Professional Corporation as the contracting entity. On October 26, 2026, the Company entered into Amendment No. 4 to the CFO consulting arrangement with BPC Consulting Ltd., effective September 1, 2026, providing for a fixed monthly consulting retainer of $27,000 replacing the prior fixed monthly retainer and up to 250,000 restricted stock units, subject to the terms of the 2020 Plan, availability of reserved shares and applicable vesting schedule and conditions.
Paolone Consulting Agreement.   On March 6, 2025, we entered into a consulting agreement in connection with Mr. Paolone’s role as Interim Chief Executive Officer, effective as of February 12, 2025, pursuant to which he will receive compensation of $12,500 per month. The Company will also defend and indemnify Mr. Paolone in his capacity as Chief Executive Officer of the Company to the fullest extent permitted under the DGCL and shall also maintain a policy for indemnifying its officers and directors, including Mr. Paolone, for all actions permitted under the DGCL taken in good faith pursuit of their duties for the Company. On September 3, 2025, in connection with his termination as Interim Chief Executive Officer and Chairman of the Board, the Company terminated the consulting agreement with Mr. Paolone. On November 28, 2025, Mr. Paolone notified the Company of his resignation as a director of the Company and in connection with this departure we entered into a Separation Agreement and Mutual Release (the “Separation Agreement”) with Mr. Paolone and 2818390 Ontario Corp., an Ontario, Canada corporation. Under the Separation Agreement we agreed to pay Mr. Paolone $500,000, consisting of an initial payment of $350,000 due upon the Effective Date (as defined in the Separation Agreement), followed by three (3) monthly payments of $50,000 each, with installments payable respectively on January 1, 2026, February 1, 2026 and March 1, 2026, along with his legal fees in the amount of $50,000 in connection with the entry into the Separation Agreement.
Sapirstein Employment Agreement.   Effective October 8, 2019, we entered into an employment agreement with Mr. Sapirstein to serve as our President and Chief Executive Officer for a term of three years, subject to further renewal upon agreement of the parties. The employment agreement with Mr. Sapirstein originally provided for a base salary of $450,000 per year, which was subsequently increased to $480,000 per year during the year ended December 31, 2020 and to $513,600 during the year ended December 31, 2023. In addition to the base salary, Mr. Sapirstein is eligible to receive (i) an initial bonus of up to 40% of his base salary on an annual basis, based on certain milestones that are yet to be determined, that was increased to a bonus of up to 50% of his base salary effective January 1, 2023; (ii) 1% of net fees received by us upon entering into license agreements with any third-party with respect to any product currently in development or upon the sale of all or substantially all of our assets; (iii) a grant of 33 restricted shares of our Common Stock which are subject to vesting as follows (a) 16 upon the first commercial sale of Adrulipase in the U.S., and (b) 17 upon our total market capitalization exceeding $1.0 billion for 20 consecutive trading days; (iv) a grant of 50 10-year stock options to purchase shares of our Common Stock which are subject to vesting as follows (a) 8 upon us initiating our next Phase 2 clinical trial in the U.S. for Adrulipase, (b) 8 upon us
 
26

Table of Contents
 
completing our next or subsequent Phase 2 clinical trial in the U.S. for Adrulipase, (c) 17 upon us initiating a Phase 2 clinical trial in the U.S. for Adrulipase, and (d) 17 upon us initiating a Phase 1 clinical trial in the U.S. for any product other than Adrulipase. Mr. Sapirstein was entitled to receive 20 days of paid vacation, participate in full employee health benefits and receive reimbursement for all reasonable expenses incurred in connection with his services to us.
Pursuant to the terms of his employment agreement, in the event that Mr. Sapirstein’s employment was terminated by us for Cause, as defined in his employment agreement, or by Mr. Sapirstein voluntarily, then he would not be entitled to receive any payments beyond amounts already earned, and any unvested equity awards will terminate. In the event that Mr. Sapirstein’s employment was terminated as a result of an Involuntary Termination Other than for Cause, as defined in the Agreement, Mr. Sapirstein would be entitled to receive the following compensation: (i) severance in the form of continuation of his salary (at the Base Salary rate in effect at the time of termination, but prior to any reduction triggering Good Reason) for a period of 12 months following the termination date; (ii) payment of Executive’s premiums to cover COBRA for a period of 12 months following the termination date; and (iii) a prorated annual bonus.
On August 2, 2024, the Board approved the termination of the employment agreement with Mr. Sapirstein. Mr. Sapirstein did not receive any additional compensation or payments in connection with the termination of his employment agreement. Also on August 2, 2024, the Company and Mr. Sapirstein entered into a consulting agreement with Mr. Sapirstein pursuant to which the Company agreed to pay Mr. Sapirstein $400 an hour monthly for services rendered to the Company. Should travel be required, Mr. Sapirstein will additionally be compensated $200 per hour for travel time plus expenses and the federal mileage rate for car travel. The consulting agreement was terminated on February 2, 2025.
Romano Employment Agreement.   Effective March 1, 2022, we entered into an employment agreement with Ms. Romano to serve as our Chief Financial Officer for a term of three years, subject to further renewal upon agreement of the parties. The employment agreement with Ms. Romano provides for a base salary of $365,000 per year, which was subsequently increased to $390,550 during the year ended December 31, 2023, and to $435,000 during the year ended December 31, 2024. In addition to the base salary, Ms. Romano is eligible to receive an annual milestone cash bonus of 35% of her annual salary based on certain milestones established by our Board or the Compensation Committee, which was subsequently increased to 40% on January 1, 2023. On March 1, 2022, Ms. Romano was granted stock options to purchase 250 shares of Common Stock on March 1, 2022, with an exercise price of $708.00 per share, which vest over a term of three years pursuant to her employment agreement. Ms. Romano was entitled to receive 20 days of paid vacation, participate in full employee health benefits and receive reimbursement for all reasonable expenses incurred in connection with her service to us.
In the event that Ms. Romano’s employment was terminated by us for Cause, as defined in Ms. Romano’s employment agreement, or by Ms. Romano voluntarily, she would not be entitled to receive any payments beyond amounts already earned, and any unvested equity awards would terminate. If we terminate her employment agreement without Cause, not in connection with a Change of Control, as such term is defined in Ms. Romano’s employment agreement, she would be entitled to (i) all salary owed through the date of termination; (ii) any unpaid annual milestone bonus; (iii) severance in the form of continuation of her salary for the greater of a period of six months following the termination date or the remaining term of the employment agreement; (iv) payment of premiums to cover COBRA for a period of six months following the termination date; (v) a prorated annual bonus equal to the target annual milestone bonus, if any, for the year of termination multiplied by the formula set forth in the agreement. If we terminate Ms. Romano’s employment agreement without Cause, in connection with a Change of Control, she would be entitled to the above and immediate accelerated vesting of any unvested options or other unvested awards.
Ms. Romano’s employment agreement expired pursuant to its terms on February 28, 2025 and Ms. Romano did not receive any additional compensation in connection with this expiration. Effective March 7, 2025 Ms. Romano resigned from her position as Chief Financial Officer.
Outstanding Equity Awards at Fiscal Year-End
As of December 31, 2025, none of the Company’s Named Executive Officers held any unexercised options or unvested stock awards.
 
27

Table of Contents
 
Equity Compensation Plan Information
Securities Authorized for Issuance Under Equity Compensation Plans
The following table provides information as of December 31, 2025 regarding equity compensation plans approved by our security holders and equity compensation plans that have not been approved by our security holders:
Plan category
​ ​
Number of
securities to be
issued upon
exercise of
outstanding
options,
warrants
and rights
​ ​
Weighted-average
exercise price of
Outstanding
option, warrants
and rights
​ ​
Number of
securities
remaining
available for
future issuance
under equity
compensation
plans reflected
in column (a)
​
​ ​ ​
(a)
​ ​ ​ ​ ​ ​ ​
Equity compensation plans approved by security holders(1)
​ ​ ​ ​ 19 ​ ​ ​ ​ $ 39,125 ​ ​ ​ ​ ​ 941,100 ​ ​
Equity compensation plans not approved by security holders
​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​
Total ​ ​ ​ ​ 19 ​ ​ ​ ​ $ 39,125 ​ ​ ​ ​ ​ 941,100 ​ ​
​
(1)
Represents outstanding stock options granted to our current or former employees, directors and consultants pursuant to the 2014 Plan and 2020 Plan.
​
PAY VERSUS PERFORMANCE
The following table presents executive compensation and financial performance for the years ended December 31, 2025, 2024 and 2023, in accordance with Item 402(v) of Regulation S-K. Compensation actually paid (CAP) is determined under SEC rules and does not represent cash received by the executives.
Year
​ ​
PEO 1
SCT
​ ​
PEO 1
CAP
​ ​
PEO 2
SCT
​ ​
PEO 2
CAP
​ ​
Non-PEO
avg. SCT
​ ​
Non-PEO
avg. CAP
​ ​
TSR
($100)
​ ​
Net loss
($)
​
2025
​ ​ ​ ​ 180,700 ​ ​ ​ ​ ​ 199,100 ​ ​ ​ ​ ​ 102,728 ​ ​ ​ ​ ​ 102,728 ​ ​ ​ ​ ​ 254,837 ​ ​ ​ ​ ​ 284,737 ​ ​ ​ ​ ​ 1.27 ​ ​ ​ ​ ​ (6,553,578) ​ ​
2024
​ ​ ​ ​ 510,308 ​ ​ ​ ​ ​ 510,308 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 451,356 ​ ​ ​ ​ ​ 451,356 ​ ​ ​ ​ ​ 1.52 ​ ​ ​ ​ ​ (18,059,336) ​ ​
2023
​ ​ ​ ​ 1,245,766 ​ ​ ​ ​ ​ 671,314 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 810,556 ​ ​ ​ ​ ​ 549,587 ​ ​ ​ ​ ​ 3.43 ​ ​ ​ ​ ​ (15,794,983) ​ ​
​
(1)
PEO 1 denotes Jason D. Sawyer for 2025 and James Sapirstein for 2024 and 2023. PEO 2 denotes Richard Paolone for 2025. Mr. Sawyer was appointed CEO effective September 4, 2025, following Mr. Paolone, who served until September 3, 2025. The PEOs are reported separately, as required for a year with more than one PEO.
​
(2)
The non-PEO named executive officer was Anna Skowron in 2025 and Sarah Romano in 2024 and 2023. The 2024 and 2023 SCT and CAP amounts are retained from the Company’s previously filed 2025 proxy statement. The 2025 SCT values are from the Company’s 2025 Form 10-K.
​
(3)
The table below reconciles 2025 SCT compensation to CAP. The December 20, 2025 Compensation Committee consent approved awards of 40,000 RSUs to Mr. Sawyer and 65,000 RSUs to Ms. Skowron, each vesting immediately upon issuance on December 22, 2025. The grant-date fair value was $2.33 per RSU; the closing share price on the vesting date was $2.79.
​
2025 executive
​ ​
SCT total ($)
​ ​
Less grant-date
awards ($)
​ ​
Add vest-date
value ($)
​ ​
CAP ($)
​
Jason D. Sawyer
​ ​ ​ ​ 180,700 ​ ​ ​ ​ ​ (93,200) ​ ​ ​ ​ ​ 111,600 ​ ​ ​ ​ ​ 199,100 ​ ​
Richard Paolone
​ ​ ​ ​ 102,728 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 102,728 ​ ​
Anna Skowron
​ ​ ​ ​ 254,837 ​ ​ ​ ​ ​ (151,450) ​ ​ ​ ​ ​ 181,350 ​ ​ ​ ​ ​ 284,737 ​ ​
​
(4)
For 2024, the previously disclosed CAP adjustments deducted grant-date stock awards of $76,400 for the PEO and $26,740 for the non-PEO NEO and added the same amounts for the fair value of awards,
​
 
28

Table of Contents
 
resulting in CAP of $510,308 and $451,356, respectively. For 2023, PEO CAP was $1,245,766 less $339,566 plus $83,168, less $208,370 and $109,684, or $671,314. Non-PEO NEO CAP was $810,556 less $185,676 plus $57,477, less $87,249 and $45,521, or $549,587. These historical amounts were previously reported.
(5)
TSR reflects the value, at each year-end, of a fixed $100 investment at December 30, 2022, assuming reinvestment of dividends, of which none were paid. Closing prices used were $122.584 at December 30, 2022 (adjusted for the 2023 splits), $4.20 at December 29, 2023, $1.866 at December 31, 2024 and $4.66 at December 31, 2025. The August 2025 1-for-3 reverse stock split was reflected in calculating comparable prices. Accordingly, the 2023, 2024 and 2025 values of the original investment were $3.43, $1.52 and $1.27, respectively.
​
(6)
Net loss is the GAAP consolidated net loss reported for the relevant fiscal year, not net loss attributable solely to common stockholders. It was $6,553,578 for 2025, $18,059,336 for 2024 and $15,794,983 for 2023.
​
Relationship Between Compensation Actually Paid and Total Shareholder Return
The value of a fixed $100 investment decreased from $3.43 at the end of 2023 to $1.52 at the end of 2024 and $1.27 at the end of 2025. CAP for the PEO was $671,314 in 2023 and $510,308 in 2024. In 2025, CAP was $199,100 for Mr. Sawyer and $102,728 for Mr. Paolone, who served in different portions of that year. Average CAP for non-PEO NEOs declined from $549,587 in 2023 to $451,356 in 2024 and $284,737 in 2025.
Relationship Between Compensation Actually Paid and Net Loss
The Company reported net losses of $15,794,983 in 2023, $18,059,336 in 2024 and $6,553,578 in 2025. Average non-PEO NEO CAP declined during this period, while the Company’s net loss increased in 2024 and decreased in 2025. The 2025 PEO amounts are presented separately due to the change in CEO.
The Company does not use the amounts calculated as compensation actually paid under Item 402(v) as a measure for determining executive compensation. The disclosed CAP values principally reflect the application of SEC valuation rules to equity-based awards, rather than the amounts of cash compensation paid.
All information provided above under the “Pay Versus Performance” heading will not be deemed to be incorporated by reference in any filing of our company under the Securities Act of 1933, as amended, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.
Related Party Transactions
ImmunogenX Merger
On March 13, 2024, we merged with ImmunogenX, Inc. (“IMGX”) (the Company’s acquisition of IMGX, the “Merger”), a private, clinical-stage biopharmaceutical company founded in 2013, which is developing the biologic Latiglutenase for the treatment of celiac disease. As a result of the Merger, IMGX became a limited liability company and our wholly owned subsidiary named “ImmunogenX, LLC” ​(“IMGX LLC”). In consideration for the Merger, the Company issued 36,830 shares of Common Stock and 11,777.418 shares of Series G Preferred Stock to the former shareholders of IMGX. The Series G Preferred Stock was valued using an estimated price of $7.00 per share of Common Stock, as agreed upon in the Merger agreement. As a result of the Merger, Dr. Syage received 15,400 shares of our Common Stock and 4,920.037 shares of Series G Preferred Stock in exchange for shares of IMGX Common Stock that he held immediately prior to the Merger. Dr. Syage is a related party as a director.
Stockholder Notes
On March 13, 2024, in connection with the Merger and in order to fund the payment of $1.0 million to Mattress Liquidators, Inc. (the “Lender”), IMGX entered into a secured promissory note in favor of Jack
 
29

Table of Contents
 
Syage, in an aggregate principal amount of $500,000 (the “Syage Note”). The Syage Note bears interest at a per annum floating rate equal to the prime rate plus 4.5% and matures on October 13, 2025. Dr. Syage entered into a patent and trademark security agreement dated March 13, 2024 (the “Shareholder Security Agreement”), pursuant to which the obligations under the Syage Note are secured by, among other things, the patents and trademarks owned by IMGX.
The foregoing descriptions of the Syage Note and the Shareholder Security Agreement do not purport to be complete and are qualified in their entirety by reference to the Form of Shareholder Note and Form of Shareholder Security Agreement, which are incorporated by reference to Exhibits 10.15 and 10.16, respectively, of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on May 1, 2026.
Pursuant to the Rescission Agreement (as defined below), it was agreed that the Company shall have no further duties, liabilities or obligations under the Syage Note and the Shareholder Security Agreement.
Rescission Agreement with IMGX and IMGX Shareholders
In March 2025, we announced that we entered into a Rescission Agreement (the “Rescission Agreement”), by and among the Company, IMGX and the former shareholders of IMGX. As part of the consideration in the Rescission Agreement, subject to approval of our stockholders, we will convey to the IMGX Shareholders all of the issued and outstanding Membership Interests of IMGX currently held by us. In addition, the parties to the Rescission Agreement agreed to rescind the issuances of the shares of Common Stock and Series G Preferred Stock that we have issued to the IMGX Shareholders as part of the Merger. The transactions contemplated by the Rescission Agreement were closed on December 31, 2025. As a result of this Rescission Agreement, the 15,400 shares of our Common Stock and 4,920.037 shares of Series G Preferred Stock that Dr. Syage received in connection with the Merger were cancelled. In addition, as a result of this Rescission Agreement we conveyed to Dr. Syage 41.78% of the Membership Interests of IMGX, previously held by us. Dr. Syage was acting as the Shareholder Representative under the Rescission Agreement. Dr. Syage is a related party as a director.
Settlement Agreement and Related Transactions
On May 8, 2025, IMGX LLC entered into a settlement agreement effective April 9, 2025 with the Lender, Dr. Syage and The Jack A. Syage and Elizabeth T. Syage Revocable Trust (the “Trust”, and Trust collectively with Dr. Syage, the “Guarantors”) (such agreement, the “Settlement Agreement”). Under the Settlement Agreement, the Guarantors agreed to pay the Lender (a) $5,500,000 to be applied to the obligations amounting to approximately $7.9 million owed by IMGX to the Lender (which amount was paid to the Lender on April 9, 2025) with the Guarantors being solely responsible for payment of all obligations due to be paid to the Lender. In addition, IMGX LLC agreed to pay all of the Lender’s attorneys’ fees and costs incurred through April 9, 2025 amounting to approximately $62,000.
The parties to the Settlement Agreement also agreed to enter into amended and restated loan documents (collectively, the “Amended and Restated Loan Documents”) dated April 9, 2025 which provide for, among others, a revolving loan of $2,436,338.30 (the “Commitment”) to IMGX LLC, to be repaid and the principal amount thereof reborrowed before the earliest of: (i) April 9, 2028, (ii) the date IMGX LLC prepays the revolving loan in full in accordance with amended and restated credit agreement or (iii) the date on which the Commitment is terminated in whole pursuant to an amended and restated credit agreement. Under amended and restated guarantees, the Guarantors unconditionally guaranteed the prompt payment of all monies owed by IMGX LLC to the Lender. Pursuant to the Settlement Agreement, the Lender agreed to release its security interest in IMGX LLC, and the parties agreed to execute a Stipulation of Dismissal with Prejudice that was filed before the District Court, Boulder County, State of Colorado. The Stipulation of Dismissal was granted on May 15, 2025. Dr. Syage is a related party as a director.
Policy and Procedures Governing Related Party Transactions
The Board is committed to upholding the highest legal and ethical conduct in fulfilling its responsibilities and recognizes that related party transactions can present a heightened risk of potential or actual conflicts of interest.
 
30

Table of Contents
 
The SEC rules define a related party transaction to include any transaction, arrangement or relationship which: (i) we are a participant; (ii) the amount involved exceeds $120,000 or, for smaller reporting companies, one percent of the average of the smaller reporting company’s total assets at year-end for the last two completed fiscal years; and (iii) any executive officer, director or director nominee, or any person who is known to be the beneficial owner of more than 5% of our Common Stock, or any person who is an immediate family member of an executive officer, director or director nominee or beneficial owner of more than 5% of our Common Stock had or will have a direct or indirect material interest.
Although we do not maintain a formal written procedure for the review and approval of transactions with such related persons, it is our policy for the disinterested members of our Board to review all related party transactions on a case-by-case basis. To receive approval, a related-party transaction must have a legitimate business purpose for us and be on terms that are fair and reasonable to us and our stockholders and as favorable to us and our stockholders as would be available from non-related entities in comparable transactions.
All related party transactions must be disclosed in our applicable filings with the SEC as required under SEC rules.
Policies and Practices Related to the Grant of Certain Equity Awards Close in Time to the Release of Material Nonpublic Information (“MNPI”)
In accordance with Item 402(x) of Regulation S-K, we are providing information regarding our procedures related to the grant of certain equity awards close in time to the release of MNPI.
The timing of equity award grants is determined with consideration to a variety of factors, including but not limited to, the achievement of pre-established performance targets, market conditions and internal milestones. Although we do not have a formal policy, program or plan that requires us to award equity or equity-based compensation on specific dates, we generally issue equity awards to our executive officers annually in the first quarter. In determining the timing and terms of an equity award, the Compensation Committee may consider MNPI to ensure that such grants are made in compliance with applicable laws and regulations. The Board’s or the Compensation Committee’s procedures to prevent the improper use of MNPI in connection with the granting of equity awards may include oversight by legal counsel and, where appropriate, delaying the grant of equity awards until the public disclosure of such MNPI. Additionally, our Insider Trading Policy prohibits directors, officers and employees from trading in our Common Stock while in possession of or on the basis of MNPI about us. We have not timed, and do not plan to time, the disclosure of MNPI for the purpose of affecting the value of executive compensation.
In the year ended December 31, 2025, no options were granted to our named executive officers within four business days prior to, or one business day following, the filing or furnishing of a periodic or current report by us that disclosed MNPI.
Delinquent Section 16(a) Reports
Section 16(a) of the Exchange Act, requires our officers, directors, and persons who beneficially own more than 10% of our Common Stock to file reports of ownership and changes in ownership with the SEC. Officers, directors, and greater-than-ten-percent stockholders are also required by the SEC to furnish us with copies of all Section 16(a) forms that they file.
Based solely upon a review of these forms that were furnished to us, we believe that all reports required to be filed by these individuals and persons under Section 16(a) were filed during the year ended December 31, 2025 and that such filings were timely, except for one Form 3 (which included no securities beneficially owned by the reporting person) that was filed late on December 29, 2025, by Anna Skowron due to administrative oversight.
Report of the Audit Committee for 2025
The following Report of the Audit Committee of the Board of Directors shall not be deemed to be soliciting material or to be incorporated by reference by any general statement incorporating by reference this proxy statement into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of
 
31

Table of Contents
 
1934, as amended, except to the extent the Company specifically incorporates this Report therein, and shall not otherwise be deemed filed under such Acts.
The Audit Committee has reviewed and discussed with management, Macias Gini & O’Connell LLP, our independent registered public accounting firm, the audited consolidated financial statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 (filed with the SEC on May 1, 2026). The Audit Committee has also discussed with Macias Gini & O’Connell LLP those matters required to be discussed by Public Company Accounting Oversight Board (“PCAOB”) Auditing Standard 1301.
Macias Gini & O’Connell LLP also provided the Audit Committee with the written disclosures and the letter required by the applicable requirements of the PCAOB regarding the independent auditor’s communication with the Audit Committee concerning independence. The Audit Committee has discussed with the registered public accounting firm its independence from our Company.
Based on its discussions with management and the independent registered public accounting firm, and its review of the representations and information provided by management and the independent registered public accounting firm, including as set forth above, the Audit Committee recommended to our Board of Directors that the audited consolidated financial statements be included in our Annual Report on Form 10-K for the year ended December 31, 2025 (filed with the SEC on May 1, 2026).
RESPECTFULLY SUBMITTED,
Edward J. Borkowski, chair
Manpreet Uppal (Mr. Uppal resigned from the Board effective October 19, 2026.)
Geordan G. Pursglove
 
32

Table of Contents​
 
BENEFICIAL OWNERSHIP OF PRINCIPAL STOCKHOLDERS AND
MANAGEMENT AND RELATED STOCKHOLDER MATTERS
The following table sets forth information regarding shares of our capital stock beneficially owned as of November 9, 2026, by:
•
each of our officers and directors;
​
•
all officers and directors as a group; and
​
•
each person known by us to beneficially own five percent or more of the outstanding shares of our capital stock. Percentage of ownership is calculated based on 10,215,090 shares of Common Stock outstanding as of November 9, 2026.
​
•
Shares issued after the October 20, 2026 record date, including shares issued in connection with the October 2026 awards described in this proxy statement, are included in the shares outstanding as of November 9, 2026 but are not entitled to vote at the Annual Meeting. Colonial Stock Transfer reported 10,215,090 shares of Common Stock outstanding on November 9, 2026. The October 20 record-date balance of 8,540,172 shares remains the voting population for the Annual Meeting.
​
Name and Address of Beneficial Owner(1)
​ ​
Number of
Shares
(2)
​ ​
Percentage of
Ownership
(3)
​
Current Executive Officers and Directors ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Jason Sawyer, Chief Executive Officer(4)
​ ​ ​ ​ 1,080,000 ​ ​ ​ ​ ​ 10.6% ​ ​
Anna Skowron, Interim Chief Financial Officer
​ ​ ​ ​ 140,000 ​ ​ ​ ​ ​ 1.4% ​ ​
Edward J. Borkowski, Director
​ ​ ​ ​ 277,327 ​ ​ ​ ​ ​ 2.7% ​ ​
Geordan Pursglove, Director
​ ​ ​ ​ 140,000 ​ ​ ​ ​ ​ 1.4% ​ ​
Jack Syage, Director
​ ​ ​ ​ 80,000 ​ ​ ​ ​ ​ * ​ ​
All directors and executive officers as a group (5 persons)
​ ​ ​ ​ 1,717,327 ​ ​ ​ ​ ​ 16.6% ​ ​
​
*
Less than 1%.
​
(1)
Unless otherwise indicated, the address of such individual is c/o GridAI Technologies Corp., 433 Plaza Real Suite 275, Boca Raton, Florida, 33432
​
(2)
Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting or investment power with respect to securities. All entries exclude beneficial ownership of shares issuable pursuant to warrants, options or other derivative securities that have not vested or that are not otherwise exercisable as of the date hereof or which will not become vested or exercisable within 60 days. Mr. Borkowski’s holdings include 100,000 shares issuable upon exercise of immediately exercisable options. Ms. Skowron’s holdings include 75,000 vested restricted stock units and exclude 175,000 unvested restricted stock units.
​
(3)
Percentages are rounded to nearest tenth of a percent. Percentages are based on 10,215,090 shares of Common Stock outstanding. Warrants, options or other derivative securities that are presently exercisable or exercisable within 60 days are deemed to be beneficially owned by the person holding such securities for the purpose of computing the percentage ownership of that person but are not treated as outstanding for the purpose of computing the percentage of any other person.
​
(4)
Access Alternative Group S.A., of which Mr. Sawyer is General Manager, is the record holder of 830,000 shares included in Mr. Sawyer’s beneficial ownership.
​
 
33

Table of Contents​
 
PROPOSAL NO. 2: REVERSE SPLIT PROPOSAL
Adoption and approval of an amendment to our Amended and Restated Certificate of Incorporation, as amended (the “Charter”), to effect a reverse stock split of our issued and outstanding shares of Common Stock, at a specific ratio, ranging from 1:2 to 1:20, at any time prior to the one-year anniversary date of the Annual Meeting, with the exact ratio to be determined by the Board without further approval or authorization of our stockholders
Overview
Our Board has determined that it is advisable and in the best interests of the Company and its stockholders, for us to amend our Charter to authorize our Board to effect a reverse stock split (the “Charter Amendment”) of our issued and outstanding shares of Common Stock at a specific ratio, ranging from 1:2 to 1:20 (the “Approved Split Ratios”), to be determined by the Board (the “Reverse Split”). A vote for this Reverse Split Proposal will constitute approval of the Reverse Split that, once authorized by the Board and effected by filing the Charter Amendment with the Secretary of State of the State of Delaware, will combine between 2 and 20 shares of our Common Stock into one share of our Common Stock. If implemented, the Reverse Split will have the effect of decreasing the number of shares of our Common Stock issued and outstanding.
Accordingly, stockholders are asked to adopt and approve the Charter Amendment set forth in Annex A to effect the Reverse Split as set forth in the Charter Amendment, subject to the Board’s determination, in its sole discretion, whether or not to implement the Reverse Split, as well as the specific ratio within the range of the Approved Split Ratios, and provided that the Reverse Split must be effected on or prior to the one-year anniversary date of the Annual Meeting. The text of Annex A remains subject to modification to include such changes as may be required by the Secretary of State of the State of Delaware and as our Board deems necessary or advisable to implement the Reverse Split.
If adopted and approved by the holders of our outstanding voting securities, the Reverse Split would be applied at an Approved Split Ratio approved by the Board prior to the one-year anniversary date of the Annual Meeting. The Board reserves the right to elect to abandon the Reverse Split if it determines, in its sole discretion, that the Reverse Split is no longer in the best interests of the Company and its stockholders.
Purpose and Rationale for the Reverse Split
On September 6, 2024, we received a letter from the Listing Qualifications Staff of Nasdaq indicating that, based upon the closing bid price of our Common Stock for the last 30 consecutive business days, the Company was not in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we were provided 180 days, or until March 5, 2025, to regain compliance with the minimum bid price requirement.
On March 6, 2025, we received a letter from Nasdaq advising that we had been granted a 180-day extension, or until September 1, 2025, to regain compliance with the minimum bid price requirement, in accordance with Nasdaq Listing Rule 5810(c)(3)(A).
On June 30, 2025, at the 2025 annual meeting of the stockholders of the Company, the stockholders voted on a similar proposal and approved the adoption and approval of an amendment to our Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of our issued and outstanding shares of Common Stock, at a specific ratio, ranging from 1:2 to 1:20, at any time prior to the one-year anniversary date of the Annual Meeting, with the exact ratio to be determined by the Board without further approval or authorization of our stockholders. Based on the 2025 annual meeting approval, on August 18, 2025, a reverse stock split at a ratio of 1:3 (the “Prior Reverse Split”) was effected.
On September 2, 2025, the Company received written notice from Nasdaq that it had regained compliance with the minimum bid price requirement.
Although the current price of our shares of Common Stock is higher than the required minimum bid price, this current Reverse Split Proposal is being brought for approval by the stockholders at the Annual
 
34

Table of Contents
 
Meeting in the event that the company will need to satisfy a $4.00 initial bid price in connection with any acquisition, including our recently announced acquisition of Pronghorn Resources LLC, and the related application to relist our shares with Nasdaq (which may be required if Nasdaq views this acquisition as a change of control) and such initial bid price would require an additional reverse stock split in short notice. There are no binding agreements at this time for any acquisition and the Company cannot predict when or if it will enter into such agreement.
Failure to approve the Reverse Split Proposal could prevent the Company from meeting Nasdaq’s $4.00 initial listing bid price requirement if a relisting application becomes necessary in connection with anacquisition, or from regaining compliance with Nasdaq’s $1.00 minimum bid price requirement if the bid price of our Common Stock later falls below $1.00. In particular, if the Company enters into an acquisition or other business combination that Nasdaq determines would result in a change of control of the Company, Nasdaq rules would require the Company to submit a new initial listing application and to satisfy all of Nasdaq’s initial listing requirements, including the $4.00 minimum bid price requirement, in connection with that transaction. Because satisfying the initial bid price requirement may require a reverse stock split on short notice, the Company may be unable to meet this requirement in time without the authority sought by this proposal. As a result, the Company may be unable to complete the transaction while keeping its Common Stock listed on Nasdaq, may be forced to delay, restructure or abandon the transaction, or, if the transaction is completed, could have its Common Stock delisted from Nasdaq. If the Company cannot meet these requirements, our Common Stock could be delisted from Nasdaq. Our shares may then be quoted on the OTC Markets or other small trading markets, which are generally considered to have less volume and be less efficient markets. We believe an investor likely would find it less convenient to sell, or to obtain accurate quotations in seeking to buy, our Common Stock on an over-the-counter market. Many investors likely would not buy or sell our Common Stock due to difficulty in accessing over-the-counter markets, policies preventing them from trading in securities not listed on a national exchange, or other reasons. In that event, the Common Stock could trade thinly as a microcap or penny stock, adversely decrease to nominal levels of trading and may be avoided by retail and institutional investors, resulting in the impaired liquidity of our Common Stock.
In addition, an investment in our Common Stock may not appeal to brokerage firms that are reluctant to recommend lower-priced securities to their clients. Investors may also be dissuaded from purchasing lower- priced stocks because the brokerage commissions, as a percentage of the total transaction, tend to be higher for such stocks. Moreover, the analysts at many brokerage firms do not monitor the trading activity or otherwise provide research coverage of lower-priced stocks. Also, the Company’s Board of Directors believes that most investment funds are reluctant to invest in lower-priced stocks.
Our Board strongly believes that the Reverse Split may be necessary to enable the Company to meet Nasdaq’s $4.00 initial listing bid price requirement if a relisting application becomes necessary in connection with any acquisition that Nasdaq views as a change of control, or to regain compliance with Nasdaq’s $1.00 minimum bid price requirement if the bid price of our Common Stock later falls below $1.00. Accordingly, the Board has recommended that our stockholders approve the Reverse Split Proposal to effect the Reverse Split, if needed, at an Approved Split Ratio to be determined by the Board, and directed that this proposal be submitted to our stockholders for approval at the Annual Meeting.
The Board believes that maintaining the current number of authorized shares of our Common Stock, irrespective of the Reverse Split, is necessary to provide us with the flexibility to act in the future with respect to raising additional financing, potential strategic collaborations and other corporate purposes without the delay and expense associated with obtaining special stockholder approval each time an opportunity requiring the issuance of shares of Common Stock may arise. Such a delay might deny us the flexibility that our Board views as important and in the interests of the Company and its stockholders.
Risks of the Proposed Reverse Split
A decline in the market price of our Common Stock after the Reverse Split is implemented may result in a greater percentage decline than would occur in the absence of a reverse stock split.
If the Reverse Split is implemented and the market price of our Common Stock declines, the percentage decline may be greater than would occur in the absence of a reverse stock split. The market price of our
 
35

Table of Contents
 
Common Stock will, however, also be based upon our performance and other factors, which are unrelated to the number of shares of Common Stock outstanding.
The proposed Reverse Split may decrease the liquidity of our Common Stock.
The liquidity of our Common Stock may be harmed by the proposed Reverse Split given the reduced number of shares of Common Stock that would be outstanding after the Reverse Split, particularly if the stock price does not increase as a result of the Reverse Split.
If we effect the Reverse Split and then the market price of our Common Stock will decline and will fail to meet the continued Nasdaq listing requirement for the minimum bid price, we may not be eligible for any compliance period.
In January 2025, the SEC approved amendments, which are now effective, to the Nasdaq listing rules that significantly affect companies seeking to use reverse stock splits to regain or maintain compliance with Nasdaq’s $1.00 minimum bid price requirement. The changes to the Nasdaq rules alter, among others, the frequency of reverse stock splits to prevent companies from repeatedly using them as part of their minimum bid price compliance strategy. Under the amended Nasdaq Listing Rule 5810(c)(3)(A)(iv), if a company’s security fails to meet the continued listing requirement for minimum bid price and the Company has effected a reverse stock split over the prior one-year period (or has effected one or more reverse stock splits over the prior two-year period with a cumulative ratio of 250 shares or more to one), then the Company shall not be eligible for any compliance period to address the bid price deficiency. Instead, Nasdaq will move forward with delisting proceedings. The Company effected the Prior Reverse Split on August 18, 2025.
The effective increase in the authorized number of shares of our Common Stock as a result of the Reverse Split could have anti-takeover implications.
The implementation of a Reverse Split will result in an effective increase in the authorized number of shares of our Common Stock available for issuance (as our authorized number of shares of Common Stock will remain unchanged), which could, under certain circumstances, have anti-takeover implications. The additional shares of Common Stock that would become available for issuance if a Reverse Split is implemented could be used by us to oppose a hostile takeover attempt or to delay or prevent changes in control or our management. For example, without further stockholder approval, the Board could adopt a “poison pill” which would, under certain circumstances related to an acquisition of our securities that is not approved by the Board, give certain holders the right to acquire additional shares of our Common Stock at a low price. The Board also could strategically sell shares of Common Stock in a private transaction to purchasers who would oppose a takeover or favor the current Board. Although this Reverse Split may be prompted by business and financial considerations and not by the threat of any hostile takeover attempt (nor is the Board currently aware of any such attempts directed at us), stockholders should be aware that approval of a Reverse Split could facilitate future efforts by us to deter or prevent changes in control, including transactions in which the stockholders might otherwise receive a premium for their shares over then current market prices
Determination of the Ratio for the Reverse Split
If the Reverse Split Proposal is approved by stockholders and the Board determines that it is in the best interests of the Company and its stockholders to move forward with the Reverse Split, the Approved Split Ratio will be selected by the Board, in its sole discretion. However, the Approved Split Ratio will not be less than a ratio of 1:2 or exceed a ratio of 1:20. In determining which Approved Split Ratio to use, the Board will consider numerous factors, including the historical and projected performance of our Common Stock, the effect of the Approved Split Ratio on our compliance with other Nasdaq listing requirements, prevailing market conditions and general economic trends, and will place emphasis on the expected closing price of our Common Stock in the period following the effectiveness of the Reverse Split. The Board will also consider the impact of the Approved Split Ratios on investor interest. The purpose of selecting a range is to give the Board the flexibility to meet business needs as they arise, to take advantage of favorable opportunities and to respond to a changing corporate environment. Based on the number of shares of Common Stock issued and outstanding as of October 20, 2026, after completion of the Reverse
 
36

Table of Contents
 
Split, we will have between approximately 427,009 and 4,270,086 shares of Common Stock issued and outstanding, depending on the Approved Split Ratio selected by the Board.
Principal Effects of the Reverse Split
After the effective date of the proposed Reverse Split, each stockholder will own a reduced number of shares of Common Stock. Except for adjustments that may result from the treatment of fractional shares as described below, the proposed Reverse Split will affect all stockholders uniformly. The proportionate voting rights and other rights and preferences of the holders of our Common Stock will not be affected by the proposed Reverse Split. For example, a holder of 2% of the voting power of the outstanding shares of our Common Stock immediately prior to a Reverse Split would continue to hold 2% of the voting power of the outstanding shares of our Common Stock immediately after such Reverse Split. The number of stockholders of record also will not be affected by the proposed Reverse Split, except to the extent that any stockholder holds only a fractional share interest and that fractional share is rounded up after the Reverse Split.
The following table contains approximate number of issued and outstanding shares of Common Stock, and the estimated per share trading price following a 1:2 to 1:20 Reverse Split, without giving effect to any adjustments for fractional shares of Common Stock or the issuance of any derivative securities, as of the Record Date.
After Each Reverse Split Ratio
​ ​ ​
Current
​ ​
1:2
​ ​
1:20
​
Common Stock Authorized
​ ​ ​ ​ 100,000,000 ​ ​ ​ ​ ​ 100,000,000 ​ ​ ​ ​ ​ 100,000,000 ​ ​
Common Stock Issued and Outstanding
​ ​ ​ ​ 8,540,172 ​ ​ ​ ​ ​ 4,270,086 ​ ​ ​ ​ ​
​
approximately
427,009
​ ​
Number of Shares of Common Stock Reserved for
Issuance
​ ​ ​ ​ 45,198,231 ​ ​ ​ ​ ​ 22,599,116 ​ ​ ​ ​ ​ 2,259,912 ​ ​
Number of Shares of Common Stock Authorized but Unissued and Unreserved
​ ​ ​ ​ 46,261,597 ​ ​ ​ ​ ​ 73,130,798 ​ ​ ​ ​ ​ 97,313,079 ​ ​
Price per share, based on the closing price of our Common Stock
on the Record Date
​ ​ ​ $ 4.63 ​ ​ ​ ​ $ 9.26 ​ ​ ​ ​ $ 92.60 ​ ​
After the effective date of the Reverse Split, our Common Stock would have a new committee on uniform securities identification procedures (CUSIP) number, a number used to identify our Common Stock.
Our Common Stock is currently registered under Section 12(b) of the Exchange Act, and we are subject to the periodic reporting and other requirements of the Exchange Act. The proposed Reverse Split will not affect the registration of our Common Stock under the Exchange Act. Our Common Stock would continue to be reported on Nasdaq under the symbol “GRDX”, assuming that we are able to maintain compliance with the minimum bid price requirement, although it is likely that Nasdaq would add the letter “D” to the end of the trading symbol for a period of twenty trading days after the effective date of the Reverse Split to indicate that the Reverse Split had occurred.
Effect on Outstanding Derivative Securities
The Reverse Split will require that proportionate adjustments be made to the conversion rate, the per share exercise price and the number of shares issuable upon the exercise or conversion of the following outstanding derivative securities issued by us, in accordance with the Approved Split Ratio (all figures are as of September 30, 2026, and are on a pre-Reverse Split basis), including:
•
One share of awarded but unissued restricted stock under our 2014 Plan;
​
•
250,000 shares of awarded but unissued restricted stock units under our 2020 Plan;
​
 
37

Table of Contents
 
•
19 shares of Common Stock reserved for issuance pursuant to the exercise of outstanding options issued under our 2020 Plan;
​
•
The 2020 Plan had an aggregate share reserve of 3,801,549 shares following the January 1, 2026 evergreen adjustment, subject to awards and issuances thereafter;
​
•
13,405,987 shares of Common Stock issuable upon exercise of outstanding warrants, comprising 4,584,191 pre-funded warrants and 8,821,796 other warrants;
​
•
786,523 shares of Common Stock potentially issuable upon conversion of 475.56 shares of Series B Preferred Stock;
​
•
1,787,424 shares of Common Stock potentially issuable upon conversion of 595.81 shares of Series G Convertible Preferred Stock; and
​
•
38,801,546 shares of Common Stock potentially issuable upon conversion of 38,801.546 shares of Series H Preferred Stock.
​
The adjustments to the above securities, as required by the Reverse Split and in accordance with the Approved Split Ratio, would result in approximately the same aggregate price being required to be paid under such securities upon exercise, and approximately the same value of shares of Common Stock being delivered upon such exercise or conversion, immediately following the Reverse Split as was the case immediately preceding the Reverse Split.
Effect on Equity Incentive Plans
As of September 30, 2026, we had one share of awarded but unissued restricted stock under our 2014 Plan, 19 outstanding stock options, and 250,000 unvested restricted stock units under our 2020 Plan. The 2020 Plan share reserve increased to 3,801,549 shares on January 1, 2026, before accounting for subsequent awards and issuances. Pursuant to the terms of the 2014 Plan and the 2020 Plan, the Board, or a designated committee thereof, as applicable, will adjust the number of shares of Common Stock underlying outstanding awards, the exercise price per share of outstanding stock options and other terms of outstanding awards issued pursuant to the 2014 Plan and the 2020 Plan to equitably reflect the effects of the Reverse Split. The number of shares subject to vesting under restricted stock awards and the number of shares issuable as contingent consideration as part of an acquisition by the Company will be similarly adjusted, subject to our treatment of fractional shares. The number of shares available for future grant under the 2014 Plan and the 2020 Plan will be similarly adjusted.
Effective Date
The proposed Reverse Split would become effective on the date of filing of the Charter Amendment with the office of the Secretary of State of the State of Delaware unless another effective date is set forth in the Charter Amendment. On the effective date, shares of Common Stock issued and outstanding shares of Common Stock held in treasury, in each case, immediately prior thereto will be combined and reclassified, automatically and without any action on the part of our stockholders, into new shares of Common Stock in accordance with the Approved Split Ratio set forth in this Reverse Split Proposal. If the proposed Charter Amendment is not adopted and approved by our stockholders, the Reverse Split will not occur.
Treatment of Fractional Shares
No fractional shares of Common Stock will be issued as a result of the Reverse Split. In lieu of issuing fractional shares of Common Stock, stockholders of record who otherwise would be entitled to receive fractional shares will be entitled to rounding up of the fractional share to the nearest whole number. For example, if as a result of a reverse stock split a record stockholder would otherwise be entitled to hold 15.3 shares of our Common Stock after giving effect to the Reverse Split, such stockholder would instead hold 16 shares of our Common Stock. The Company does not intend to round up fractional shares at the beneficial level and will instead round any such fractional shares up at the participant level.
Record and Beneficial Stockholders
If the Reverse Split is authorized by our stockholders and our Board elects to implement the Split, stockholders of record holding some or all of their shares of Common Stock electronically in book entry
 
38

Table of Contents
 
form under the direct registration system for securities will receive a transaction statement at their address of record indicating the number of shares of Common Stock they hold after the Reverse Split. Non-registered stockholders holding Common Stock through a bank, broker or other nominee should note that such banks, brokers or other nominees may have different procedures for processing the consolidation than those that would be put in place by us for registered stockholders. If you hold your shares with such a bank, broker or other nominee and if you have questions in this regard, you are encouraged to contact your nominee.
If the Reverse Split is authorized by the stockholders and our Board elects to implement the Reverse Split, stockholders of record holding some or all of their shares in certificate form will receive a letter of transmittal, as soon as practicable after the effective date of the Reverse Split. Our transfer agent will act as “exchange agent” for the purpose of implementing the exchange of stock certificates. Holders of pre-Reverse Split shares will be asked to surrender to the exchange agent certificates representing pre-Reverse Split shares in exchange for post-Reverse Split shares in accordance with the procedures to be set forth in the letter of transmittal. Until surrender, each certificate representing shares before the Reverse Split would continue to be valid and would represent the adjusted number of whole shares based on the approved exchange ratio of the Reverse Split selected by the Board. No new post-Reverse Split share certificates will be issued to a stockholder until such stockholder has surrendered such stockholder’s outstanding certificate(s) together with the properly completed and executed letter of transmittal to the exchange agent.
STOCKHOLDERS SHOULD NOT DESTROY ANY PRE-REVERSE SPLIT STOCK CERTIFICATE AND SHOULD NOT SUBMIT ANY CERTIFICATES UNTIL THEY ARE REQUESTED TO DO SO.
Accounting Consequences
The par value per share of Common Stock would remain unchanged at $0.0001 per share after the Reverse Split. As a result, on the effective date of the Reverse Split, the stated capital on our balance sheet attributable to the Common Stock will be reduced proportionally, based on the Approved Split Ratio selected by the Board, from its present amount, and the additional paid-in capital account shall be credited with the amount by which the stated capital is reduced. The per share Common Stock net income or loss and net book value will be increased because there will be fewer shares of Common Stock outstanding. The shares of Common Stock held in treasury, if any, will also be reduced proportionately based on the Approved Split Ratio selected by the Board. Retroactive restatement will be given to all share numbers in the financial statements, and accordingly all amounts including per share amounts will be shown on a post-split basis. We do not anticipate that any other accounting consequences would arise as a result of the Reverse Split.
No Appraisal Rights
Our stockholders are not entitled to dissenters’ or appraisal rights under the Delaware General Corporation Law with respect to this Reverse Split Proposal and we will not independently provide our stockholders with any such right if the Reverse Split is implemented.
Material Federal U.S. Income Tax Consequences of the Reverse Split
The following discussion is a summary of certain material U.S. federal income tax considerations of the Reverse Split applicable to U.S. holders (as defined below). This discussion does not purport to be a complete analysis of all potential tax consequences that may be relevant to a U.S. holder. The effects of U.S. federal tax laws other than U.S. federal income tax laws, such as estate and gift tax laws, and any applicable state, local or non-U.S. tax laws are not discussed. This discussion is based on the U.S. Internal Revenue Code of 1986, as amended (the “Code”), Treasury Regulations promulgated thereunder, judicial decisions, and published rulings and administrative pronouncements of the IRS, in each case in effect as of the date hereof. These authorities may change or be subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely affect a U.S. holder. We have not sought and do not intend to seek any rulings from the IRS regarding the matters discussed below. There can be no assurance the IRS or a court will not take a position contrary to that discussed below regarding the tax consequences of the Reverse Split.
 
39

Table of Contents
 
This discussion is limited to U.S. holders that hold Common Stock as a “capital asset” within the meaning of Section 1221 of the Code (generally, property held for investment). This discussion does not address all U.S. federal income tax consequences relevant to a U.S. holder’s particular circumstances, including the impact of the alternative minimum tax, the rules related to “qualified small business stock” within the meaning of Section 1202 of the Code or the Medicare contribution tax on net investment income. In addition, it does not address consequences relevant to U.S. holders subject to special rules, including, without limitation:
•
U.S. expatriates and former citizens or long-term residents of the United States;
​
•
U.S. holders whose functional currency is not the U.S. dollar;
​
•
persons holding Common Stock as part of a hedge, straddle or other risk reduction strategy or as part of a conversion transaction or other integrated investment;
​
•
banks, insurance companies, and other financial institutions;
​
•
real estate investment trusts or regulated investment companies;
​
•
brokers, dealers or traders in securities;
​
•
corporations that accumulate earnings to avoid U.S. federal income tax;
​
•
S corporations, partnerships or other entities or arrangements treated as partnerships for U.S. federal income tax purposes (and investors therein);
​
•
tax-exempt organizations or governmental organizations;
​
•
persons deemed to sell Common Stock under the constructive sale provisions of the Code;
​
•
persons who hold or received Common Stock pursuant to the exercise of any employee stock option or otherwise as compensation; and tax-qualified retirement plans.
​
If an entity treated as a partnership for U.S. federal income tax purposes holds Common Stock, the tax treatment of a partner in the partnership will generally depend on the status of the partner, the activities of the partnership and certain determinations made at the partner level. Accordingly, partnerships holding Common Stock and the partners in such partnerships should consult their tax advisors regarding the U.S. federal income tax consequences to them.
THIS DISCUSSION IS FOR INFORMATION PURPOSES ONLY AND IS NOT TAX ADVICE. HOLDERS SHOULD CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE APPLICATION OF THE U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE REVERSE STOCK SPLIT ARISING UNDER THE U.S. FEDERAL ESTATE OR GIFT TAX LAWS OR UNDER THE LAWS OF ANY STATE, LOCAL OR NON-U.S. TAXING JURISDICTION OR UNDER ANY APPLICABLE INCOME TAX TREATY.
The Reverse Split should constitute a “recapitalization” for U.S. federal income tax purposes. As a result, a U.S. holder of Common Stock generally should not recognize gain or loss upon the Reverse Split. A U.S. holder’s aggregate tax basis in the shares of Common Stock received pursuant to the Reverse Split should equal the aggregate tax basis of the shares of the Common Stock surrendered, and such U.S. holder’s holding period in the shares Common Stock received should include the holding period in the shares of Common Stock surrendered. Treasury Regulations provide detailed rules for allocating the tax basis and holding period of the shares of Common Stock surrendered to the shares of Common Stock received in a recapitalization pursuant to the Reverse Split. U.S. holders of shares of Common Stock acquired on different dates and at different prices should consult their tax advisors regarding the allocation of the tax basis and holding period of such shares.
As noted above, we will not issue fractional shares in connection with the Reverse Split. Instead, stockholders who otherwise would be entitled to receive fractional shares will be automatically entitled to receive an additional fraction of a share of Common Stock to round up to the next whole post-split share. The U.S. federal income tax treatment of the receipt of such a fractional share in a Reverse Split is not clear. It is possible that the receipt of such an additional fraction of a share of Common Stock may be treated as a distribution taxable as a dividend or as an amount received in exchange for Common Stock. We intend to
 
40

Table of Contents
 
treat the issuance of such an additional fraction of a share of Common Stock in the Reverse Split as a non-recognition event, but there can be no assurance that the Internal Revenue Service or a court would not successfully assert otherwise.
Required Vote and Recommendation
Pursuant to changes to Section 242 of the Delaware General Corporation Law which became effective on August 1, 2023 (the “DGCL Change”), the necessary stockholder vote to approve reverse stock splits and an increase in authorized share capital was reduced from a majority of outstanding shares entitled to vote, to a majority of votes actually cast at a meeting. In addition to reducing the required shareholder vote for approval of these actions, the DGCL Change has the effect of causing abstentions to have no effect on a stockholder vote. This reduced vote requirement only applies to companies (like ours) whose stock is listed on a national securities exchange and who would continue to meet the listing requirements of the exchange immediately after giving effect to such actions.
Pursuant to the DGCL Change, approval and adoption of this Reverse Split Proposal requires the affirmative vote of at least a majority of votes actually cast at the meeting. Abstentions and broker non-votes, if any, with respect to this proposal are not counted as votes cast and will not affect the outcome of such proposal.
OUR BOARD RECOMMENDS A VOTE “FOR” THE REVERSE SPLIT PROPOSAL.
 
41

Table of Contents​
 
PROPOSAL NO. 3: THE EQUITY PLAN AMENDMENT PROPOSAL
To approve an amendment to the Company’s 2020 Omnibus Equity Incentive Plan (the “Plan”) to: (i) increase the number of shares of Common Stock authorized for issuance under the Plan from 3,801,549 to 10,000,000, including an increase in the number of shares available for grants of incentive stock options (“ISOs”) from 357 to 10,000,000; and (ii) increase the maximum number of shares that may be granted to any non-employee director in a calendar year from 250,000 to 6,500,000 (the “Equity Plan Amendment Proposal”)
General
The general purpose of our 2020 Omnibus Equity Incentive Plan (the “Plan”), is to benefit our Company and its stockholders by assisting the Company and its subsidiaries to attract, retain and provide incentives to key management employees, officers, directors, and consultants of the Company and its affiliates, and to align the interests of such service providers with those of the Company’s stockholders.
Our Board believes that the granting of stock options, restricted stock awards, restricted stock units, stock appreciation rights and similar kinds of cash-based and equity-based compensation promotes continuity of management and provides a critical incentive to align the interests of those who are primarily responsible for shaping and carrying out our long range plans and securing our growth and financial success with the interests of our stockholders.
On October 26, 2026 our Board approved an amendment (i) increasing the number of shares of our Common Stock available for issuance under the Plan from 3,801,549 to 10,000,000, (ii) increasing the number of shares of our Common Stock otherwise available under the Plan that may be granted as ISOs under Section 422 of the Internal Revenue Code of 1986, as amended (the “Code”) from 357 to 10,000,000 shares, and (iii) increasing the number of shares that may be granted to any non-employee director of the Board in a calendar year from 250,000 to 6,500,000. The Board directed that the amendment be submitted to the stockholders for approval at the Annual Meeting. A copy of the amendment is attached as Annex B.
If the Company’s stockholders do not approve the increase in the number of shares available for issuance under the Plan, the Company will continue to operate the Plan under its current provisions, but will be limited in its ability to make future grants and incentives under the Plan to individuals we believe are and in the future will be critical to the Company’s success.
Description of the Existing Plan
The following description of the material terms of the Plan is intended to be a summary only. This summary is qualified in its entirety by the full text of the Plan, as amended, which is incorporated herein by reference to Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on November 16, 2020 and by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on June 23, 2023.
Administration.   The Plan is administered by a committee of our Board (the “Committee”). The Committee has authority to determine the persons to whom options to purchase shares of our Common Stock, stock appreciation rights (“SARs”), restricted stock units, restricted or unrestricted shares of our Common Stock, performance stock awards, performance units, other cash-based awards and other stock- based awards (collectively, “Awards”) may be granted. The Committee may also establish rules and regulations for the administration of the Plan and amendments or modifications of outstanding Awards. The Committee may delegate authority to one or more “reporting persons” ​(as defined in the Plan), including officers, to grant options and other Awards to employees (other than themselves), subject to applicable law and the Plan. No options, stock purchase rights or other Awards may be made under the Plan on or after August 10, 2030, but the Plan will continue thereafter while previously granted options, SARs or other Awards remain outstanding.
Eligibility.   Persons eligible to receive options, SARs or other Awards under the Plan are all employees, officers, directors, consultants, advisors or other individual service providers of our Company and our affiliates, or any person who is determined by the Committee to be a prospective employee, officer, director, consultant, advisor or other individual service provider of the Company or any affiliate (including
 
42

Table of Contents
 
prospective employees, officers, directors, consultants, advisors or other individual service providers as long as they commence employment or engagement with the Company or any affiliate).
As of [      ], 2026, the Company and its affiliates had 6 employees, 2 executive officers who are providing their services to the Company pursuant to service agreements, 3 non-employee directors, and approximately [      ] consultants, other advisors, and individual service providers.
Shares Subject to the Plan.   As of the Record Date, after giving effect to four reverse stock splits, previous amendments to the Plan, and increases in the shares available under the Plan in accordance with the “evergreen provision” discussed below, an aggregate of 3,801,549 shares of our Common Stock were reserved for issuance under the Plan, of which approximately [      ] shares remain available for issuance as of the date of this proxy statement. If this Equity Plan Amendment Proposal is approved by our stockholders, the aggregate Share Reserve under the Plan will increase from 3,801,549 shares to 10,000,000 shares (subject to future increase in accordance with the Plan’s evergreen provision). If this Equity Plan Amendment Proposal is approved, the maximum number of shares with respect to which Awards may be granted to any non-employee director in any calendar year will increase from 250,000 to 6,500,000.
On October 26, 2026, the Board approved, among other awards, an aggregate of 240,000 restricted stock units for certain non-employee directors (100,000 to Mr. Borkowski, 40,000 to Dr. Syage and 100,000 to Mr. Pursglove) and an immediately exercisable option for Mr. Borkowski to purchase 100,000 shares of Common Stock at $5.55 per share. In addition, on October 26, 2026, the Company entered into Amendment No. 4 with BPC Consulting Ltd., providing for up to 250,000 restricted stock units to Ms. Skowron, subject to availability of reserved shares under the Plan. Shares underlying these awards are counted against the Plan Share Reserve.
The Plan contains an “evergreen provision” providing for an annual increase in the number of shares of our Common Stock available for issuance under the Plan on each January 1st so as to be equal to ten percent (10%) of the total number of shares of Common Stock outstanding on each December 31st of the immediately preceding year on an “as converted basis.” As converted shares include all shares of our outstanding Common Stock and all shares of our Common Stock issuable upon the conversion of outstanding preferred stock, warrants and other convertible securities, but do not include any shares of Common Stock issuable upon the exercise of options and other Awards pursuant to the Plan or the Company’s Amended and Restated 2014 Omnibus Equity Incentive Plan. The Board may determine that no increase in the share reserve will be made for any year or that a lesser number of shares to be added.
If any option or SAR granted under the Plan terminates without having been exercised in full or if any other Award is forfeited, or if shares of Common Stock are withheld to cover withholding taxes on options or other Awards or applied to the payment of the exercise price of an option or purchase price of an Award, the number of shares of Common Stock as to which such option or Award was forfeited, withheld or paid, will be available for future grants under the Plan.
Up to 357 shares of Common Stock available under the Plan may be granted as ISOs. If this Proposal No. 3 is approved by stockholders, up to 10,000,000 shares of Common Stock that may otherwise become available for Awards under the Plan may be granted as ISOs.
The number of shares authorized for issuance under the Plan and the foregoing share limitations are subject to customary adjustments for stock splits, stock dividends or similar transactions.
Terms and Conditions of Options.   Options granted under the Plan may be either ISOs or “nonstatutory stock options” that do not meet the requirements of Section 422 of the Code. The Committee will determine the exercise price of options granted under the Plan. The exercise price of stock options may not be less than the fair market value per share of our Common Stock on the date of grant (or 110% of fair market value in the case of ISOs granted to a ten-percent stockholder).
If on the date of grant our Common Stock is listed on a stock exchange or is quoted on the automated quotation system of Nasdaq, the fair market value will generally be the closing sale price on the date of grant (or the last trading day before the date of grant if no trades occurred on the date of grant). If no such prices are available, the fair market value will be determined in good faith by the Committee based on the
 
43

Table of Contents
 
reasonable application of a reasonable valuation method. On October 20, 2026, the closing sale price of a share of our Common Stock on Nasdaq was $4.63.
No option may be exercisable for more than ten years (five years in the case of an ISO granted to a ten-percent stockholder) from the date of grant. Options granted under the Plan will be exercisable at such time or times as the Committee prescribes at the time of grant. No employee may receive ISOs that first become exercisable in any calendar year in an amount exceeding $100,000. The Committee may, in its discretion, permit a holder of an option to exercise the option before it has otherwise become exercisable, in which case the shares of our Common Stock issued to the recipient will continue to be subject to the vesting requirements that applied to the option before exercise.
Generally, the option price may be paid (a) in cash or by certified check, bank draft or money order, (b) through delivery of shares of our Common Stock having a fair market value equal to the purchase price, or (c) a combination of these methods. The Committee is also authorized to establish a cashless exercise program and to permit the exercise price (or tax withholding obligations) to be satisfied by reducing from the shares otherwise issuable upon exercise a number of shares having a fair market value equal to the exercise price.
No option may be transferred other than by will or by the laws of descent and distribution, and during a recipient’s lifetime an option may be exercised only by the recipient or the recipient’s guardian or legal representative. However, the Committee may permit the holder of an option, SAR or other Award to transfer the option, right or other award to family members or a family trust for estate planning purposes. The Committee will determine the extent to which a holder of a stock option may exercise the option following termination of service with us.
Stock Appreciation Rights.   The Committee may grant SARs, independent of or in connection with an option. The Committee will determine the other terms applicable to SARs. The exercise price per share of a SAR will not be less than 100% of the fair market value of a share of our Common Stock on the date of grant, as determined by the Committee. The maximum term of any SAR granted under the Plan is ten years from the date of grant. Generally, each SAR will entitle a participant upon exercise to an amount equal to:
•
the excess of the fair market value on the exercise date of one share of our Common Stock over the exercise price, multiplied by
​
•
the number of shares of Common Stock covered by the SAR.
​
Payment may be made in shares of our Common Stock, in cash, or partly in Common Stock and partly in cash, all as determined by the Committee.
Restricted Stock, Unrestricted Stock and Restricted Stock Units.   The Committee may award restricted Common Stock, unrestricted shares of Common Stock and/or restricted stock units under the Plan. Restricted stock awards consist of shares of Common Stock that are transferred to a participant subject to restrictions that may result in forfeiture if specified conditions are not satisfied. Unrestricted stock awards consist of shares of Common Stock that are not subject to any restrictions. Restricted stock units confer the right to receive shares of our Common Stock, cash, or a combination of shares and cash, at a future date upon or following the attainment of certain conditions specified by the Committee. The restrictions and conditions applicable to each award of restricted stock or restricted stock units may include performance-based conditions. Dividends with respect to restricted stock or unrestricted stock may be paid to the holder of the shares as and when dividends are paid to stockholders or at the time that the restricted stock vests, if applicable, as determined by the Committee. Dividend equivalent amounts may be paid with respect to restricted stock units either when cash dividends are paid to stockholders or when the units vest. Unless the Committee determines otherwise, holders of restricted stock and unrestricted stock will have the right to vote the shares.
Performance Stock Awards and Performance Units.   The Committee may award performance stock awards and/or performance units under the Plan. Performance stock awards and performance units are awards, denominated in either shares of Common Stock or U.S. dollars, which are earned during a specified
 
44

Table of Contents
 
performance period subject to the attainment of performance criteria, as established by the Committee. The Committee will determine the restrictions and conditions applicable to each award of performance stock awards and performance units.
Incentive Bonus Awards, Other Stock-Based and Cash-Based Awards.   The Committee may award other types of equity-based or cash-based awards under the Plan, including the grant or offer for sale of shares of our Common Stock that do not have vesting requirements and the right to receive one or more cash payments subject to satisfaction of such conditions as the Committee may impose.
Effect of Certain Corporate Transactions.   The Committee may, at the time of the grant of an Award provide for the effect of a change of control (as defined in the Plan) on any Award, including (i) accelerating or extending the time periods for exercising, vesting in, or realizing gain from any award, (ii) eliminating or modifying the performance or other conditions of an award, or (iii) providing for the cash settlement of an award for an equivalent cash value, as determined by the committee. The Committee may, in its discretion and without the need for the consent of any recipient of an award, also take one or more of the following actions contingent upon the occurrence of a change of control: (a) cause any or all outstanding options and SARs to become immediately exercisable, in whole or in part; (b) cause any other Awards to become non- forfeitable, in whole or in part; (c) cancel any option or SAR in exchange for a substitute option; (d) cancel any Award of restricted stock, restricted stock units, performance stock awards or performance units in exchange for a similar Award of the capital stock of any successor corporation; (e) redeem any restricted stock, restricted stock unit, performance share or performance unit for cash and/or other substitute consideration with a value equal to the fair market value of an unrestricted share of our Common Stock on the date of the change of control; or (f) cancel any option or SAR in exchange for cash and/or other substitute consideration based on the value of our Common Stock on the date of the change of control, and cancel any option or SAR without any payment if its exercise price exceeds the value of our Common Stock on the date of the change of control.
Amendment, Termination.   Our Board may at any time amend the Plan for the purpose of satisfying the requirements of the Code, or other applicable law or regulation or for any other legal purpose, provided that, without the consent of our stockholders, the Board may not (a) increase the number of shares of Common Stock available under the Plan, or (b) change the group of individuals eligible to receive options, SARs and/or other awards.
New Plan Benefits
Grants of Awards under the Plan are discretionary, and we cannot determine now the number or type of options or other awards to be granted in the future to any particular person or group. No awards have been granted under the Plan that are subject to stockholder approval of this Equity Plan Amendment Proposal.
Material Federal Income Tax Consequences
The following is a summary of the principal federal income tax consequences of option and other Awards under the Plan. Optionees and recipients of other rights and Awards granted under the Plan are advised to consult their personal tax advisors before exercising an option or SAR or disposing of any stock received pursuant to the exercise of an option or SAR or following vesting of a restricted stock award or restricted stock unit or upon grant of an unrestricted stock award. In addition, the following summary is based upon an analysis of the Code as currently in effect, existing laws, judicial decisions, administrative rulings, regulations and proposed regulations, all of which are subject to change and does not address state, local or other tax laws.
Treatment of Options
The Code treats incentive stock options and nonstatutory stock options differently. However, as to both types of options, no income will be recognized to the optionee at the time of the grant of the options under the Plan, nor will our Company be entitled to a tax deduction at that time.
Generally, upon exercise of a nonstatutory stock option (including an option intended to be an incentive stock option but which has not continued to qualify at the time of exercise), an optionee will
 
45

Table of Contents
 
recognize ordinary income tax on the excess of the fair market value of the stock on the exercise date over the option price. Our Company will be entitled to a tax deduction in an amount equal to the ordinary income recognized by the optionee in the fiscal year which includes the end of the optionee’s taxable year. We will be required to satisfy applicable withholding requirements in order to be entitled to a tax deduction. In general, if an optionee, in exercising a nonstatutory stock option, tenders shares of our Common Stock in partial or full payment of the option price, no gain or loss will be recognized on the tender. However, if the tendered shares were previously acquired upon the exercise of an incentive stock option and the tender is within two years from the date of grant or one year after the date of exercise of the incentive stock option, the tender will be a disqualifying disposition of the shares acquired upon exercise of the incentive stock option.
For incentive stock options, there is no taxable income to an optionee at the time of exercise. However, the excess of the fair market value of the stock on the date of exercise over the exercise price will be taken into account in determining whether the “alternative minimum tax” will apply for the year of exercise. If the shares acquired upon exercise are held until at least two years from the date of grant and more than one year from the date of exercise, any gain or loss upon the sale of such shares, if held as capital assets, will be long-term capital gain or loss (measured by the difference between the sales price of the stock and the exercise price). Under current federal income tax law, a long-term capital gain will be taxed at a rate which is less than the maximum rate of tax on ordinary income. If the two-year and one year holding period requirements are not met (a “disqualifying disposition”), an optionee will recognize ordinary income in the year of disposition in an amount equal to the lesser of (i) the fair market value of the stock on the date of exercise minus the exercise price or (ii) the amount realized on disposition minus the exercise price. The remainder of the gain will be treated as long-term capital gain, depending upon whether the stock has been held for more than a year. If an optionee makes a disqualifying disposition, our Company will be entitled to a tax deduction equal to the amount of ordinary income recognized by the optionee.
In general, if an optionee, in exercising an incentive stock option, tenders shares of Common Stock in partial or full payment of the option price, no gain or loss will be recognized on the tender. However, if the tendered shares were previously acquired upon the exercise of another incentive stock option and the tender is within two years from the date of grant or one year after the date of exercise of the other option, the tender will be a disqualifying disposition of the shares acquired upon exercise of the other option.
As noted above, the exercise of an incentive stock option could subject an optionee to the alternative minimum tax. The application of the alternative minimum tax to any particular optionee depends upon the particular facts and circumstances which exist with respect to the optionee in the year of exercise. However, as a general rule, the amount by which the fair market value of the Common Stock on the date of exercise of an option exceeds the exercise price of the option will constitute an item of “adjustment” for purposes of determining the alternative minimum taxable income on which the alternative tax may be imposed. As such, this item will enter into the tax base on which the alternative minimum tax is computed and may therefore cause the alternative minimum tax to become applicable in any given year.
Treatment of Stock Appreciation Rights
Generally, the recipient of a SAR will not recognize any income upon grant of the SAR, nor will our Company be entitled to a deduction at that time. Upon exercise of a SAR, the holder will recognize ordinary income, and our Company generally will be entitled to a corresponding deduction equal to the fair market value of our Common Stock at that time.
Treatment of Stock Awards
Generally, absent an election to be taxed currently under Section 83(b) of the Code (a “Section 83(b) Election”), there will be no federal income tax consequences to either the recipient or our Company upon the grant of a restricted stock award. At the expiration of the restriction period and the satisfaction of any other restrictions applicable to the restricted shares, the recipient will recognize ordinary income and our Company generally will be entitled to a corresponding deduction equal to the fair market value of the Common Stock at that time. If a Section 83(b) Election is made within 30 days after the date the restricted stock award is granted, the recipient will recognize an amount of ordinary income at the time of the receipt of the restricted shares, and our Company generally will be entitled to a corresponding deduction, equal to
 
46

Table of Contents
 
the fair market value (determined without regard to applicable restrictions) of the shares at such time, less any amount paid by the recipient for the shares. If a Section 83(b) Election is made, no additional income will be recognized by the recipient upon the lapse of restrictions on the shares (and prior to the sale of such shares), but, if the shares are subsequently forfeited, the recipient may not deduct the income that was recognized pursuant to the Section 83(b) Election at the time of the receipt of the shares.
The recipient of an unrestricted stock award will recognize ordinary income, and our Company generally will be entitled to a corresponding deduction, equal to the fair market value of our Common Stock that is the subject of the award when the award is made.
The recipient of a restricted stock unit will recognize ordinary income as and when the units vest and shares of our Common Stock are issued. The amount of the income will be equal to the fair market value of the shares of our Common Stock issued at that time, and our Company will be entitled to a corresponding deduction. The recipient of a restricted stock unit will not be permitted to make a Section 83(b) Election with respect to such award.
The federal income tax consequences of performance share awards, performance unit awards, other cash- based awards and other stock-based awards will depend on the terms and conditions of those awards but, in general, participants will be required to recognize ordinary income in an amount equal to the cash and the fair market value of any fully vested shares of our Common Stock paid, determined at the time of such payment, in connection with such awards.
Section 409A.   If an award is subject to Section 409A of the Code but does not comply with the requirements of Section 409A of the Code, the taxable events as described above could apply earlier than described and could result in the imposition of additional taxes and penalties. Participants are urged to consult with their tax advisors regarding the applicability of Section 409A of the Code to their awards.
Potential Limitation on Company Deductions
Section 162(m) of the Code generally disallows a tax deduction for compensation in excess of $1 million paid in a taxable year by a publicly held corporation to its chief executive officer and certain other “covered employees.” The Committee intends to consider the potential impact of Section 162(m) on grants made under the Plan but reserves the right to approve grants of options and other awards for an executive officer that exceed the deduction limit of Section 162(m).
Tax Withholding
As and when appropriate, we shall have the right to require each optionee purchasing shares of Common Stock and each grantee receiving an award of shares of Common Stock under the Plan to pay any federal, state or local taxes required by law to be withheld.
 
47

Table of Contents
 
Equity Compensation Plan Information
The following table reproduces the equity compensation plan information reported in the Company’s Form 10-K for the fiscal year ended December 31, 2025. Subsequent 2026 equity awards are discussed separately in this proxy statement:
Plan category
​ ​
Number of
securities to be
issued upon
exercise of
outstanding
options, warrants
and rights
​ ​
Weighted-average
exercise price of
outstanding
option, warrants
and rights
​ ​
Number of
securities
remaining
available for
future issuance
under equity
compensation
plans reflected
in column (a)
​
Equity compensation plans approved by security
holders
(1)
​ ​ ​ ​ 19 ​ ​ ​ ​ $ 39,125 ​ ​ ​ ​ ​ 941,100 ​ ​
Equity compensation plans not approved by security
holders
​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​
Total
​ ​ ​ ​ 19 ​ ​ ​ ​ $ 39,125 ​ ​ ​ ​ ​ 941,100 ​ ​
​
(1)
Represents outstanding stock options granted to our current or former employees, directors and consultants pursuant to the 2014 Plan, and 2020 Plan.
​
Required Vote and Recommendation
In accordance with our Charter, Bylaws and Delaware law, and as further discussed above under “The Annual Meeting — Quorum; Abstentions and Broker Non-Votes,” approval and adoption of this Equity Plan Amendment Proposal requires the affirmative (“FOR”) vote of a majority of votes cast by shares of our Common Stock present or represented by proxy and entitled to vote at the Annual Meeting and voting affirmatively or negatively on such matter. Unless otherwise instructed on the proxy or unless authority to vote is withheld, shares represented by executed proxies will be voted “FOR” this proposal. Abstentions and broker non-votes, if any, with respect to this proposal are not counted as votes cast and will not affect the outcome of such proposal.
OUR BOARD RECOMMENDS A VOTE “FOR” PROPOSAL THREE.
 
48

Table of Contents​
 
PROPOSAL NO. 4: THE NASDAQ PROPOSAL
To approve the issuance of up to 1,520,000 shares of Common Stock upon the exercise of warrants issued or issuable pursuant to that certain Securities Purchase Agreement dated October 17, 2025, as amended to date, by and among the Company and the investors party thereto, as required by and in accordance with Nasdaq Listing Rule 5635(d)
Background
In October 2025, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Company agreed to sell to the Investor in a private placement (“Offering”) up to $5,000,000 Promissory Notes (the “Notes”) and a Common Stock purchase warrant to purchase up to an aggregate of 1,520,000 shares of Common Stock (the “Warrant,” and the shares issuable upon exercise of the Warrant, the “Warrant Shares”). The Purchase Agreement permits subsequent closings after the initial closing, for all or any portion of the remaining aggregate offering amount not sold at the time of the initial closing or any subsequent closing. The initial closing took place on October 17, 2025, pursuant to which the Company sold to the Investor a Note in the principal amount of $500,000 and a Warrant to purchase up to 200,000 shares of Common Stock, for gross proceeds of $500,000.
On December 16, 2025, the Company entered into amendment No. 1 to the Purchase Agreement (the “Amendment”), pursuant to which additional investors (and together with the Investor, the “Investors”) joined the Purchase Agreement. The Amendment did not change the maximum number of securities issuable under the Purchase Agreement (up to $5,000,000 Notes and Warrants to purchase up to 1,520,000 Warrant Shares). From October 17 through December 26, 2025, the Company issued Notes in an aggregate principal amount of $2,300,000, including the initial $500,000 closing, and Warrants to purchase an aggregate of 713,600 shares of Common Stock, for aggregate gross proceeds of $2,300,000.
Each Warrant becomes exercisable upon the date of stockholder approval of this proposal (the “Stockholder Approval Date”) and expires five (5) years from the Stockholder Approval Date. Each Warrant has an exercise price of $2.50 per share, subject to adjustment for stock splits, stock dividends, recapitalizations, and similar customary adjustments.
Why We Need Stockholder Approval
The Company is seeking stockholder approval of the issuance of shares of Common Stock upon exercise of the Warrants in order to comply with the applicable rules of The Nasdaq Stock Market LLC. Nasdaq Listing Rule 5635(d) requires stockholder approval prior to the issuance of securities in connection with a transaction, other than a public offering, involving the sale, issuance, or potential issuance by the Company of Common Stock (or securities convertible into or exercisable for Common Stock) equal to 20% or more of the Common Stock or 20% or more of the voting power outstanding before the issuance, at a price that is less than the lower of (i) the closing price immediately preceding the signing of the binding agreement or (ii) the average closing price of the Common Stock for the five trading days immediately preceding the signing of the binding agreement. The Company is asking stockholders to approve the issuance because in the absence of stockholder approval, such issuances could result in the issuance violating Nasdaq Listing Rule 5635(d).
Consequences of Not Approving This Proposal
If our stockholders do not approve this proposal, the Warrants will not become exercisable. Although there can be no assurance that the Investors will exercise any of the Warrants for cash, without stockholder approval the Company will be unable to receive up to $3.8 million in gross proceeds that would result from the cash exercise of the Warrants in full. The loss of access to these proceeds could have a material adverse effect on the Company’s financial condition, results of operations and liquidity. In addition, failure to approve this proposal could impair the Company’s ability to raise additional capital in the future.
 
49

Table of Contents
 
Resolution
We are asking stockholders to approve the following resolution:
“RESOLVED, that the stockholders of GridAI Technologies Corp. hereby approve, for purposes of complying with Nasdaq Listing Rule 5635(d) and any other applicable Nasdaq Listing Rules, the issuance of up to 1,520,000 shares of Common Stock (subject to adjustment for stock splits, stock dividends, recapitalizations, and similar corporate events) upon exercise of the Warrants issued or issuable pursuant to the Securities Purchase Agreement entered into on October 17, 2025, as amended to date, at an exercise price of $2.50 per share (subject to adjustment as set forth in the Warrants), which Warrants shall become exercisable upon the date of stockholder approval of this proposal and shall expire five (5) years from such date.”
Vote Required
The approval of this proposal requires the affirmative (“FOR”) vote of a majority of the votes cast by shares of our Common Stock present or represented by proxy and entitled to vote at the Annual Meeting. Abstentions and broker non-votes, if any, with respect to this proposal are not counted as votes cast and will not affect the outcome of the voting on this proposal.
Board Recommendation
THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT STOCKHOLDERS VOTE “FOR” THE APPROVAL OF THE ISSUANCE OF UP TO 1,520,000 SHARES OF COMMON STOCK UPON THE EXERCISE OF WARRANTS ISSUED OR ISSUABLE PURSUANT TO THAT CERTAIN SECURITIES PURCHASE AGREEMENT DATED OCTOBER 17, 2025, AS AMENDED TO DATE, BY AND AMONG THE COMPANY AND THE INVESTORS PARTY THERETO, AS REQUIRED BY AND IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(D).
 
50

Table of Contents​
 
PROPOSAL NO. 5: THE SAY ON PAY PROPOSAL
Approval, on an advisory basis, of the executive compensation of the Company’s named executive officers as described in this proxy statement
At our 2022 annual meeting of stockholders, we conducted a non-binding stockholder vote on the frequency of future Say-on-Pay votes (commonly known as a “Say-When-on-Pay” vote). We recommended that such votes be conducted annually and our stockholders approved that recommendation. We will hold a Say-on-Pay vote at each annual meeting until the time our stockholders vote to hold a Say-on-Pay vote at a different frequency.
Q:
What are you voting on?
​
A:
In accordance with Section 14A of the Securities Exchange Act of 1934, we are asking stockholders to vote, on an advisory basis, on:
​
Say-on-pay.   Approval of the compensation of our named executive officers as disclosed in this proxy statement, including the various compensation tables and the related narrative disclosures.
Q:
Why does your Board recommend a vote “FOR” the say-on-pay proposal (Proposal 5)?
​
A.
The Board believes that the Company’s compensation policies and practices are effective in achieving our goals of motivating and retaining our executives by:
​
•
rewarding excellence in leadership and sustained financial performance; and
​
•
aligning our executives’ interests with those of our stockholders to create long-term value.
​
Q:
What are the effects of these votes?
​
A:
The Say on Pay Proposal is advisory and non-binding on our Board. However, the Board and the Compensation Committee will review and consider the results of this vote when evaluating our executive compensation program.
​
The Say on Pay Proposal is as follows:
“Resolved, that the compensation of the Company’s named executive officers, as described in the Company’s proxy statement for the 2026 Annual Meeting of Stockholders, including the various compensation tables and the related narrative disclosures, is hereby APPROVED.”
Required Vote and Recommendation
In accordance with our Charter, Bylaws and Delaware law, and as further discussed above under “The Annual Meeting — Quorum; Abstentions and Broker Non-Votes,” approval and adoption of this Say on Pay Proposal requires the affirmative (“FOR”) vote of a majority of votes cast by shares of our Common Stock present or represented by proxy and entitled to vote at the Annual Meeting and voting affirmatively or negatively on such matter. Unless otherwise instructed on the proxy or unless authority to vote is withheld, shares represented by executed proxies will be voted “FOR” this proposal. Abstentions and broker non-votes, if any, with respect to this proposal are not counted as votes cast and will not affect the outcome of such proposal.
OUR BOARD RECOMMENDS A VOTE “FOR” PROPOSAL FIVE.
 
51

Table of Contents​
 
PROPOSAL NO. 6:
Ratification of the appointment of Macias Gini & O’Connell LLP to serve as our independent registered public accounting firm for the fiscal year ending December 31, 2026
General
The Audit Committee of the Board appointed Macias Gini & O’Connell LLP (“MGO”) as our independent registered public accounting firm for the year ending December 31, 2026, subject to ratification by the Company’s stockholders, and the Board hereby recommends that the stockholders ratify such appointment. The Board may terminate the appointment of MGO as our independent registered public accounting firm without the approval of our stockholders whenever the Board deems such termination necessary or appropriate.
Representatives of MGO will be present at the Annual Meeting or available by telephone and will have an opportunity to make a statement if they so desire and to respond to any appropriate questions from stockholders.
Audit Fees
The following table presents fees for professional services billed by MGO, Mazars USA LLP (“Mazars”) and Forvis Mazars (“Forvis”), as applicable, for the fiscal years ended December 31, 2025 and December 31, 2024 in relation to services rendered in connection with the audit of our consolidated financial statements and for tax services rendered with respect to tax-related compliance, advice and planning. MGO has served as our independent registered public accounting firm since August 27, 2024. Mazars was engaged for the quarterly review of the period ended March 31, 2024. Forvis was engaged for the quarterly review of the period ended June 30, 2024.
​ ​ ​
For the years ended
​
​ ​ ​
December 31,
​
​ ​ ​
2025
​ ​
2024
​
Audit fees(1)
​ ​ ​ $ 360,150 ​ ​ ​ ​ $ 280,500 ​ ​
Audit-related fees(2)
​ ​ ​ ​ 53,000 ​ ​ ​ ​ ​ 227,700 ​ ​
Tax fees
​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​
All other fees(3)
​ ​ ​ ​ — ​ ​ ​ ​ ​ 20,249 ​ ​
Total
​ ​ ​ $ 413,150 ​ ​ ​ ​ $ 528,449 ​ ​
​
(1)
Professional services rendered by MGO for the audit of our annual financial statements and review of financial statements included in our Form 10-Qs. MGO billed fees of $360,150 for 2025 and $280,500 for 2024.
​
(2)
The aggregate fees billed for assurance and related services by Mazars in 2025 and by Mazars and Forvis in 2024, which are reasonably related to the performance of the audit or review of our financial statements and are not reported under Note 1 above, principally related to registration statement filings. Mazars billed fees of $53,000 for 2025 and $227,700 for 2024.
​
(3)
The aggregate fees billed for products and services provided by MGO in 2025 and by Mazars in 2024, other than the services reported in Notes 1 and 2 above.
​
Audit Committee Pre-Approval Policies and Procedures
The Audit Committee has the sole authority for the appointment, compensation and oversight of the work of our independent auditors. The Audit Committee has established a policy regarding pre-approval of all auditing services and the terms thereof and non-audit services (other than non-audit services prohibited under Section 10A(g) of the Exchange Act or the applicable rules of the SEC or the Public Company Accounting Oversight Board) to be provided to us by the independent auditor. However, the pre-approval
 
52

Table of Contents
 
requirement may be waived with respect to the provision of non-audit services for us if the “de minimis” provisions of Section 10A(i)(1)(B) of the Exchange Act are satisfied.
The Audit Committee has considered whether the provision of audit-related fees, tax fees, and all other fees as described above is compatible with maintaining Mazars’, Forvis’ and MGO’s independence and has determined that such services for fiscal year 2024 and 2025 were compatible. All such services were approved by the Audit Committee pursuant to Rule 2-01(c)(7)(i)(C) of Regulation S-X to the extent that rule was applicable.
The Audit Committee is responsible for reviewing and discussing the audited financial statements with management, discussing with the independent registered public accountants the matters required by PCAOB Auditing Standard 1301, receiving written disclosures from the independent registered public accountants required by the applicable requirements of the Public Company Accounting Oversight Board regarding the independent registered public accountants’ communications with the Audit Committee concerning independence and discussing with the independent registered public accountants their independence, and recommending to our board of directors that the audited financial statements be included in our annual report on Form 10-K.
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
Appointment of Forvis Mazars, LLP
In 2024, the Company was notified that Mazars, the Company’s independent registered public accounting firm, entered into a transaction with FORVIS whereby substantially all of the partners and employees of Mazars joined Forvis. As a result, on the effective date of June 1, 2024, Mazars changed its name to Forvis Mazars, LLP (“Forvis Mazars”) and Mazars resigned as the Company’s independent public accounting firm. The Audit Committee of the Company’s Board of Directors appointed Forvis Mazars to serve as the Company’s independent registered public accounting firm effective June 1, 2024, subject to ratification by the Company’s stockholders at the Company’s annual meeting of stockholders.
The audit reports of Mazars on the financial statements of the Company for the fiscal years ended December 31, 2023 and 2022 did not contain an adverse opinion or a disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope, or accounting principles.
During the Company’s fiscal years ended December 31, 2023 and 2022, and the subsequent interim period preceding the engagement of Forvis Mazars, there were no disagreements between the Company and Mazars on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Mazars, would have caused Mazars to make reference to any subject matter of the disagreements in connection with its audit reports on the Company’s financial statements. During the Company’s previous fiscal years ended December 31, 2023 and 2022, and the interim period through the engagement of Forvis Mazars, Mazars did not advise the Company of any matters specified in Item 304(a)(1)(v) of Regulation S-K.
During the Company’s two most recently completed fiscal years and through the date of engagement of Forvis Mazars, neither the Company nor anyone on behalf of the Company consulted with Mazars regarding (a) the application of accounting principles to a specific transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company’s financial statements as to which the Company received a written report or oral advice that was an important factor in reaching a decision on any accounting, auditing or financial reporting issue; or (b) any matter that was the subject of a disagreement or a reportable event as defined in Items 304(a)(1)(iv) and (v), respectively, of Regulation S-K. During the Company’s fiscal years ended December 31, 2023 and 2022, and the subsequent period through the date hereof, the Company did not consult with Forvis Mazars regarding any of the matters set forth in Items 304(a)(2)(i) and (ii) of Regulation S-K.
Resignation of Forvis Mazars, LLP
On August 9, 2024, Forvis Mazars notified the Company that it had decided to resign as the independent registered public accounting firm of the Company, effective immediately. As mentioned, the Audit Committee
 
53

Table of Contents
 
of the Company appointed Forvis Mazars to serve as the Company’s independent registered public accounting firm on June 1, 2024, and as such, Forvis Mazars did not provide any audit reports on the financial statements of the Company for the fiscal years ended December 31, 2023 and 2022.
Forvis Mazars resigned due to a belief that the Company could no longer generate reliable information to prepare its financial statements as a result of the cost reduction measures and other corporate developments.
The Company disagreed with Forvis Mazars’ belief (the “Disagreement”). Notwithstanding Forvis Mazars’ resignation, the Company believed it had sufficient management and governance in place, including a full- time Chief Financial Officer and corporate controller, and an Audit Committee of the Company’s Board that fully satisfied the corporate governance requirements of the Nasdaq Stock Market LLC and Securities Exchange Act Rule 10A-3. Members of the Audit Committee, upon being notified by Forvis Mazars of the resignation, discussed the Disagreement with Forvis Mazars. The Company authorized Forvis Mazars to respond fully to the inquiries of any successor accountant concerning the subject matter of the Disagreement.
From the appointment of Forvis Mazars to the date of Forvis Mazars’ resignation (the “Interim Period”), there were no disagreements between the Company and Forvis Mazars on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Forvis Mazars, would have caused Forvis Mazars to make reference to any subject matter of the disagreements in connection with its audit reports on the Company’s financial statements. During the Interim Period, Forvis Mazars did not advise the Company of any matters specified in Item 304(a)(1)(v) of Regulation S-K other than the subject matter of the Disagreement discussed above.
Appointment of Macias Gini & O’Connell LLP
On August 28, 2024, the Audit Committee appointed MGO to serve as the Company’s independent registered public accounting firm effective August 27, 2024, subject to ratification by the Company’s stockholders at the Company’s annual meeting of stockholders.
During the fiscal years ended December 31, 2024 and 2023 and through August 27, 2024, neither the Company nor anyone on behalf of the Company consulted with MGO regarding (a) the application of accounting principles to a specific transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company’s financial statements as to which the Company received a written report or oral advice that was an important factor in reaching a decision on any accounting, auditing or financial reporting issue; or (b) any matter that was the subject of a disagreement or a reportable event as defined in Items 304(a)(1)(iv) and (v), respectively, of Regulation S-K. During the fiscal years ended December 31, 2024 and 2023 and the interim period from January 1, 2024 through August 27, 2024, the Company did not consult with MGO regarding any of the matters set forth in Items 304(a)(2)(i) and (ii) of Regulation S-K.
Required Vote and Recommendation
This proposal requires the affirmative (“FOR”) vote of a majority of votes cast by shares present or represented by proxy and entitled to vote at the Annual Meeting and voting affirmatively or negatively on such matter. Unless otherwise instructed on the proxy or unless authority to vote is withheld, shares represented by executed proxies will be voted “FOR” this proposal. Any abstentions are not counted as votes cast and will not affect the outcome of this proposal, although they will be counted for purposes of determining whether there is a quorum present. No broker non-votes are expected on this Proposal.
OUR BOARD RECOMMENDS A VOTE “FOR” PROPOSAL SIX.
 
54

Table of Contents​
 
PROPOSAL NO. 7: THE ADJOURNMENT PROPOSAL
Approval of the adjournment of the annual meeting to the extent there are insufficient proxies at the annual meeting to approve any one or more of the foregoing proposals
Adjournment of the Annual Meeting
In the event that the number of shares of Common Stock present or represented by proxy at the Annual Meeting and voting “FOR” the adoption of any one or more of the foregoing proposals are insufficient to approve any such proposal, we may move to adjourn the Annual Meeting in order to enable us to solicit additional proxies in favor of the adoption of any such proposal. In that event, we will ask stockholders to vote only upon the adjournment proposal and not on any other proposal discussed in this proxy statement. If the adjournment is for more than thirty (30) days, a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting.
For the avoidance of doubt, any proxy authorizing the adjournment of the Annual Meeting shall also authorize successive adjournments thereof, at any meeting so adjourned, to the extent necessary for us to solicit additional proxies in favor of the adoption of any such proposal.
Required Vote and Recommendation
In accordance with our Charter, Bylaws and Delaware law, and as further discussed above under “The Annual Meeting — Quorum; Abstentions and Broker Non-Votes,” approval and adoption of this Adjournment Proposal requires the affirmative (“FOR”) vote of a majority of votes cast by shares of our Common Stock present or represented by proxy and entitled to vote at the Annual Meeting and voting affirmatively or negatively on such matter. Unless otherwise instructed on the proxy or unless authority to vote is withheld, shares represented by executed proxies will be voted “FOR” this proposal. Abstentions and broker non-votes, if any, with respect to this proposal are not counted as votes cast and will not affect the outcome of this proposal.
OUR BOARD RECOMMENDS A VOTE “FOR” PROPOSAL SEVEN.
 
55

Table of Contents​​
 
INTERESTS OF DIRECTORS AND EXECUTIVE OFFICERS IN THE PROPOSALS
Other than the election of directors and the approval of the advisory vote on executive compensation (the “Say on Pay Proposal”), the Reverse Split Proposal and the Equity Plan Amendment Proposal, none of our directors, nominees for director, executive officers, any person who has served as a director or executive officer since the beginning of the last fiscal year, or their associates have any interest, direct or indirect, by security holdings or otherwise, in any of the matters to be acted upon at the Annual Meeting as described in this Proxy Statement. Mr. Sawyer has an interest in the Reverse Split Proposal because the A&R Consulting Agreement provides for a $20,000 quarterly fee for each quarter that the Company remains in compliance with Nasdaq rules and listing requirements. Mr. Sawyer also has an interest in the Equity Plan Amendment Proposal because the A&R Consulting Agreement provides for 400,000 shares issuable under the Company’s equity incentive plan and restricted stock units covering 1,000,000 shares, and approval of the proposal is necessary to ensure that a sufficient number of shares are available under the Plan for those awards. Ms. Skowron has an interest in the Equity Plan Amendment Proposal because Amendment No. 4 to her consulting arrangement with BPC Consulting Ltd. provides for up to 250,000 restricted stock units, subject to availability of reserved shares under the Plan. Our non-employee directors also have an interest in the Equity Plan Amendment Proposal because the proposal would increase the maximum number of shares that may be granted to any non-employee director, and non-employee directors receive an annual restricted stock unit grant under the Non-Executive Director Compensation Policy. and Mr. Borkowski and Dr. Syage received the October 2026 equity awards described under “Non-Executive Director Compensation”.
ADDITIONAL INFORMATION
Deadline for Receipt of Stockholder Proposals for the 2027 Annual Meeting
Pursuant to Rule 14a-8 under the Exchange Act, stockholder proposals to be included in our proxy statement for the 2027 Annual Meeting must be received by our Chief Financial Officer by writing to GridAI Technologies Corp., Attention: Chief Financial Officer — 433 Plaza Real, Suite 275, Boca Raton, Florida 33432, no later than [      ], 2027, which is 120 calendar days before the anniversary of the date this proxy statement is released, or, if the date of the 2027 Annual Meeting changes by more than 30 days from the anniversary date of the 2026 Annual Meeting, within a reasonable time before we begin to print and send our proxy materials for the 2027 Annual Meeting. Submitted proposals must comply with applicable Delaware law, the rules and regulations promulgated by the SEC and the procedures set forth in our Bylaws.
Our Bylaws state that a stockholder must provide timely written notice of any nominations of persons for election to our Board or any other proposal to be brought before the meeting together with supporting documentation, and must be present at such meeting, either in person or by a representative. For our 2027 annual meeting of stockholders, a stockholder’s notice shall be timely received by us at our principal executive office no later than [      ], 2027 and no earlier than [      ], 2027; provided, however, that in the event the Annual Meeting is scheduled to be held on a date more than thirty (30) days before the anniversary date of the immediately preceding Annual Meeting of Stockholders (the “Anniversary Date”) or more than seventy (70) days after the Anniversary Date, a stockholder’s notice shall be timely if received by the Company at our principal executive office not earlier than the close of business on the one hundred twentieth (120th) day prior to such annual meeting and not later than the close of business on the later of (i) the ninetieth (90th) day prior to the scheduled date of such annual meeting or (ii) the tenth (10th) day following the day on which such public announcement of the date of such Annual Meeting is first made by the Company. In addition, to comply with Rule 14a-19, a stockholder intending to solicit proxies in support of director nominees other than the Company’s nominees must provide notice no later than 60 calendar days before the anniversary of the preceding year’s annual meeting, together with the information required by Rule 14a-19. Proxies solicited by our Board will confer discretionary voting authority with respect to these nominations or proposals, subject to the SEC’s rules and regulations governing the exercise of this authority. Any such nomination or proposal shall be mailed to: GridAI Technologies Corp., Attention: Chief Financial Officer —  433 Plaza Real, Suite 275, Boca Raton, Florida 33432.
We reserve the right to reject, rule out of order, or take other appropriate action with respect to any proposal that does not comply with these and all other applicable requirements.
 
56

Table of Contents​​​
 
Householding of Proxy Materials
The SEC has adopted rules that permit companies and intermediaries (e.g., brokers) to satisfy the delivery requirements for proxy statements and annual reports with respect to two or more stockholders sharing the same address by delivering a single proxy statement and annual report addressed to those stockholders. This process, which is commonly referred to as “householding,” potentially means extra convenience for stockholders and cost savings for companies.
A number of brokers with account holders who are stockholders of the Company will be “householding” our proxy materials. A single set of our proxy materials will be delivered to multiple stockholders sharing an address unless contrary instructions have been received from the affected stockholders. Once you have received notice from your broker that they will be “householding” communications to your address, “householding” will continue until you are notified otherwise or until you revoke your consent. If, at any time, you no longer wish to participate in “householding” and would prefer to receive a separate set of our proxy materials at no charge, please notify your broker or direct a written request to GridAI Technologies Corp., Attention: Chief Financial Officer — 433 Plaza Real, Suite 275, Boca Raton, Florida 33432, or contact us at (416) 312-0442. We undertake to deliver promptly, upon any such verbal or written request, a separate copy of our proxy materials to a stockholder at a shared address to which a single copy of these documents was delivered. Stockholders who currently receive multiple copies of our proxy materials at their address and would like to request “householding” of their communications should contact their broker, bank or other nominee, or contact us at the above address or phone number.
Other Matters
At the date of this proxy statement, we know of no other matters, other than those described above, that will be presented for consideration at the Annual Meeting. If any other business should come before the Annual Meeting, it is intended that the proxy holders will vote all proxies using their best judgment in the interest of the Company and the stockholders.
Solicitation of Proxies
The solicitation of proxies pursuant to this proxy statement is being made by us. Proxies may be solicited, among other methods, by mail, telephone, email, the Internet and in person.
The expenses of preparing, printing and distributing this proxy statement and the accompanying form of proxy and the cost of soliciting proxies will be borne by us.
Copies of soliciting materials will be furnished to banks, brokerage houses and other custodians, nominees and fiduciaries for forwarding to the beneficial owners of shares of Common Stock for whom they hold shares, and we will reimburse them for their reasonable out-of-pocket expenses in connection therewith.
REGARDLESS OF WHETHER YOU PLAN TO ATTEND THE ANNUAL MEETING, PLEASE READ THE PROXY STATEMENT AND THEN SUBMIT A PROXY TO VOTE BY INTERNET, TELEPHONE OR MAIL AS PROMPTLY AS POSSIBLE TO ENSURE THAT YOUR SHARES ARE REPRESENTED AT THE ANNUAL MEETING.
BY ORDER OF THE BOARD OF DIRECTORS,
​ Boca Raton, Florida
[       ], 2026
​ ​
/s/ Jason D. Sawyer
​
Jason D. Sawyer
Chief Executive Officer and Director
​
If you have any questions or require any assistance in voting your shares you may contact GridAI’s Investor Relations Department at Jason Assad (IR@gridaipower.com) or by calling (678) 570-6791.
 
57

Table of Contents​
 
ANNEX A
CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF GRIDAI TECHNOLOGIES CORP.
CERTIFICATE OF AMENDMENT TO THE
AMENDED AND RESTATED CERTIFICATE
OF INCORPORATION
OF
GRIDAI TECHNOLOGIES CORP.
GridAI Technologies Corp. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify as follows:
FIRST:   That a resolution was duly adopted on [•], 202[6], by the Board of Directors of the Corporation pursuant to Section 242 of the General Corporation Law of the State of Delaware setting forth an amendment to the Certificate of Incorporation of the Corporation and declaring said amendment to be advisable. The stockholders of the Corporation duly approved said proposed amendment at an annual meeting of stockholders held on [      ], 2026, in accordance with Section 242 of the General Corporation Law of the State of Delaware. The proposed amendment set forth as follows:
Article FOURTH of the Amended and Restated Certificate of Incorporation of the Corporation, as amended to date, be and hereby is further amended by replacing the second, third and fourth paragraphs of Article FOURTH with the following:
Upon effectiveness (“Effective Time”) of this amendment to the Amended and Restated Certificate of Incorporation of the Corporation, a one-for-[   ]1 reverse stock split (the “Reverse Split”) of the Corporation’s Common Stock shall become effective, pursuant to which each [   ] shares of Common Stock outstanding and held of record by each stockholder of the Corporation (including treasury shares) immediately prior to the Effective Time (“Old Common Stock”) shall automatically, and without any action by the holder thereof, be reclassified and combined into one (1) validly issued, fully paid and non-assessable share of Common Stock (“New Common Stock”), subject to the treatment of fractional interests as described below and with no corresponding reduction in the number of authorized shares of our Common Stock. The Reverse Split shall also apply to any outstanding securities or rights convertible into, or exchangeable or exercisable for, Old Common Stock and all references to such Old Common Stock in agreements, arrangements, documents and plans relating thereto or any option or right to purchase or acquire shares of Old Common Stock shall be deemed to be references to the New Common Stock or options or rights to purchase or acquire shares of New Common Stock, as the case may be, after giving effect to the Reverse Split.
No fractional shares of Common Stock will be issued in connection with the reverse stock split. The Board of Directors shall make provision for the issuance of that number of fractions of Common Stock such that any fractional share of a holder otherwise resulting from the reverse stock split shall be rounded up to the next whole number of shares of Common Stock.
Each holder of record of a certificate or certificates for one or more shares of the Old Common Stock shall be entitled to receive as soon as practicable, upon surrender of such certificate, a certificate or certificates representing the number of whole shares (after rounding
​
1
Shall be a whole number equal to or greater than 2 and equal to or lesser than 20, which number is referred to as the “Reverse Split Factor” ​(it being understood that any Reverse Split Factor within such range shall, together with the remaining provisions of this Certificate of Amendment not appearing in brackets, constitute a separate amendment being approved and adopted by the board and stockholders in accordance with Section 242 of the Delaware General Corporation Law).
​
 
A-1

Table of Contents
 
up any fractional share) of New Common Stock to which such holder shall be entitled pursuant to the provisions of the immediately preceding paragraphs. Each stock certificate that, immediately prior to the Effective Time, represented shares of Old Common Stock that were issued and outstanding immediately prior to the Effective Time shall, from and after the Effective Time, automatically and without the necessity of presenting the same for exchange, represent that number of whole shares of New Common Stock after the Effective Time into which the shares formerly represented by such certificate have been reclassified.
SECOND:   That said amendment will have an Effective Time of 12:01 A.M., Eastern Time, on [      ]        .
IN WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to be signed by its Chief Executive Officer this           day of        , 202  .
/s/ Jason D. Sawyer
​
Jason D. Sawyer
Chief Executive Officer and Director
 
A-2

Table of Contents​
 
ANNEX B​
SECOND AMENDMENT TO
THE GRIDAI
TECHNOLOGIES CORP.
2020 OMNIBUS EQUITY INCENTIVE PLAN
DATED: [      ], 2026
WHEREAS, the Board of Directors (the “Board”) of GridAI Technologies Corp. (formerly Entero Therapeutics, Inc. and AzurRx BioPharma, Inc.), a Delaware corporation (the “Company”) heretofore established the AzurRx BioPharma, Inc. 2020 Omnibus Equity Incentive Plan, as amended and restated as of August 11, 2020 and amended on April 20, 2023 (the “Plan”); and
WHEREAS, after giving effect to multiple reverse stock splits and increases in accordance with the “evergreen” provisions of the Plan, the maximum number of shares of common stock of the Company (“Common Stock”) currently available for grants of “Awards” ​(as defined under the Plan) is [      ] (not counting shares of Common Stock that have previously been issued pursuant to the Plan or that are the subject of outstanding Awards under the Plan), all of which are available as grants as Incentive Stock Options, and the number of shares that may be granted to any non-employee director of the Board in a calendar year is 250,000 (not counting shares of Common Stock that have previously been issued pursuant to the Plan or that are the subject of outstanding Awards under the Plan); and
WHEREAS, in order to ensure that a sufficient number of shares of Common Stock are available under the Plan in order to properly incentivize those eligible to participate in the Plan, including future eligible participants, the Board believes it to be in the best interests of the Company and its stockholders to increase the maximum number of shares of Common Stock available for grants of Awards thereunder by 6,198,451 additional shares of Common Stock (the “Additional Reserved Shares”) (from 3,801,549 to 10,000,000 shares), not counting shares of Common Stock that have previously been issued pursuant to the Plan or that are the subject of outstanding Awards under the Plan; and
WHEREAS, the Board further believes it to be in the best interests of the Company and its shareholders to increase the number of shares of Common Stock that may be granted under the Plan as “incentive stock options” ​(“ISOs”), within the meaning of Section 422 of the Internal Revenue Code of 1986, as amended, to 10,000,000 shares in order to allow the Additional Reserved Shares and such other additional shares of Common Stock that may become available under the Plan in accordance with the Plan’s evergreen provisions to be granted as ISOs; and
WHEREAS, the Board further believes it to be in the best interests of the Company and its stockholders to increase the number of shares of Common Stock that may be granted to any non-employee director of the Board in a calendar year from 250,000 shares to 6,500,000 shares; and
WHEREAS, Article XIX of the Plan authorizes the Board to amend the Plan, subject to stockholder approval to the extent that such approval is required by applicable law;
NOW, THEREFORE, subject to approval of the Company’s stockholders, effective the date hereof, the Plan is hereby amended as follows:
Section 5.1 of the Plan is hereby amended in its entirety, to read as follows:
“Authorized Shares and Award Limits.    The Committee may from time to time grant Awards to one or more Employees, Directors and/or Consultants determined by it to be eligible for participation in the Plan in accordance with the provisions of Article VI. Subject to Article XVIII, the number of Shares that may be issued under all Awards granted under the Plan shall be 10,000,000 (the “Share Reserve”); provided that, subject to Article XVIII, the Share Reserve (as adjusted as set forth herein) shall automatically be increased, but not decreased, on January 1 of each calendar year (beginning January 1, 2021) so as to be equal to ten percent (10%) of the issued and outstanding shares of the Company’s Common Stock on December 31 of the preceding calendar year on an as converted basis (the “As Converted Shares”). Notwithstanding the foregoing, the Board may in its discretion, determine
 
B-1

Table of Contents
 
that no increase in the Share Reserve shall be made for any year or determine that a lesser number of Shares shall be added to the Share Reserve than would otherwise have been added pursuant to the preceding sentence. For calculation purposes, the As Converted Shares shall include all shares of the Company’s outstanding Common Stock and all shares of the Company’s Common Stock issuable upon the conversion of outstanding preferred stock, warrants and other convertible securities, but shall not include any shares of Common Stock issuable upon the exercise of options and other convertible securities issued pursuant to the Plan or the Company’s Amended and Restated 2014 Omnibus Equity Incentive Plan. Subject to Article XVIII, the maximum number of Shares available for issuance in respect of Incentive Stock Options is 10,000,000, but in no event may Incentive Stock Options be granted in excess of the Share Reserve as the same may be increased in accordance with the foregoing provisions of this Section. To the extent that an Award lapses, expires, is canceled, is terminated unexercised or ceases to be exercisable for any reason, or the rights of its Holder terminate, any Shares subject to such Award shall again be available for the grant of a new Award. Shares that otherwise would have been issued upon the exercise of an Option or Stock Appreciation Right or in payment with respect to any other form of Award, that are surrendered in payment or partial payment of the exercise price thereof and/or taxes withheld with respect to the exercise thereof or the making of such payment, will no longer be counted against the foregoing maximum share limitations and may again be made subject to Awards under the Plan pursuant to such limitations.”
Section 5.2 of the Plan is hereby amended in its entirety, to read as follows:
“Individual Holder Limitations.   Subject to adjustment as provided in Article XVIII, the number of Shares with respect to which Awards may be granted during any calendar year to any Director who is a non-employee director of the Board shall not exceed 6,500,000.”
[Signature Page Follows]
 
B-2

Table of Contents
 
IN WITNESS WHEREOF, the undersigned has executed this Amendment as evidence of its adoption by the Board of Directors of the Company on the date set forth above.
GRIDAI TECHNOLOGIES CORP.
By:
 
​
​
Name Jason D. Sawyer
Title   Chief Executive Officer and Director
Date: [      ], 2026
 

Table of Contents
[MISSING IMAGE: px_26grdxproxy01pg01-4c.jpg]
PRELIMINARY PROXY CARD — SUBJECT TO COMPLETIONSCAN TOVIEW MATERIALS & VOTE GRIDAI TECHNOLOGIES CORP. 433 PLAZA REAL, SUITE 275 BOCA RATON, FLORIDA 33432 VOTE BY INTERNETBefore The Meeting - Go to www.proxyvote.com or scan the QR Barcode aboveUse the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 p.m. Eastern Time on the day before the Annual Meeting. Have your proxy card in hand when you access the website and follow the instructions to obtain your records and to create an electronic voting instruction form.During The Meeting - Go to www.virtualshareholdermeeting.com/GRDX2026You may attend the Annual Meeting via the Internet and vote during the meeting. Have the information that is printed in the box marked by the arrow available and follow the instructions.VOTE BY PHONE - 1-800-690-6903Use any touch-tone telephone to transmit your voting instructions up until 11:59 p.m. Eastern Time on the day before the Annual Meeting. Have your proxy card in hand when you call and then follow the instructions.VOTE BY MAILMark, sign and date your proxy card and return it in the postage-paid envelope we have provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717. TO VOTE, MARK BLOCKS
BELOW IN BLUE OR BLACK INK AS FOLLOWS: T05087-Z94165 KEEP THIS PORTION FOR YOUR RECORDS THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. DETACH AND RETURN THIS PORTION ONLY GRIDAI TECHNOLOGIES CORP. For Withhold For All To withhold authority to vote for any individual The Board of Directors recommends you vote "FOR" each of the director nominees listed in Proposal 1: AllAllExcept nominee(s), mark "For All Except" and write the number(s) of the nominee(s) on the line below. 1.Election of four director nominees named in the proxy statement, each for a term of one year expiring at our 2027 annual meeting of stockholders or until their respective successors are duly elected and qualified (the "Director Election Proposal");Nominees: !!! 01)Edward J. Borkowski02)Jason D. Sawyer 03)Jack Syage04)Geordan G. Pursglove The Board of Directors recommends you vote "FOR" Proposals 2, 3, 4, 5, 6 and 7:For Against Abstain2.Adoption and approval of an amendment to our Amended and Restated Certificate of Incorporation, as amended (the "Charter"), to effect a reverse stock split of our issuedand outstanding shares of Common Stock, at a specific ratio, ranging from 1:2 to 1:20, at any time prior to the one-year anniversary date of the Annual Meeting, with the ! ! !exact ratio to be determined by the Board without further approval or authorization of our stockholders (the "Reverse Split Proposal");3.To approve an amendment to the Company’s 2020 Omnibus Equity Incentive Plan (the "Plan") to: (i) increase the number of shares of Common Stock authorized for issuance under the Plan from 3,801,549 to 10,000,000, including an increase in the number of shares available for grants of incentive stock options ("ISOs") from 357 to 10,000,000; and (ii) increase the maximum number of shares that may be granted to any non-employee director in a calendar year from 250,000 to 6,500,000 (the "Equity Plan Amendment Proposal");4.To approve the issuance of up to 1,520,000 shares of Common Stock upon the exercise of warrants issued or issuable pursuant to that certain Securities Purchase Agreement dated October 17, 2025, as amended to date, by and among the Company and the investors party thereto, as required by and in accordance with Nasdaq Listing Rule 5635(d) (the "Nasdaq Proposal");5.Approval, on an advisory basis, of the executive compensation of the Company’s named executive officers as described in the proxy statement (the "Say on Pay Proposal");!!!6.Ratification of the appointment of Macias Gini & O’Connell LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026 (the "Auditor Ratification Proposal"); and7.Approval of the adjournment of the Annual Meeting to the extent there are insufficient proxies at the Annual Meeting to approve any one or more of the foregoing proposals!!!(the "Adjournment Proposal").NOTE: In their discretion, the proxies are authorized to vote upon such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.Please sign exactly as your name(s) appear(s) hereon. When signing as attorney, executor, administrator, trustee or guardian, please give full title as such. Joint owners should each sign personally. All holders must sign. If a corporation or partnership, please sign in full corporate or partnership name by an authorized officer.Signature [PLEASE SIGN WITHIN BOX]DateSignature (Joint Owners)Date
​

Table of Contents
[MISSING IMAGE: px_26grdxproxy01pg02-4c.jpg]
Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting:The Notice of Annual Meeting, Proxy Statement and Annual Report are available at www.proxyvote.com. T05088-Z94165GRIDAI TECHNOLOGIES CORP. ANNUAL MEETING OF STOCKHOLDERS [●], 2026, [●] [A.M./P.M.] EASTERN TIMETHIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORSThe stockholder(s) hereby appoint(s) [●] and [●], or either of them, as proxies, each with the power to appoint a substitute, and hereby authorize(s) them to represent and to vote, as designated on the reverse side of this proxy card, all of the shares of Common Stock of GridAI Technologies Corp. that the stockholder(s) is/are entitled to vote at the Annual Meeting of Stockholders to be held virtually at www.virtualshareholdermeeting.com/GRDX2026 on [●], 2026, at [●] [a.m./p.m.] Eastern Time, and any adjournment or postponement thereof, and, in their discretion, upon such other business as may properly come before the meeting or any adjournment or postponement thereof.This proxy, when properly executed, will be voted in the manner directed herein. If no such direction is made, this proxy will be voted "FOR" each of the director nominees listed in Proposal 1 and "FOR" Proposals 2, 3, 4, 5, 6 and 7, in accordance with the Board of Directors' recommendations. If any nominee becomes unable or unwilling to serve, this proxy will be voted for a substitute nominee recommended by the Board of Directors.Continued and to be signed on the reverse side

PRE 14A 0001604191 false 0001604191 2025-01-01 2025-12-31 0001604191 grdx:JasonDSawyerMember 2025-01-01 2025-12-31 0001604191 grdx:RichardPaoloneMember 2025-01-01 2025-12-31 0001604191 grdx:JamesSapirsteinMember 2024-01-01 2024-12-31 0001604191 grdx:RichardPaoloneMember 2024-01-01 2024-12-31 0001604191 2024-01-01 2024-12-31 0001604191 grdx:JamesSapirsteinMember 2023-01-01 2023-12-31 0001604191 grdx:RichardPaoloneMember 2023-01-01 2023-12-31 0001604191 2023-01-01 2023-12-31 0001604191 2025-09-04 2025-12-31 0001604191 2025-01-01 2025-09-03 0001604191 grdx:JasonDSawyerMember 2025-12-22 2025-12-22 0001604191 grdx:AnnaSkowronMember 2025-12-22 2025-12-22 0001604191 2025-12-22 2025-12-22 0001604191 2025-12-22 0001604191 ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember ecd:PeoMember grdx:JasonDSawyerMember 2025-01-01 2025-12-31 0001604191 ecd:EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember ecd:PeoMember grdx:JasonDSawyerMember 2025-01-01 2025-12-31 0001604191 ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember ecd:PeoMember grdx:RichardPaoloneMember 2025-01-01 2025-12-31 0001604191 ecd:EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember ecd:PeoMember grdx:RichardPaoloneMember 2025-01-01 2025-12-31 0001604191 ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember ecd:NonPeoNeoMember 2025-01-01 2025-12-31 0001604191 ecd:EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember ecd:NonPeoNeoMember 2025-01-01 2025-12-31 0001604191 ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember ecd:PeoMember grdx:JamesSapirsteinMember 2024-01-01 2024-12-31 0001604191 ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember ecd:PeoMember grdx:JamesSapirsteinMember 2024-01-01 2024-12-31 0001604191 ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember ecd:NonPeoNeoMember 2024-01-01 2024-12-31 0001604191 ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember ecd:NonPeoNeoMember 2024-01-01 2024-12-31 0001604191 ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember ecd:PeoMember grdx:JamesSapirsteinMember 2023-01-01 2023-12-31 0001604191 ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember ecd:PeoMember grdx:JamesSapirsteinMember 2023-01-01 2023-12-31 0001604191 ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember ecd:PeoMember grdx:JamesSapirsteinMember 2023-01-01 2023-12-31 0001604191 ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember ecd:PeoMember grdx:JamesSapirsteinMember 2023-01-01 2023-12-31 0001604191 ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember ecd:NonPeoNeoMember 2023-01-01 2023-12-31 0001604191 ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember ecd:NonPeoNeoMember 2023-01-01 2023-12-31 0001604191 ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember ecd:NonPeoNeoMember 2023-01-01 2023-12-31 0001604191 ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember ecd:NonPeoNeoMember 2023-01-01 2023-12-31 0001604191 2020-12-30 0001604191 2023-12-29 0001604191 2024-12-31 0001604191 2025-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares